WO1998008840A1 - Integrin antagonists - Google Patents

Integrin antagonists Download PDF

Info

Publication number
WO1998008840A1
WO1998008840A1 PCT/US1997/014912 US9714912W WO9808840A1 WO 1998008840 A1 WO1998008840 A1 WO 1998008840A1 US 9714912 W US9714912 W US 9714912W WO 9808840 A1 WO9808840 A1 WO 9808840A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
aryl
oxo
tetrahydro
naphthyridin
Prior art date
Application number
PCT/US1997/014912
Other languages
French (fr)
Inventor
Mark E. Duggan
George D. Hartman
William F. Hoffman
Robert S. Meissner
James J. Perkins
Ben C. Askew
Paul J. Coleman
John H. Hutchinson
Adel M. Naylor-Olsen
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9703015.9A external-priority patent/GB9703015D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to JP51178398A priority Critical patent/JP2002511052A/en
Priority to US09/242,885 priority patent/US6211184B1/en
Priority to CA002263999A priority patent/CA2263999A1/en
Priority to AU40865/97A priority patent/AU724191B2/en
Priority to EP97938568A priority patent/EP0934305A4/en
Publication of WO1998008840A1 publication Critical patent/WO1998008840A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention provides novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor ligands. More particularly, the compounds of the present invention are ⁇ v ⁇ 3 antagonists, v ⁇ 5 antagonists or dual ⁇ v ⁇ 3/ ⁇ v ⁇ 5 antagonists useful for inhibiting bone reso ⁇ tion, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
  • This invention relates to compounds for inhibiting bone resorption that is mediated by the action of a class of cells known as osteoclasts.
  • Osteoclasts are multinucleated cells of up to 400 ⁇ m in diameter that resorb mineralized tissue, chiefly calcium carbonate and calcium phosphate, in vertebrates. They are actively motile cells that migrate along the surface of bone. They can bind to bone, secrete necessary acids and proteases and thereby cause the actual reso ⁇ tion of mineralized tissue from the bone.
  • osteoclasts are believed to exist in at least two physiological states.
  • the secretory state osteoclasts are flat, attach to the bone matrix via a tight attachment zone (sealing zone), become highly polarized, form a ruffled border, and secrete lysosomal enzymes and protons to resorb bone.
  • the adhesion of osteoclasts to bone surfaces is an important initial step in bone reso ⁇ tion.
  • the osteoclasts migrate across bone matrix and do not take part in reso ⁇ tion until they attach again to bone.
  • Integrins are transmembrane, heterodimeric, glycoproteins which interact with extracellular matrix and are involved in osteoclast attachment, activation and migration.
  • the most abundant integrin in osteoclasts (rat, chicken, mouse and human) is the vitronectin receptor, or txv ⁇ 3, thought to interact in bone with matrix proteins that contain the RGD sequence.
  • Antibodies to ⁇ v ⁇ 3 block bone reso ⁇ tion in vitro indicating that this integrin plays a key role in the reso ⁇ tive process.
  • v ⁇ 3 ligands can be used effectively to inhibit osteoclast mediated bone resoption in vivo in mammals.
  • osteoporosis hypercalcemia of malignancy
  • osteopenia due to bone metastases
  • periodontal disease hype ⁇ arathyroidism
  • periarticular erosions in rheumatoid arthritis Paget's disease
  • immobilization-induced osteopenia and glucocorticoid treatment.
  • All these conditions are characterized by bone loss, resulting from an imbalance between bone reso ⁇ tion (breakdown) and bone formation, which continues throughout life at the rate of about 14% per year on the average.
  • the rate of bone turnover differs from site to site, for example, it is higher in the trabecular bone of the vertebrae and the alveolar bone in the jaws than in the cortices of the long bones.
  • the potential for bone loss is directly related to turnover and can amount to over 5% per year in vertebrae immediately following menopause, a condition which leads to increased fracture risk.
  • ⁇ v ⁇ 3 ligands have been found to be useful in treating and/or inhibiting restenosis (recurrence of stenosis after corrective surgery on the heart valve), atherosclerosis, diabetic retinopathy, macular degeneration and angiogenesis (formation of new blood vessels).
  • restenosis recurrence of stenosis after corrective surgery on the heart valve
  • atherosclerosis recurrence of stenosis after corrective surgery on the heart valve
  • diabetic retinopathy diabetic retinopathy
  • macular degeneration macular degeneration
  • angiogenesis formation of new blood vessels.
  • ⁇ v ⁇ 3 antagonists which inhibit angiogenesis, are therefore useful in the treatment of cancer for inhibiting tumor growth. (See e.g., Brooks et al., CV7, 79:1157-1164 (1994)).
  • compounds of this invention can also inhibit neovascularization by acting as antagonists of the integrin receptor ⁇ v ⁇ 5.
  • a monoclonal antibody for ⁇ v ⁇ 5 has been shown to inhibit VEGF-induced angiogenesis in rabbit cornea and the chick chorioallantoic membrane model; M.C. Friedlander, et.al., Science 270, 1500-1502, 1995.
  • compounds that antagonize ⁇ v ⁇ 5 are useful for treating and preventing macular degeneration, diabetic retinopathy, and tumor growth.
  • certain compounds of this invention antagonize both the v ⁇ 3 and ⁇ v ⁇ 5 receptors.
  • These compounds referred to as “dual ⁇ v ⁇ 3/ v ⁇ 5 antagonists,” are useful for inhibiting bone reso ⁇ tion, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
  • the compounds of the present invention are useful for inhibiting bone reso ⁇ tion in mammals.
  • the compounds of the present invention are useful for preventing or reducing the incidence of osteoporosis.
  • the ⁇ v ⁇ 3 ligands of the present invention are also useful for treating and/or inhibiting restenosis, diabetic retinopathy, macular degeneration, atherosclerosis and/or angiogenesis in mammals.
  • the present invention provides a method of eliciting a vitronectin receptor antagonizing effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound of the formula
  • a 9- to 10-membered polycyclic ring system wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1 , 2, 3 or 4 heteroatoms selected from N, O or S, and wherein the polycyclic ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups chosen from Rl , R ⁇ , Rl5 or R ⁇ 6;
  • Y is selected from
  • Z is a 5-1 1 membered aromatic or nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups independently selected from R4, R5 ? R6 and R7 ; provided that Z is not a 6-membered monocyclic aromatic ring system, an isoxazoline ring or an isoxazole ring; Rl , R2, R4, R5 ? R 13, R 14 ?
  • R 15 and Rl6 are each independently selected from hydrogen, halogen, Cl -io alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, C3-8 cycloalkyl Cl-6 alkyl, C3-8 cycloheteroalkyl Cl-6 alkyl, aryl, aryl Cl -8 alkyl, amino, amino Cl -8 alkyl, Cl-3 acylamino, Cl-3 acylamino Cl -8 alkyl, (Cl-6 alky qamino, (Cl -6 alkyl)qamino Cl-8 alkyl, Cl-4 alkoxy, Cl-4 alkoxy Cl -6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl-6 alkyl, Cl-3 alkoxy carbonyl, Cl-3 alkoxycarbonyl Cl -6 alkyl, hydroxy carbonyl -
  • Cl-6 alkyloxy hydroxy, hydroxy Cl -6 alkyl, Cl-6 alkyloxy- Cl -6 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, Cl -8 alkyl-S(0)q, (Cl -8 alkyOqaminocarbonyl, Cl -8 alkyloxycarbonylamino, (Cl -8 alkyl)qaminocarbonyloxy, oxo, (aryl Cl -8 alkyl)qamino, (aryl)qamino, aryl Cl-8 alkylsulfonylamino or Cl -8 alkylsulfonylamino;
  • R3 is selected from hydrogen, aryl, aryl-(CH2)p-, hydroxyl,
  • R6> R7, R8 ? R9 ? R IO and Rl 1 are each independently selected from hydrogen, aryl, aryl-(CH2)p-, aryl-(CH2)n-0-(CH2)m-, aryl-(CH2)n-S(0) q -(CH2)m-, aryl-(CH2)n-C(0)-(CH 2 )m-, aryl-(CH2)n-C(0)-N(R3)-(CH 2 )m-, aryl-(CH2)n-N(R3)-C(0)-(CH2)m-, aryl-(CH2)n-N(R3)-(CH2)m-, halogen, hydroxyl,
  • aryl Cl-8 alkyOqaminocarbonyl or (aryl Cl-8 alkyOqaminocarbonyl Cl-6 alkyl, wherein any of the alkyl groups may be unsubstituted or substituted with R l3 and Rl4; and provided that the carbon atom to which R& and R ⁇ are attached is itself attached to no more than one heteroatom; and provided further that the carbon atom to which RlO and R* 1 are attached is itself attached to no more than one heteroatom;
  • Rl2 i s selected from hydrogen, Cl-8 alkyl, aryl, aryl Cl-8 alkyl,
  • n is an integer from 1 to 3
  • p is an integer from 1 to 4
  • q is an integer from 0 to 2
  • r is an integer from 0 to 6; and the pharmaceutically acceptable salts thereof.
  • X is a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1 , 2, 3 or 4 heteroatoms selected from N, O or S, and wherein the polycyclic ring system is either unsubstituted or substituted on a carbon atom with R and R ⁇ ; and
  • Z is selected from
  • Y is selected from -(CH2)r or -(CH2)m-NR 3 -(CH2)t-;
  • R is selected from hydrogen, aryl-(CH2)p-,
  • R4 is selected from hydrogen, Cl-6 alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, C3-8 cycloalkyl Cl-6 alkyl, C3-8 cycloheteroalkyl Cl-6 alkyl, aryl or aryl Cl -8 alkyl
  • R ⁇ is selected from hydrogen, aryl, aryl-(CH2)p-,
  • r is an integer from 0 to 3; and all other variables are as defined above; and the pharmaceutically acceptable salts thereof.
  • R ⁇ is selected from hydrogen
  • Cl-6 alkylaryl-CH CH-(CH2)s-, Ci- 6 alkyl-S ⁇ 2-(CH2)s-,
  • R l2 i selected from hydrogen or Cl -8 alkyl; s is an integer from 0 to 3; and all other variables are as defined above; and the pharmaceutically acceptable salts thereof.
  • the compound is selected from:
  • Exemplifying the invention is the method wherein the vitronectin receptor antagonizing effect is an ⁇ v ⁇ 3 antagonizing effect.
  • An illustration of the invention is the method wherein the v ⁇ 3 antagonizing effect is selected from inhibition of: bone reso ⁇ tion, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation or tumor growth.
  • the cxv ⁇ 3 antagonizing effect is the inhibition of bone reso ⁇ tion.
  • An example of the invention is the method wherein the vitronectin receptor antagonizing effect is an ⁇ v ⁇ 5 antagonizing effect.
  • the txv ⁇ 5 antagonizing effect is selected from inhibition of: restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation or tumor growth.
  • Illustrating the invention is the method wherein the vitronectin receptor antagonizing effect is a dual ⁇ v ⁇ 3/ ⁇ v ⁇ 5 antagonizing effect.
  • the dual ⁇ v ⁇ 3/ ⁇ v ⁇ 5 antagonizing effect is selected from inhibition of: bone reso ⁇ tion, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation or tumor growth.
  • a second embodiment of the present invention is a method of eliciting an ⁇ v ⁇ 3 antagonizing effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound of the formula
  • Y is selected from
  • Z is a 5-11 membered aromatic or nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups independently selected from R 4 , R5, R6 nd R ⁇ ; provided that Z is not a 6-membered monocyclic aromatic ring system; preferably, Z is selected from
  • R 1 , R 2 , R3, R4 5 R5, R13 and R* 4 are each independently selected from hydrogen, halogen, C] -10 alkyl, C3-8 cycloalkyl, aryl, aryl Cl -8 alkyl, amino, amino Cl-8 alkyl, Cl -3 acylamino, Cl -3 acylamino Cl -8 alkyl, Cl -6 alkylamino, Cl -6 alkylamino- Cl -8 alkyl, Cl-6 dialkylamino, Cl-6 dialkylamino Cl-8 alkyl, Cl-4 alkoxy, Cl-4 alkoxy Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl-6 alkyl, Cl -3 alkoxycarbonyl, Cl -3 alkoxycarbonyl Cl-6 alkyl, hydroxycarbonyl- Cl -6 alkyloxy, hydroxy or hydroxy Cl -6 alkyl;
  • R6, R , R8, R9, R IO and R 1 ! are each independently selected from hydrogen, aryl,
  • Cl -8 alkyl either unsubstituted or substituted, with one or more groups selected from: halogen, hydroxyl, Cl-5 alkylcarbonylamino, aryl Cl-5 alkoxy, Cl-5 alkoxycarbonyl, aminocarbonyl, Cl-5 alkylaminocarbonyl, Cl-5 alkylcarbonyloxy, C3-8 cycloalkyl, oxo, amino, Cl -3 alkylamino, amino Cl-3 alkyl, arylamino- carbonyl, aryl Cl-5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cl -4 alkyl, hydroxycarbonyl, or hydroxycarbonyl Cl-5 alkyl,
  • any of the alkyl groups may be unsubstituted or substituted with R l and R ⁇ 4 ; and provided that the carbon atom to which R& and R9 are attached is itself attached to no more than one heteroatom; and provided further that the carbon atom to which RlO and R ⁇ are attached is itself attached to no more than one heteroatom;
  • R 2 is selected from hydrogen
  • n is an integer from 1 to 3
  • p is an integer from 1 to 4
  • q is an integer from 0 to 2
  • r is an integer from 0 to 6
  • s is an integer from 0 to 3
  • t is an integer from 0 to 3;
  • a third embodiment of the invention is a method of eliciting an ctv ⁇ 3 antagonizing effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound of the formula
  • polycyclic ring system a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1, 2, 3 or 4 heteroatoms selected from N, O or
  • Y is selected from - (CH 2 )- ,
  • Z is a 5-1 1 membered aromatic or nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups independently selected from R 4 , R5, R6 and R7; provided that Z is not a 6-membered monocyclic aromatic ring system; preferably Z is selected from
  • Rl, R 2 , R 4 , R5, Rl3 a nd Rl 4 are each independently selected from hydrogen, halogen, Ci-io alkyl, C3- cycloalkyl, aryl, aryl Cl -8 alkyl, amino, amino Cl- alkyl, Cl -3 acylamino, Cl-3 acylamino Cl-8 alkyl, Cl-6 alkylamino, Cl -6 alkylamino- Cl -8 alkyl, Cl-6 dialkylamino, Cl-6 dialkylamino Cl-8 alkyl, Ci-4 alkoxy, Cl-4 alkoxy Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl-6 alkyl, Cl-3 alkoxycarbonyl, Cl-3 alkoxycarbonyl Cl-6 alkyl, hydroxycarbonyl- Ci-6 alkyloxy, hydroxy, hydroxy Cl -6 alkyl, Cl-6 alkyloxy- Cl -6 alkyl, nitro, cyano, trifluoromethyl, trifluo
  • R6, R7, R8 ? R9 ? RIO anc j R1 1 a re each independently selected from hydrogen, aryl,
  • Cl-8 alkyl either unsubstituted or substituted, with one or more groups selected from: halogen, hydroxyl,
  • Cl-8 alkylsulfonylamino Cl-8 alkylsulfonylamino, Cl-8 alkylsulfonylamino C l -6 alkyl, arylsulfonylamino Cl-6 alkyl, aryl Cl-6 alkylsulfonylamino, aryl Cl-6 alkylsulfonylamino Cl-6 alkyl,
  • any of the alkyl groups may be unsubstituted or substituted with Rl3 and R ⁇ 4 ; and provided that the carbon atom to which R& and R ⁇ are attached is itself attached to no more than one heteroatom; and provided further that the carbon atom to which R ⁇ O and R 1 1 are attached is itself attached to no more than one heteroatom;
  • R 2 is selected from hydrogen
  • Cl-8 dialkylaminocarbonylmethyleneoxy m is an integer from 0 to 3; n is an integer from 1 to 3; p is an integer from 1 to 4; q is an integer from 0 to 2; r is an integer from 0 to 6; and s is an integer from 0 to 3;
  • the ⁇ v ⁇ 3 antagonizing effect is selected from inhibition of bone reso ⁇ tion, inhibition of restenosis, inhibition of angiogenesis, inhibition of diabetic retinopathy, inhibition of macular degeneration, inhibition of atherosclerosis, inflammation or inhibition of tumor growth.
  • the ocv ⁇ 3 antagonizing effect is the inhibition of bone reso ⁇ tion.
  • X is a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1, 2, 3 or 4 heteroatoms selected from N, O or S, and wherein the polycyclic ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups chosen from Rl , R 2 , R ! 5 or Rl6;
  • Y is selected from R ⁇ O
  • Z is a 5-11 membered aromatic or nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups independently selected from R 4 , R5, R6 and R7; provided that Z is not a 6-membered monocyclic aromatic ring system, an isoxazoline ring or an isoxazole ring;
  • R 1 , R 2 , R 4 , R5, Rl3, R14 ? R15 and R!6 are each independently selected from hydrogen, halogen, Ci -10 alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, C3-8 cycloalkyl Cl -6 alkyl,
  • R6, R7, R R9 ? RIO a nd R 1 1 are each independently selected from hydrogen, aryl, aryl-(CH2)p-, aryl-(CH2)n-0-(CH2)m-, aryl-(CH2)n-S(0) q -(CH2)m-, aryl-(CH2)n-C(0)-(CH2)m-, aryl-(CH2)n-C(0)-N(R3)-(CH2)m-, aryl-(CH2)n-N(R3)-C(0)-(CH2)m-, aryl-(CH2)n-N(R3)-(CH2)m-, halogen, hydroxyl,
  • Cl-8 alkyl either unsubstituted or substituted, with one or more groups selected from: halogen, hydroxyl, Cl-5 alkylcarbonylamino, aryl Cl-5 alkoxy,
  • Cl-6 alkylsulfonyl Cl-6 alkylsulfonyl, Cl-6 alkylsulfonyl Cl-6 alkyl, arylsulfonyl Cl-6 alkyl, aryl Cl-6 alkylsulfonyl, aryl Cl-6 alkylsulfonyl Cl-6 alkyl,
  • aryl Cl-8 alkyOqaminocarbonyl Cl-6 alkyl wherein any of the alkyl groups may be unsubstituted or substituted with Rl and R ⁇ 4 ; and provided that the carbon atom to which R ⁇ and R9 are attached is itself attached to no more than one heteroatom; and provided further that the carbon atom to which RlO and R ⁇ are attached is itself attached to no more than one heteroatom;
  • R1 is selected from hydrogen
  • n is an integer from 1 to 3
  • p is an integer from 1 to 4
  • q is an integer from 0 to 2
  • r is an integer from 0 to 6; and the pharmaceutically acceptable salts thereof.
  • Z is a 5-1 1 membered nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups independently selected from R 4 , R ⁇ , R6 and R7; and all other variables are as defined above.
  • Exemplifying the invention is the compound wherein
  • Z is selected from
  • An example of the invention is the compound of the formula
  • Y is selected from -(CH2)r- or -(CH2) m -NR 3 -(CH2)t-;
  • R is selected from hydrogen, aryl-(CH2)p-, Cl- alkoxycarbonyl,
  • R 4 is selected from hydrogen, Cl-6 alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl,
  • r is an integer from 0 to 3; wherein all other variables are as defined above; and the pharmaceutically acceptable salts thereof.
  • R8 is selected from hydrogen
  • Ci-6 alkyl-CH CH-(CH2)s-
  • Rl2 is selected from hydrogen or Cl-8 alkyl; and s is an integer from 0 to 3; and all other variables are as defined above; and the pharmaceutically acceptable salts thereof.
  • the compound is selected from:
  • An additional example of the invention is a compound of the formula
  • X is a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1 , 2, 3 or 4 heteroatoms selected from N, O or S, and wherein the polycyclic ring system is either unsubstituted or substituted on a carbon atom with R ⁇ and R2;
  • Y is selected from R 3 R 3 ° O
  • Z is a 5-1 1 membered aromatic or nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups independently selected from R 4 , R5, R6 and R7; provided that Z is not a 6-membered monocyclic aromatic ring system; preferably, Z is selected from
  • R 1 , R 2 , R3, R 4 , R5, R 13 and R14 ar e each independently selected from hydrogen, halogen, Cl-lO alkyl, C3-8 cycloalkyl, aryl, aryl Cl -8 alkyl, amino, amino Cl-8 alkyl, Cl-3 acylamino, Cl -3 acylamino Cl-8 alkyl, Cl-6 alkylamino, Cl-6 alkylamino- C ⁇ _8 alkyl, Cl-6 dialkylamino, Cl-6 dialkylamino Cl- alkyl, Cl-4 alkoxy, Cl-4 alkoxy Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl-6 alkyl, Cl _3 alkoxycarbonyl, Cl-3 alkoxycarbonyl Cl-6 alkyl, hydroxycarbonyl- Cl-6 alkyloxy, hydroxy or hydroxy Cl -6 alkyl;
  • Cl-8 alkyl either unsubstituted or substituted, with one or more groups selected from: halogen, hydroxyl, Cl-5 alkylcarbonylamino, aryl Cl -5 alkoxy,
  • Cl-6 alkylsulfonyl Cl-6 alkylsulfonyl, Cl-6 alkylsulfonyl Cl-6 alkyl, arylsulfonyl Cl-6 alkyl, aryl Cl-6 alkylsulfonyl, aryl C 1 -6 alkylsulfonyl C 1 -6 alkyl,
  • Cl-6 alkylcarbonyl Cl-6 alkylcarbonyl, Cl-6 alkylcarbonyl Cl-6 alkyl, arylcarbonyl Cl-6 alkyl, aryl Cl-6 alkylcarbonyl, aryl Cl-6 alkylcarbonyl Cl-6 alkyl,
  • any of the alkyl groups may be unsubstituted or substituted with R l and R ⁇ 4 ; and provided that the carbon atom to which R$ and R9 are attached is itself attached to no more than one heteroatom; and provided further that the carbon atom to which RlO and R 1 1 are attached is itself attached to no more than one heteroatom;
  • Rl ⁇ is selected from hydrogen, Cl-8 alkyl, aryl, aryl Cl-8 alkyl, hydroxy, Cl-8 alkoxy, aryloxy, aryl Cl -6 alkoxy,
  • n is an integer from 1 to 3
  • p is an integer from 1 to 4
  • q is an integer from 0 to 2
  • r is an integer from 0 to 6
  • s is an integer from 0 to 3; and the pharmaceutically acceptable salts thereof.
  • An additional illustration of the invention is a compound of the formula wherein X is a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1 , 2, 3 or 4 heteroatoms selected from N, O or
  • Y is selected from
  • Z is a 5-11 membered aromatic or nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups independently selected from R 4 , R5, R6 and R ; provided that Z is not a 6-membered monocyclic aromatic ring system; preferably, Z is selected from 63 -
  • Rl , R 2 , R 4 , R5, R13 and R ⁇ 4 are each independently selected from hydrogen, halogen, Cl -10 alkyl, C3-8 cycloalkyl, aryl, aryl Cl-8 alkyl, amino, amino Cl-8 alkyl, Cl -3 acylamino,
  • Cl-6 alkyloxy hydroxy, hydroxy Cl-6 alkyl, Cl-6 alkyloxy- Cl -6 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, Cl-8 alkyl-S(0)q, Cl-8 aminocarbonyl, Cl -8 dialkylaminocarbonyl, Cl-8 alkyloxycarbonylammo, Cl-8 alkylaminocarbonyloxy or Cl -8 alkylsulfonylamino;
  • R3 is selected from hydrogen, aryl, -(CH )p-aryl, hydroxyl, Cl-5 alkoxycarbonyl, aminocarbonyl,
  • Cl-8 alkyl either unsubstituted or substituted, with one or more groups selected from: halogen, hydroxyl,
  • Cl-8 alkylsulfonylamino Cl-8 alkylsulfonylamino, Cl-8 alkylsulfonylamino Cl -6 alkyl, arylsulfonylamino Cl-6 alkyl, aryl Cl-6 alkylsulfonylamino, aryl Cl-6 alkylsulfonylamino Cl-6 alkyl,
  • R! is selected from hydrogen, Cl-8 alkyl, aryl, aryl Cl-8 alkyl, hydroxy,
  • n is an integer from 1 to 3
  • p is an integer from 1 to 4
  • q is an integer from 0 to 2
  • r is an integer from 0 to 6
  • s is an integer from 0 to 3; and the pharmaceutically acceptable salts thereof.
  • a pharmaceutical composition comprising any of the compounds described above and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition made by combining any of the compounds described above and a pharmaceutically acceptable carrier is another illustration of the invention.
  • Another illustration of the invention is a process for making a pharmaceutical composition comprising combining any of the compounds described above and a pharmaceutically acceptable carrier.
  • the condition is selected from bone reso ⁇ tion, osteoporosis, restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, cancer and tumor growth. More preferably, the condition is selected from osteoporosis and cancer. Most preferably, the condition is osteoporosis.
  • the vitronectin antagonizing effect is an ⁇ v ⁇ 3 antagonizing effect; more specifically the ⁇ v ⁇ 3 antagonizing effect is selected from inhibition of bone resorption, inhibition of restenosis, inhibition of atherosclerosis, inhibition of angiogenesis, inhibition of diabetic retinopathy, inhibition of macular degeneration, inhibition of inflammation or inhibition of tumor growth.
  • the ⁇ v ⁇ 3 antagonizing effect is inhibition of bone resorption.
  • the vitronectin antagonizing effect is an ⁇ v ⁇ 5 antagonizing effect or a dual ⁇ v ⁇ 3/ocv ⁇ 5 antagonizing effect.
  • ⁇ v ⁇ 5 antagonizing effects are inhibition of: restenosis, atherosclerosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation or tumor growth.
  • dual ⁇ v ⁇ 3/ ⁇ v ⁇ 5 antagonizing effects are inhibition of: bone resorption, restenosis, atherosclerosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation or tumor growth.
  • Additional examples of the invention are methods of inhibiting bone resorption and of treating and/or preventing osteoporosis in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions decribed above.
  • compositions described above further comprising a therapeutically effective amount of a second bone reso ⁇ tion inhibitor; preferably, the second bone reso ⁇ tion inhibitor is alendronate.
  • More particularly illustrating the invention is any of the methods of treating and/or preventing osteoporosis and/or of inhibiting bone resoption described above, wherein the compound is administered in combination with a second bone reso ⁇ tion inhibitor; preferably, the second bone reso ⁇ tion inhibitor is alendronate.
  • Additional illustrations of the invention are methods of treating hypercalcemia of malignancy, osteopenia due to bone metastases, periodontal disease, hype ⁇ arathyroidism, periarticular erosions in rheumatoid arthritis, Paget's disease, immobilization-induced osteopenia, and glucocorticoid treatment in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above. More particularly exemplifying the invention is the use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of osteoporosis in a mammal in need thereof.
  • Still further exemplifying the invention is the use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of: bone reso ⁇ tion, tumor growth, cancer, restenosis, atherosclerosis, diabetic retinopathy, macular degeneration, inflammation and/or angiogenesis.
  • Additional illustrations of the invention are methods of treating tumor growth in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound described above and one or more agents known to be cy to toxic or antiproliferative, e.g., taxol and doxorubicin.
  • Representative compounds of the present invention are integrin antagonists which display submicromolar affinity for the human v ⁇ 3 receptor. Compounds of this invention are therefore useful for treating mammals suffering from a bone condition caused or mediated by increased bone reso ⁇ tion, who are in need of such therapy.
  • Pharmacologically effective amounts of the compounds, including pharamaceutically acceptable salts thereof, are administered to the mammal, to inhibit the activity of mammalian osteoclasts.
  • the compounds of the present invention are administered in dosages effective to antagonize the ⁇ v ⁇ 3 receptor where such treatment is needed, as, for example, in the prevention or treatment of osteoporosis.
  • salts of the compounds of this invention refer to non-toxic “pharmaceutically acceptable salts.”
  • Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts.
  • Salts encompassed within the term "pharmaceutically acceptable salts” refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts include the following:
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.
  • the compounds of the present invention may have chiral centers and occur as racemates, racemic mixtures, diastereomeric mixtures, and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. Therefore, where a compound is chiral, the separate enantiomers, substantially free of the other, are included within the scope of the invention; further included are all mixtures of the two enantiomers. Also included within the scope of the invention are polymo ⁇ hs and hydrates of the compounds of the instant invention.
  • the present invention includes within its scope prodrugs of the compounds of this invention.
  • prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound.
  • the term “administering” shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985. Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu.
  • terapéuticaally effective amount shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician.
  • vitronectin receptor antagonist refers to a compound which binds to and antagonizes either the ⁇ v ⁇ 3 receptor or the v ⁇ 5 receptor, or a compound which binds to and antagonizes both the ocv ⁇ 3 and ⁇ v ⁇ 5 receptors (i.e., a dual ⁇ v ⁇ 3/ ⁇ v ⁇ 5 receptor antagonist).
  • bone reso ⁇ tion refers to the process by which osteoclasts degrade bone.
  • alkyl shall mean straight or branched chain alkanes of one to ten total carbon atoms, or any number within this range (i.e., methyl, ethyl, 1-propyl, 2-propyl, n-butyl, s-butyl, t-butyl, etc.).
  • alkenyl shall mean straight or branched chain alkenes of two to ten total carbon atoms, or any number within this range.
  • alkynyl shall mean straight or branched chain alkynes of two to ten total carbon atoms, or any number within this range.
  • cycloalkyl shall mean cyclic rings of alkanes of three to eight total carbon atoms, or any number within this range (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl).
  • cycloheteroalkyl shall mean a 3- to 8-membered fully saturated heterocyclic ring containing one or two heteroatoms chosen from N, O or S.
  • cycloheteroalkyl groups include, but are not limited to piperidinyl, pyrrolidinyl, azetidinyl, mo ⁇ holinyl, piperazinyl.
  • alkoxy refers to straight or branched chain alkoxides of the number of carbon atoms specified (e.g., Cl-5 alkoxy), or any number within this range (i.e., methoxy, ethoxy, etc.).
  • aryl refers to a monocyclic or polycyclic system composed of 5- and 6-membered fully unsaturated or partially unsaturated rings, such that the system comprises at least one fully unsaturated ring, wherein the rings contain 0, 1 , 2, 3 or 4 heteroatoms chosen from N, O or S, and either unsubstituted or substituted with one or more groups independently selected from hydrogen, halogen, Cl-10 alkyl, C3- cycloalkyl, aryl, aryl Cl -8 alkyl, amino, amino Cl -8 alkyl, Cl-3 acylamino, Cl -3 acylamino Cl -8 alkyl, Cl -6 alkylamino, C] -6 alkylamino Cl -8 alkyl, Cl-6 dialkylamino, Cl-6 dialkylamino-Ci-8 alkyl, Cl-4 alkoxy, Cl -4 alkoxy Cl -6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl-6 alkyl, Cl
  • aryl examples include, but are not limited to, phenyl, naphthyl, pyridyl, pyrazinyl, pyrimidinyl, imidazolyl, benzimidazolyl, indolyl, thienyl, furyl, dihydrobenzofuryl, benzo(l,3) dioxolane, oxazolyl, isoxazolyl and thiazolyl, which are either unsubstituted or substituted with one or more groups independently selected from hydrogen, halogen, Cl -10 alkyl, C3-8 cycloalkyl, aryl, aryl Cl -8 alkyl, amino, amino Cl-8 alkyl, Cl-3 acylamino, Cl -3 acylamino Cl-8 alkyl, Cl-6 alkylamino, Cl-6 alkylamino-Cl-8 alkyl, Cl -6 dialkylamino, Cl-6 dialkylamino Cl-8 alkyl, Cl-4 alkoxy, Cl-4
  • the aryl group is unsubstituted, mono-, di-, tri- or tetra-substituted with one to four of the above-named substituents; more preferably, the aryl group is unsubstituted, mono-, di- or tri-substituted with one to three of the above-named substituents; most preferably, the aryl group is unsubstituted, mono- or di-substituted with one to two of the above-named substituents.
  • alkyl or aryl or either of their prefix roots appear in a name of a substituent (e.g., aryl Q)-8 alkyl) it shall be inte ⁇ reted as including those limitations given above for "alkyl” and "aryl.”
  • Designated numbers of carbon atoms e.g., Cl-10 shall refer independently to the number of carbon atoms in an alkyl or cyclic alkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.
  • arylalkyl and “alkylaryl” include an alkyl portion where alkyl is as defined above and to include an aryl portion where aryl is as defined above.
  • arylalkyl include, but are not limited to, benzyl, fluorobenzyl, chlorobenzyl, phenylethyl, phenylpropyl, fluorophenylethyl, chlorophenylethyl, thienylmethyl, thienylethyl, and thienylpropyl.
  • alkylaryl include, but are not limited to, toluene, ethylbenzene, propylbenzene, methylpyridine, ethylpyridine, propylpyridine and butylpyridine.
  • R 1 , R 2 , R 3 , R 4 , R5, R6, R7, R8, R9, R!0, Rl 1 , Rl , Rl3 or R* 4 includes the definition Co (e.g., aryl C ⁇ -8 alkyl), the group modified by Co is not present in the substituent.
  • the group modified by the variable is not present; for example, when s is zero, the group "-(CH2)s C ⁇ CH” is "-C ⁇ CH".
  • the Cl-6 alkyl groups can be the same (e.g., dimethylamino) or different (e.g., N(CH3)(CH2CH3)).
  • halogen shall include iodine, bromine, chlorine and fluorine.
  • oxy means an oxygen (O) atom.
  • thio means a sulfur (S) atom.
  • substituted shall be deemed to include multiple degrees of substitution by a named substitutent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the (two or more) substituents can be the same or different. Under standard nonmenclature used throughout this disclosure, the terminal portion of the designated side chain is described first, followed by the adjacent functionality toward the point of attachment. For example, a Cl -5 alkylcarbonylamino Cl-6 alkyl substituent is equivalent to
  • the present invention is also directed to combinations of the compounds of the present invention with one or more agents useful in the prevention or treatment of osteoporosis.
  • the compounds of the instant invention may be effectively administered in combination with effective amounts of other agents used in the treatment of osteoporosis such as bisphosphonate bone reso ⁇ tion inhibitors; preferably, the bone reso ⁇ tion inhibitor is the bisphosphonate alendronate, now sold as FOSAMAX®.
  • Preferred combinations are simultaneous or alternating treatments of an ⁇ v ⁇ 3 receptor antagonist of the present invention and FOSAMAX®.
  • the integrin ( ⁇ v ⁇ 3) antagonist compounds of the present invention may be effectively administered in combination with a growth hormone secretagogue in the therapeutic or prophylactic treatment of disorders in calcium or phosphate metabolism and associated diseases.
  • diseases include conditions which can benefit from a reduction in bone reso ⁇ tion.
  • a reduction in bone reso ⁇ tion should improve the balance between reso ⁇ tion and formation, reduce bone loss or result in bone augmentation.
  • a reduction in bone reso ⁇ tion can alleviate the pain associated with osteolytic lesions and reduce the incidence and/or growth of those lesions.
  • osteoporosis including estrogen deficiency, immobilization, glucocorticoid induced and senile
  • osteodystrophy Paget's disease
  • myositis ossificans Bechterew's disease
  • malignant hypercalcemia metastatic bone disease
  • metastatic bone disease periodontal disease
  • cholelithiasis nephrolithiasis
  • urolithiasis urolithiasis
  • urinary calculus hardening of the arteries (sclerosis), arthritis, bursitis, neuritis and tetany.
  • Increased bone reso ⁇ tion can be accompanied by pathologically high calcium and phosphate concentrations in the plasma, which would be alleviated by this treatment.
  • the present invention would be useful in increasing bone mass in patients with growth hormone deficiency.
  • preferred combinations are simultaneous or alternating treatments of an v ⁇ 3 receptor antagonist of the present invention and a growth hormone secretagogue, optionally including a third component comprising FOSAMAX®.
  • vitronectin receptor antagonist compounds of the present invention may be effectively administered in combination with one or more agents known to be cytoxic or antiproliferative, e.g, taxol and doxorubicin.
  • the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
  • the instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be inte ⁇ reted accordingly. It will be understood that the scope of combinations of the compounds of this invention with other agents useful for treating ocv ⁇ 3 related conditions includes in principle any combination with any pharmaceutical composition useful for treating osteoporosis.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • the compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, topical (e.g., ocular eyedrop), subcutaneous, intramuscular or transdermal (e.g., patch) form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an v ⁇ 3 inhibitor.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed.
  • An ordinarily skilled physician, veterinarian or clinician can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Oral dosages of the present invention when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, preferably 0.01 to 10 mg/kg/day, and most preferably 0.1 to 5.0 mg/kg/day.
  • the compositions are preferably provided in the form of tablets containing 0.01 , 0.05, 0.1 , 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably, from about 1 mg to about 100 mg of active ingredient.
  • the most preferred doses will range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion.
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
  • preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art.
  • the dosage administration will, of course, be continuous rather than intermittant throughout the dosage regimen.
  • the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as 'carrier' materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
  • suitable pharmaceutical diluents, excipients or carriers collectively referred to herein as 'carrier' materials
  • the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • suitable binders, lubricants, disintegrating agents and coloring agents can also be inco ⁇ orated into the mixture.
  • Suitable binders include starch, gelatin, natural sugars such as glucose or beta- lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • the compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcho lines.
  • Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxy- ethylaspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
  • the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polyactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
  • a drug for example, polylactic acid, polyglycolic acid, copolymers of polyactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
  • novel compounds of the present invention were prepared according to the procedure of the following schemes and examples, using appropriate materials and are further exemplified by the following specific examples.
  • the most preferred compounds of the invention are any or all of those specifically set forth in these examples. These compounds are not, however, to be construed as forming the only genus that is considered as the invention, and any combination of the compounds or their moieties may itself form a genus.
  • the following examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless otherwise noted.
  • the following Schemes and Examples describe procedures for making representative compounds of the present invention.
  • the iodide hi (2.4 g, 10 mmol) (J. Org. Chem., 1983, 48, 5381) was added to the orange solution and the resulting solution stirred for 2 h at -78°C, 3 h at -15°C and then 16 h at ambient temperature.
  • the reaction mixture was concentrated and then treated with IN HC1 (30 mL). The mixture was then basified with IN
  • TLC RF 0.74 (silica, 70:15:15 CHCl3/EtOAc/CH3 ⁇ H); - I l l -
  • TLC RF 0.71 (silica, 70:15:15 CHCI3/E1OAC/CH3OH);
  • TLC RF 0.71 (silica, 70:15:15 CHCl3/EtOAc/CH3 ⁇ H);
  • Analytical and preparative HPLC was carried out using a Waters 600E Powerline Multi Solvent Delivery System with 0.1 mL heads with a Rheodyne 7125 injector and a Waters 990 Photodiode Array Detector with a Gilson FC203 Microfraction collector.
  • analytical and preparative HPLC a Vydac peptide-protein C-18 column, 4.6 x 250 mm was used with a C-18 Brownlee modular guard column.
  • the acetonitrile used for the HPLC analyses was Fisher Optima grade.
  • the HPLC radiodetector used was a Beckman 170 Radioisotope detector.

Abstract

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are αvβ3 antagonists, αvβ5 antagonists or dual αvβ3/αvβ5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.

Description

TITLE OF THE INVENTION INTEGRIN ANTAGONISTS
FIELD OF THE INVENTION The present invention is related to U.S. provisional applications Serial Nos. 60/047,177, filed May 20, 1997, 60/033,579, filed December 19, 1996, and 60/025,123, filed August 29, 1996, the contents of which are hereby incorporated by reference.
The present invention provides novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor ligands. More particularly, the compounds of the present invention are αvβ3 antagonists, vβ5 antagonists or dual αvβ3/αvβ5 antagonists useful for inhibiting bone resoφtion, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
BACKGROUND OF THE INVENTION
This invention relates to compounds for inhibiting bone resorption that is mediated by the action of a class of cells known as osteoclasts.
Osteoclasts are multinucleated cells of up to 400 μm in diameter that resorb mineralized tissue, chiefly calcium carbonate and calcium phosphate, in vertebrates. They are actively motile cells that migrate along the surface of bone. They can bind to bone, secrete necessary acids and proteases and thereby cause the actual resoφtion of mineralized tissue from the bone.
More specifically, osteoclasts are believed to exist in at least two physiological states. In the secretory state, osteoclasts are flat, attach to the bone matrix via a tight attachment zone (sealing zone), become highly polarized, form a ruffled border, and secrete lysosomal enzymes and protons to resorb bone. The adhesion of osteoclasts to bone surfaces is an important initial step in bone resoφtion. In the migratory or motile state, the osteoclasts migrate across bone matrix and do not take part in resoφtion until they attach again to bone.
Integrins are transmembrane, heterodimeric, glycoproteins which interact with extracellular matrix and are involved in osteoclast attachment, activation and migration. The most abundant integrin in osteoclasts (rat, chicken, mouse and human) is the vitronectin receptor, or txvβ3, thought to interact in bone with matrix proteins that contain the RGD sequence. Antibodies to αvβ3 block bone resoφtion in vitro indicating that this integrin plays a key role in the resoφtive process. There is increasing evidence to suggest that vβ3 ligands can be used effectively to inhibit osteoclast mediated bone resoption in vivo in mammals.
The current major bone diseases of public concern are osteoporosis, hypercalcemia of malignancy, osteopenia due to bone metastases, periodontal disease, hypeφarathyroidism, periarticular erosions in rheumatoid arthritis, Paget's disease, immobilization-induced osteopenia, and glucocorticoid treatment.
All these conditions are characterized by bone loss, resulting from an imbalance between bone resoφtion (breakdown) and bone formation, which continues throughout life at the rate of about 14% per year on the average. However, the rate of bone turnover differs from site to site, for example, it is higher in the trabecular bone of the vertebrae and the alveolar bone in the jaws than in the cortices of the long bones. The potential for bone loss is directly related to turnover and can amount to over 5% per year in vertebrae immediately following menopause, a condition which leads to increased fracture risk.
There are currently 20 million people with detectable fractures of the vertebrae due to osteoporosis in the United States. In addition, there are 250,000 hip fractures per year attributed to osteoporosis. This clinical situation is associated with a 12% mortality rate within the first two years, while 30% of the patients require nursing home care after the fracture.
Individuals suffering from all the conditions listed above would benefit from treatment with agents which inhibit bone resoφtion. Additionally, αvβ3 ligands have been found to be useful in treating and/or inhibiting restenosis (recurrence of stenosis after corrective surgery on the heart valve), atherosclerosis, diabetic retinopathy, macular degeneration and angiogenesis (formation of new blood vessels). Moreover, it has been postulated that the growth of tumors depends on an adequate blood supply, which in turn is dependent on the growth of new vessels into the tumor; thus, inhibition of angiogenesis can cause tumor regression in animal models. (See, Harrison's Principles of Internal Medicine. 12th ed., 1991). αvβ3 antagonists, which inhibit angiogenesis, are therefore useful in the treatment of cancer for inhibiting tumor growth. (See e.g., Brooks et al., CV7, 79:1157-1164 (1994)).
Moreover, compounds of this invention can also inhibit neovascularization by acting as antagonists of the integrin receptor αvβ5. A monoclonal antibody for αvβ5 has been shown to inhibit VEGF-induced angiogenesis in rabbit cornea and the chick chorioallantoic membrane model; M.C. Friedlander, et.al., Science 270, 1500-1502, 1995. Thus, compounds that antagonize αvβ5 are useful for treating and preventing macular degeneration, diabetic retinopathy, and tumor growth.
In addition, certain compounds of this invention antagonize both the vβ3 and αvβ5 receptors. These compounds, referred to as "dual αvβ3/ vβ5 antagonists," are useful for inhibiting bone resoφtion, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation and tumor growth.
It is an object of the present invention to identify compounds which bind to the αvβ3 receptor, vβ5 receptor or both the αvβ3 and vβ5 receptors. It is a further object of the invention to identify compounds which act as antagonists of the αvβ3 receptor. It is another object of the invention to identify αvβ3 antagonist compounds which are useful agents for inhibiting: bone resoφtion mediated by osteoclast cells, restenosis, atherosclerosis, inflammation, diabetic retinopathy, macular degeneration and angiogenesis in animals, preferably mammals, especially humans. Still another object of the invention is to identify αvβ3 antagonists which cause tumor regression and/or inhibit tumor growth in animals. A further object of the invention is to identify αvβ3 antagonists useful for preventing or treating osteoporosis. An additional object of the invention is to identify αvβ3 antagonists useful for treating cancer.
It has now been found that the compounds of the present invention, vβ3 ligands, are useful for inhibiting bone resoφtion in mammals. Thus, the compounds of the present invention are useful for preventing or reducing the incidence of osteoporosis. Additionally, the αvβ3 ligands of the present invention are also useful for treating and/or inhibiting restenosis, diabetic retinopathy, macular degeneration, atherosclerosis and/or angiogenesis in mammals.
SUMMARY OF THE INVENTION
The present invention provides a method of eliciting a vitronectin receptor antagonizing effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound of the formula
Figure imgf000006_0001
wherein X is selected from
N' R 1 NR2
-C-NR1R2 — NR^C- NRΪ R2
a 5- or 6-membered monocyclic aromatic or nonaromatic ring system containing 0, 1 , 2, 3 or 4 heteroatoms selected from N, O or S wherein the 5- or 6-membered ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups chosen from R1 , R^, Rl5 0r R 6;
a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1 , 2, 3 or 4 heteroatoms selected from N, O or S, and wherein the polycyclic ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups chosen from Rl , R^, Rl5 or R^6;
Y is selected from
R O
-(CH^-N-fCH;,)— , — (CH2)r-C-(CH2)^
Figure imgf000007_0001
■(CH2)^S(0)2-N-(CH2)- , (CH2)Γ-N— S(0)2- (CH2)-
R^ R3
— (CH^-SCOJq-CCH^ , — (CH2) O-(CH2)^ or - (CH2)-;
Z is a 5-1 1 membered aromatic or nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups independently selected from R4, R5? R6 and R7; provided that Z is not a 6-membered monocyclic aromatic ring system, an isoxazoline ring or an isoxazole ring; Rl , R2, R4, R5? R 13, R 14? R 15 and Rl6 are each independently selected from hydrogen, halogen, Cl -io alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, C3-8 cycloalkyl Cl-6 alkyl, C3-8 cycloheteroalkyl Cl-6 alkyl, aryl, aryl Cl -8 alkyl, amino, amino Cl -8 alkyl, Cl-3 acylamino, Cl-3 acylamino Cl -8 alkyl, (Cl-6 alky qamino, (Cl -6 alkyl)qamino Cl-8 alkyl, Cl-4 alkoxy, Cl-4 alkoxy Cl -6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl-6 alkyl, Cl-3 alkoxy carbonyl, Cl-3 alkoxycarbonyl Cl -6 alkyl, hydroxy carbonyl -
Cl-6 alkyloxy, hydroxy, hydroxy Cl -6 alkyl, Cl-6 alkyloxy- Cl -6 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, Cl -8 alkyl-S(0)q, (Cl -8 alkyOqaminocarbonyl, Cl -8 alkyloxycarbonylamino, (Cl -8 alkyl)qaminocarbonyloxy, oxo, (aryl Cl -8 alkyl)qamino, (aryl)qamino, aryl Cl-8 alkylsulfonylamino or Cl -8 alkylsulfonylamino;
R3 is selected from hydrogen, aryl, aryl-(CH2)p-, hydroxyl,
Ci-5 alkoxy, aminocarbonyl, C3-8 cycloalkyl, amino Cl -6 alkyl,
(aryl)qaminocarbonyl,
(aryl Cl-5 alkyOqaminocarbonyl, hydroxycarbonyl Cl -6 alkyl, Cl-8 alkyl, aryl Cl-6 alkyl,
(Cl-6 alkyl )qamino Cl-6 alkyl,
(aryl Cl-6 alkyOqamino Cl -6 alkyl,
Cl -8 alkylsulfonyl, Cl -8 alkoxycarbonyl, aryloxy carbonyl, aryl Cl-8 alkoxycarbonyl,
Cl-8 alkylcarbonyl, arylcarbonyl, aryl Cl-6 alkylcarbonyl,
(Cl -8 alkyOqaminocarbonyl, aminosulfonyl,
Cl- alkylaminosulfonyl, (aryl)qaminosulfonylamino,
(aryl Cl-8 alkyOqaminosulfonyl,
Cl-6 alkylsulfonyl, arylsulfonyl, aryl Cl -6 alkylsulfonyl, aryl Cl-6 alkylcarbonyl,
Cl-6 alkylthiocarbonyl, arylthiocarbonyl, or aryl Cl-6 alkylthiocarbonyl, wherein any of the alkyl groups may be unsubstituted or substituted with Rl3 and Rl4;
R6> R7, R8? R9? R IO and Rl 1 are each independently selected from hydrogen, aryl, aryl-(CH2)p-, aryl-(CH2)n-0-(CH2)m-, aryl-(CH2)n-S(0)q-(CH2)m-, aryl-(CH2)n-C(0)-(CH2)m-, aryl-(CH2)n-C(0)-N(R3)-(CH2)m-, aryl-(CH2)n-N(R3)-C(0)-(CH2)m-, aryl-(CH2)n-N(R3)-(CH2)m-, halogen, hydroxyl,
Cl-8 alkylcarbonylamino, aryl Cl -5 alkoxy, Cl-5 alkoxycarbonyl, (Cl-8 alkyOqaminocarbonyl, Cl-6 alkylcarbonyloxy, C3-8 cycloalkyl, oxo,
(Cl -6 alkyOqamino, amino Cl -6 alkyl, arylaminocarbonyl, aryl Cl -5 alky laminocarbonyl, aminocarbonyl, aminocarbonyl Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl -6 alkyl, Cl-8 alkyl, either unsubstituted or substituted, with one or more groups selected from: halogen, hydroxyl, Cl-5 alkylcarbonylamino, aryl Cl-5 alkoxy, Cl-5 alkoxycarbonyl, aminocarbonyl, (Cl -5 alkyOqaminocarbonyl, Cl-5 alkylcarbonyloxy, C3-8 cycloalkyl, oxo, (Cl -3 alkyOqamino, amino Cl -3 alkyl,
(aryOqaminocarbonyl, (aryl Cl -5 alkyOqaminocarbonyl, aminocarbonyl, aminocarbonyl Cl -4 alkyl, hydroxycarbonyl or hydroxycarbonyl Cl -5 alkyl, CH≡C-(CH2)s-, Cl-6 alkyl-C≡C-(CH2)s-,
C3-7 cycloalkyl-C≡C-(CH2)s-, aryl-C≡C-(CH2)s-, Cl -6 alkylaryl-C≡C-(CH2)s-, CH2=CH-(CH2)s-, Cl-6 alkyl-CH=CH-(CH2)s-,
C3-7 cycloalkyl-CH=CH-(CH2)s-, aryl-CH=CH-(CH2)s-,
Cl-6 alkylaryl-CH=CH-(CH2)s-,
Cl-6 alky l-Sθ2-(CH2)s-, Cl -6 alkylaryl-S02-(CH2)s-,
Cl-6 alkoxy, aryl Cl-6 alkoxy, aryl Cl-6 alkyl, (Cl -6 alkyOqamino Cl -6 alkyl,
(aryl)qamino,
(aryl)qamino Cl-6 alkyl,
(aryl Cl-6 alkyOqamino,
(aryl Cl -6 alkyOqamino Cl -6 alkyl, arylcarbonyloxy, aryl Cl-6 alkylcarbonyloxy,
(Cl-6 alkyOqaminocarbonyloxy,
Cl -8 alkylsulfonylamino, arylsulfonylamino, Cl -8 alkylsulfonylamino Cl -6 alkyl, arylsulfonylamino Cl-6 alkyl, aryl Cl-6 alkylsulfonylamino, aryl Cl-6 alkylsulfonylamino Cl-6 alkyl,
Cl -8 alkoxycarbonylamino, Cl -8 alkoxycarbonylamino Cl-8 alkyl, aryloxycarbonylamino Cl-8 alkyl, aryl Cl-8 alkoxycarbonylamino, aryl Cl-8 alkoxycarbonylamino Cl-8 alkyl,
Cl -8 alkylcarbonylamino, Cl-8 alkylcarbonylamino Cl-6 alkyl, arylcarbonylamino Cl-6 alkyl, aryl Cl-6 alkylcarbonylamino, aryl Cl-6 alkylcarbonylamino Cl-6 alkyl, aminocarbonylamino Cl-6 alkyl, (C 1 -8 alkyOqaminocarbonylamino,
(Cl-8 alkyOqaminocarbonylamino Cl-6 alkyl,
(aryOqaminocarbonylamino Cl-6 alkyl,
(aryl Cl-8 alkyOqaminocarbonylamino,
(aryl Cl-8 alkyOqaminocarbonylamino Cl -6 alkyl, aminosulfonylamino Cl-6 alkyl,
(Cl-8 alkyOqaminosulfonylamino,
(Cl-8 alkyOqaminosulfonylamino Cl -6 alkyl,
(aryl)qaminosulfonylamino Cl-6 alkyl, (aryl Cl-8 alkyOqaminosulfonylamino,
(aryl Cl -8 alkyOqaminosulfonylamino Cl -6 alkyl,
Cl-6 alkylsulfonyl,
Cl-6 alkylsulfonyl Cl-6 alkyl, arylsulfonyl Cl-6 alkyl, aryl Cl -6 alkylsulfonyl, aryl Cl-6 alkylsulfonyl Cl-6 alkyl,
Cl-6 alkylcarbonyl,
Cl-6 alkylcarbonyl Cl -6 alkyl, arylcarbonyl Cl-6 alkyl, aryl Cl-6 alkylcarbonyl, aryl Cl-6 alkylcarbonyl Cl -6 alkyl,
Cl -6 alkylthiocarbonylamino,
Cl -6 alkylthiocarbonylamino Cl-6 alkyl, arylthiocarbonylamino Cl-6 alkyl, aryl Cl -6 alkylthiocarbonylamino, aryl Cl -6 alkylthiocarbonylamino Cl -6 alkyl,
(Cl -8 alkyOqaminocarbonyl Cl -6 alkyl,
(aryOqaminocarbonyl Cl -6 alkyl,
(aryl Cl-8 alkyOqaminocarbonyl, or (aryl Cl-8 alkyOqaminocarbonyl Cl-6 alkyl, wherein any of the alkyl groups may be unsubstituted or substituted with R l3 and Rl4; and provided that the carbon atom to which R& and R^ are attached is itself attached to no more than one heteroatom; and provided further that the carbon atom to which RlO and R* 1 are attached is itself attached to no more than one heteroatom;
Rl2 is selected from hydrogen, Cl-8 alkyl, aryl, aryl Cl-8 alkyl,
Cl-8 alkylcarbonyloxy Cl -4 alkyl, aryl Cl-8 alkylcarbonyloxy Cl -4 alkyl, Cl-8 alkylaminocarbonylmethylene, or
Cl -8 dialkylaminocarbonylmethylene;
m, s and t are each independently an integer from 0 to 3; n is an integer from 1 to 3; p is an integer from 1 to 4; q is an integer from 0 to 2; r is an integer from 0 to 6; and the pharmaceutically acceptable salts thereof.
In one embodiment of the present invention is the method of eliciting a vitronectin antagonizing effect wherein X is a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1 , 2, 3 or 4 heteroatoms selected from N, O or S, and wherein the polycyclic ring system is either unsubstituted or substituted on a carbon atom with R and R^; and
Z is selected from
Figure imgf000014_0001
Figure imgf000014_0002
Figure imgf000015_0001
and all other variables are as defined above; and the pharmaceutically acceptable salts thereof. Preferably, Z is selected from
Figure imgf000015_0002
Figure imgf000016_0001
In a class of the invention is the method of eliciting a vitronectin antagonizing effect wherein the compound has the formula
Figure imgf000016_0002
wherein X is selected from
Figure imgf000017_0001
Y is selected from -(CH2)r or -(CH2)m-NR3-(CH2)t-; R is selected from hydrogen, aryl-(CH2)p-,
Cl-5 alkoxycarbonyl,
C3-8 cycloalkyl,
(aryl)qaminocarbonyl,
(aryl Cl-5 alkyOqaminocarbonyl, Cl-8 alkyl, aryl Cl-6 alkyl,
Cl -8 alkylsulfonyl, arylsulfonyl, aryl Cl -6 alkylsulfonyl, Cl-8 alkoxycarbonyl, aryloxycarbonyl, aryl Cl -8 alkoxycarbonyl,
Cl-8 alkylcarbonyl, arylcarbonyl, aryl Cl-6 alkylcarbonyl,
(Cl -8 alkyOqaminocarbonyl,
Cl -6 alkylsulfonyl, or aryl Cl -6 alkylcarbonyl, wherein any of the alkyl groups may be unsubstituted or substituted with R 13 and R14;
R4 is selected from hydrogen, Cl-6 alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, C3-8 cycloalkyl Cl-6 alkyl, C3-8 cycloheteroalkyl Cl-6 alkyl, aryl or aryl Cl -8 alkyl, R^ is selected from hydrogen, aryl, aryl-(CH2)p-,
CH≡C-(CH2)s-,
Ci-6 alkyl-C≡C-(CH2)s-,
C3-7 cycloalkyl-C≡C-(CH2)s-, aryl-C≡C-(CH2)s-, Cl -6 alkylaryl-C≡C-(CH2)s-,
CH2=CH-(CH2)s-,
Cl-6 alkyl-CH=CH-(CH2)s-,
C3.7 cycloalkyl-CH=CH-(CH2)s-, aryl-CH=CH-(CH2)s-, Cl-6 alkylaryl-CH=CH-(CH2)s-,
Cl-6 alkyl-S02-(CH2)s-,
Cl-6 alkylaryl-S02-(CH2)s-; and
r is an integer from 0 to 3; and all other variables are as defined above; and the pharmaceutically acceptable salts thereof.
In a subclass of the invention is the method wherein the compound has the formula
Figure imgf000018_0001
wherein Z is selected from
Figure imgf000019_0001
R^ is selected from hydrogen,
Figure imgf000019_0002
indolyl-(CH2)p-,
CH≡C-(CH2)s-,
Cl-6 alkyl-C≡C-(CH2)s-,
C3-7 cycloalkyl-C≡C-(CH2)s-, aryl-C≡C-(CH2)s-,
Cl -6 alkylaryl-C≡C-(CH2)s-,
CH2=CH-(CH2)s-,
Cl-6 alkyl-CH=CH-(CH2)s-,
C3-7 cycloalkyl-CH=CH-(CH2)s-, aryl-CH=CH-(CH2)s-,
Cl-6 alkylaryl-CH=CH-(CH2)s-, Ci-6 alkyl-Sθ2-(CH2)s-,
Cl-6 alkylaryl-Sθ2-(CH2)s-; and
R l2 i selected from hydrogen or Cl -8 alkyl; s is an integer from 0 to 3; and all other variables are as defined above; and the pharmaceutically acceptable salts thereof.
Illustrative of the invention is the method of eliciting a vitronectin antagonizing effect wherein the compound is selected from
2-Oxo-3-f2-(5,6,7,8-tetrahydro[ l ,8J-naphthyridin-2-yl)ethyl]piperidin- l -yl-acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-3-f2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2-yl)ethyl]piperin- l -yl-acetyl-3(S)-pyridin-3-yl-β-alanine trifluoroacetate;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(S)-alkynyl-β-alanine ethyl ester;
2-Oxo-3(S)-r2-(5,6,7,8-tetrahydrof 1 ,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,81-naphthyridin-2-yl)ethyl]- pyrrolidin-l -yl)acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydroll ,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(S)-alkynyl-β-alanine ethyl ester;
2-Oxo-3(R)-l2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine; 2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[l ,81-naphthyridin-2-yl)ethyl]- pyrrolidin-l-yl)acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
Ethyl 2-oxo-3-[2-(5,6,7,8-tetrahydro[l ,8]naphmyridin-2-yl)ethyl]- tetrahydropyrimidin-l-yl-acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3-[2-(5,6,7,8-tetrahydro[l ,81naphthyridin-2-yl}ethyll- tetrahydropyrimidin-l-yl-acetyl-3(S)-pyridin-3-yl-β-alanine;
Ethyl 2-oxo-3-[2-(5,6,7,8-tetrahydro[l,8]naphthyridin-2- yl)ethylJimidazolidin-l-yl-acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3-l2-(5,6,7,8-tetrahydro[l ,8]naphthyridin-2-yl Jethyl]- imidazolidin-l -yl-acetyl-3(S)-pyridin-3-yl-β-alanine;
Ethyl 2-oxo-3(R)-[2-(5,6,7,8-tetrahydro[ 1 ,8]naphthyridin-2- y])ethyl]pyrrolidin-l-yl)acetyl-3(R)-(2-ethylindol-3-yl)-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[ 1 ,8]naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(R)-(2-ethylindol-3-yl)-β-alanine;
Ethyl 3-(2-{ 2-oxo-3(S)-[(5,6,7,8-tetrahydro-[l,8]naphthyridin-2- ylmethyl)-amino]-pyrrolidin-l -yl}-acetylamino)-3-(S)-pyridin-3-yl- propionic acid;
3-(2-{ 2-Oxo-3(S)-[(5,6,7,8-tetrahydro-[l ,81naphthyridin-2-ylmethy0- amino]pyrrolidin-l-yl }-acetylamino)-3-(S)-pyridin-3-yl-propionic acid;
3-{2-[6-Oxo-l-(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-ylmethyl)- hexahydro-(3aS, 6aS)pyrrolo[3,4-b]pyrrol-5-yl]-acetylamino}-3-(S)- pyridin-3-yl-propionic acid; 3- { 2-[6-Oxo-l -(5,6,7,8-tetrahydro-[ 1 ,8Jnaphthyridin-2-ylmethyl)- hexahydro-(3aR, 6aR)pyrrolol3,4-b]pyrrol-5-yl]-acetylamino ) -3(S)- pyridin-3-yl-propionic acid;
2-Oxo-5(R)-methyl-3(S)-[2-(5,6,7,8-tetrahydrofl ,8]-naphthyridin-2-y0- ethyl]pyrrolidin-l-yl)acetyl-3(S)-alkynyl-β-alanine ethyl ester;
2-Oxo-5(R)-methyl-3(S)-[2-(5,6,7,8-tetrahydrof l ,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-5(S)-benzyl-3(S)-[2-(5,6,7,8-tetrahydro| l ,8J-naphthyridin-2-y0- ethyl]pyrrolidin-l -yl)acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-5(S)-benzyl-3(S)-[2-(5,6,7,8-tetrahydro ,8]-naphthyridin-2- y l)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
5(R)-Methyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydrol l ,8]-naphthyridin-2- ylmethyl)-amino]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine ethyl ester;
5(R)-Methyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- ylmethyI)-amino]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine;
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2- { 2-oxo-3(S)-[2-(5,6,7,8- tetrahydro-[ 1 ,8]naphthyridin-2-yl)-ethyl]-pyrrolidin- 1 -yl } - acetylamino)-propionic acid ethyl ester; or
3(.SH2,3-Dihydro-benzofuran-6-y0-3-(2- {2-oxo-3(S)-[2-(5,6,7,8- tetrahydro-[l ,8]naphthyridin-2-y0-ethyl]-pyrrolidin-l -yl }- acetylamino)-propionic acid;
3-{2-(2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro-[l ,8Jnaphthyridin-2-yl)-ethyl]- pyrrolidin-l -yl)-acetylamino}-3(S)-quinolin-3-yl-propionic acid; 3-(2-(5(S)-Ethyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydro-[l,8]naphthyridin-2- yl)-ethyl]-pyrolidin-l -yl)-acetylamino)-3-(S)-quinolin-3-yl-propionic acid trifluoroacetate;
3-(2-{ 6-Methyl-2-oxo-3-[(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2- ylmethyl)-amino]-2H-pyridin-l -yl} -acetylamino)-3(S)-pyridin-3-yl- propionic acid bis trifluoroacetate; or
3-(2-{6-Methyl-2-oxo-3-[(5,6,7,8-tetrahydro-U,8]naρthyridin-2- ylmethy0-amino]-2H-pyridin-l-yl }-acetylamino)-3(S)-pyridin-3-yl- propionic acid ethyl ester;
and the pharmaceutically acceptable salts thereof. Preferably, the compound is selected from
2-Oxo-3-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2-yl)ethyl]piperin- 1 -yl-acetyl-3(S)-pyridin-3-yl-β-alanine trifluoroacetate;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[ 1 ,81-naphthyridin-2- y l)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- y l)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acety l-3(S)-alkynyl-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3-[2-(5,6,7,8-tetrahydro[ 1 ,8]naphthyridin-2-yl }ethyl]- imidazolidin- 1 -yl-acetyl-3-(S)-pyridin-3-yl-β-alanine; 2-Oxo-3-[2-(5,6,7,8-tetrahydrol 1 ,81naphthyridin-2-yl } ethyl] - tetrahydropyrimidin- 1 -yl-acetyl-3-(S)-pyridin-3-yl-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[ 1 ,81naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(R)-(2-ethylindol-3-yl)-β-alanine;
3-(2-{ 2-oxo-3(S)-l(5,6,7,8-tetrahydro-r i ,8]naphthyridin-2-ylmethy0- amino]pyrrolidin-l -yl }-acetylamino)-3-(S)-pyridin-3-yl-propionic acid;
3- { 2-[6-Oxo- 1 -(5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-ylmethyl)- hexahydro-(3aS, 6aS)pyrrolo[3,4-blpyrrol-5-yl]-acetylamino } -3-(S)- pyridin-3-yl-propionic acid;
3-{2-[6-Oxo-l -(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-ylmethy0- hexahydro-(3aR, 6aR)pyrrolo[3,4-b]pyrrol-5-yl]-acetylamino}-3-(S)- pyridin-3-yl-propionic acid;
2-Oxo-5(R)-methyl-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-5(S)-benzyl-3(S)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l -yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
5(R)-Methyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- ylmethyl)-amino]pyrrolidin-l -yl)acetyl-3(S)-alkynyl-β-alanine; or
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2- {2-oxo-3(S)-[2-(5,6,7,8- tetrahydro-[ l ,8]naphthyridin-2-yl)-ethyll-pyrrolidin-l-yl }- acetylamino)-propionic acid;
and the pharmaceutically acceptable salts thereof.
Exemplifying the invention is the method wherein the vitronectin receptor antagonizing effect is an αvβ3 antagonizing effect. An illustration of the invention is the method wherein the vβ3 antagonizing effect is selected from inhibition of: bone resoφtion, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation or tumor growth. Preferably, the cxvβ3 antagonizing effect is the inhibition of bone resoφtion. An example of the invention is the method wherein the vitronectin receptor antagonizing effect is an αvβ5 antagonizing effect. More specifically, the txvβ5 antagonizing effect is selected from inhibition of: restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation or tumor growth. Illustrating the invention is the method wherein the vitronectin receptor antagonizing effect is a dual αvβ3/αvβ5 antagonizing effect. More particularly, the dual αvβ3/αvβ5 antagonizing effect is selected from inhibition of: bone resoφtion, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation or tumor growth.
In a second embodiment of the present invention is a method of eliciting an αvβ3 antagonizing effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound of the formula
Figure imgf000025_0001
wherein X is selected from
Figure imgf000025_0002
a 5- or 6-membered monocyclic aromatic or nonaromatic ring system containing 0, 1 , 2, 3 or 4 heteroatoms selected from N, O or S wherein the 5- or 6-membered ring system is either unsubstituted or substituted on a carbon atom with Rl and R2, or a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1 , 2, 3 or 4 heteroatoms selected from N, O or S, and wherein the polycyclic ring system is either unsubstituted or substituted on a carbon atom with Rl and R2;
Y is selected from
Figure imgf000026_0001
(CH2)t-S(0)2-N-(CH2)^- , (CH2)-N— S(0)2-(CH2)-
R3 R3
— (CH2)t-S(0)q-(CH2)^ - — (CH2)r 0-(CH2)^ or - (CH2)r-;
Z is a 5-11 membered aromatic or nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups independently selected from R4, R5, R6 nd R^; provided that Z is not a 6-membered monocyclic aromatic ring system; preferably, Z is selected from
Figure imgf000026_0002
Figure imgf000027_0001
R1, R2, R3, R45 R5, R13 and R*4 are each independently selected from hydrogen, halogen, C] -10 alkyl, C3-8 cycloalkyl, aryl, aryl Cl -8 alkyl, amino, amino Cl-8 alkyl, Cl -3 acylamino, Cl -3 acylamino Cl -8 alkyl, Cl -6 alkylamino, Cl -6 alkylamino- Cl -8 alkyl, Cl-6 dialkylamino, Cl-6 dialkylamino Cl-8 alkyl, Cl-4 alkoxy, Cl-4 alkoxy Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl-6 alkyl, Cl -3 alkoxycarbonyl, Cl -3 alkoxycarbonyl Cl-6 alkyl, hydroxycarbonyl- Cl -6 alkyloxy, hydroxy or hydroxy Cl -6 alkyl;
R6, R , R8, R9, R IO and R1 ! are each independently selected from hydrogen, aryl,
-(CH2)p-aryl, halogen, hydroxy 1,
Cl -8 alkylcarbonylamino, aryl Cl-5 alkoxy,
Cl-5 alkoxycarbonyl, aminocarbonyl, Cl-8 alkylaminocarbonyl,
Cl-6 alkylcarbonyloxy,
C3-8 cycloalkyl, oxo, amino, Cl-6 alkylamino, amino Cl -6 alkyl, arylaminocarbonyl, aryl Cl-5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cl -6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl -6 alkyl,
Cl -8 alkyl, either unsubstituted or substituted, with one or more groups selected from: halogen, hydroxyl, Cl-5 alkylcarbonylamino, aryl Cl-5 alkoxy, Cl-5 alkoxycarbonyl, aminocarbonyl, Cl-5 alkylaminocarbonyl, Cl-5 alkylcarbonyloxy, C3-8 cycloalkyl, oxo, amino, Cl -3 alkylamino, amino Cl-3 alkyl, arylamino- carbonyl, aryl Cl-5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cl -4 alkyl, hydroxycarbonyl, or hydroxycarbonyl Cl-5 alkyl,
-(CH2)S OCH,
-(CH2)S C≡C-C 1 -6 alkyl, -(CH2)s C≡C-C3-7 cycloalkyl,
-(CH2)s C≡C-aryl,
-(CH2)s C≡C-Cl -6 alkylaryl,
-(CH2)s CH=CH2,
-(CH2)S CH=CH Cl-6 alkyl, -(CH2)s CH=CH-C3-7 cycloalkyl,
-(CH2)s CH=CH aryl,
-(CH2)s CH=CH Cl -6 alkylaryl,
-(CH2)S S02Cl-6 alkyl,
-(CH2)s SO2CI-6 alkylaryl, Cl-6 alkoxy, aryl Cl-6 alkoxy, aryl Cl-6 alkyl,
Cl-6 alkylamino Cl-6 alkyl, arylamino, arylamino Cl-6 alkyl, aryl Cl-6 alkylamino, aryl Cl -6 alkylamino Cl-6 alkyl, arylcarbonyloxy, aryl Cl-6 alkylcarbonyloxy, Cl -6 dialkylamino,
Cl -6 dialkylamino Cl-6 alkyl,
Cl-6 alkylaminocarbonyloxy,
Cl-8 alkylsulfonylamino,
Cl-8 alkylsulfonylamino Cl-6 alkyl, arylsulfonylamino Cl -6 alkyl, aryl Cι_6 alkylsulfonylamino, aryl Cl-6 alkylsulfonylamino Cl -6 alkyl,
Cl-8 alkoxycarbonylamino, Cl-8 alkoxycarbonylamino Cl-8 alkyl, aryloxycarbonylamino Cl -8 alkyl, aryl Cl -8 alkoxycarbonylamino, aryl Cl -8 alkoxycarbonylamino Cl -8 alkyl,
Cl -8 alkylcarbonylamino, Cl -8 alkylcarbonylamino Cl-6 alkyl, arylcarbonylamino C] -6 alkyl, aryl Cl-6 alkylcarbonylamino, aryl Cl-6 alkylcarbonylamino Cl-6 alkyl, aminocarbonylamino Cl-6 alkyl, Cl-8 alkylaminocarbonylammo,
Cl -8 alkylaminocarbonylammo Cl -6 alkyl, arylaminocarbonylamino Cl -6 alkyl, aryl Cl-8 alkylaminocarbonylamino, aryl Cl-8 alkylaminocarbonylamino Cl -6 alkyl, aminosulfonylamino Cl-6 alkyl,
Cl -8 alkylaminosulfonylammo,
Cl -8 alkylaminosulfonylammo Cl -6 alkyl, arylaminosulfonylamino Cl-6 alkyl, aryl Cl -8 alkylaminosulfonylammo, aryl Cl-8 alkylaminosulfonylamino Cl -6 alkyl,
Cl -6 alkylsulfonyl,
Cl -6 alkylsulfonyl Cl-6 alkyl, arylsulfonyl Cl-6 alkyl, aryl Cl-6 alkylsulfonyl, aryl Cl-6 alkylsulfonyl Cl-6 alkyl,
Cl-6 alkylcarbonyl,
Cl-6 alkylcarbonyl Cl -6 alkyl, arylcarbonyl Cl-6 alkyl, aryl Cl -6 alkylcarbonyl, aryl Cl-6 alkylcarbonyl Cl -6 alkyl,
Cl -6 alkylthiocarbonylamino,
Cl -6 alkylthiocarbonylamino Cl-6 alkyl, arylthiocarbonylamino Cl -6 alkyl, aryl Cl -6 alkylthiocarbonylamino, aryl Cl-6 alkylthiocarbonylamino Cl-6 alkyl,
Cl -8 alkylaminocarbonyl Cl-6 alkyl, arylaminocarbonyl Cl -6 alkyl, aryl Cl-8 alkylaminocarbonyl, or aryl Cl -8 alkylaminocarbonyl Cl -6 alkyl, wherein any of the alkyl groups may be unsubstituted or substituted with R l and R^4; and provided that the carbon atom to which R& and R9 are attached is itself attached to no more than one heteroatom; and provided further that the carbon atom to which RlO and R^ are attached is itself attached to no more than one heteroatom;
R 2 is selected from hydrogen,
Cl-8 alkyl, aryl, aryl Cl -8 alkyl, hydroxy,
Cl -8 alkoxy, aryloxy, aryl Cl-6 alkoxy,
Cl-8 alkylcarbonyloxy Cl -4 alkoxy, aryl Cl-8 alkylcarbonyloxy Cl -4 alkoxy,
Cl-8 alkylaminocarbonylmethyleneoxy, or
Cl -8 dialkylaminocarbonylmethyleneoxy;
m is an integer from 0 to 3; n is an integer from 1 to 3 p is an integer from 1 to 4 q is an integer from 0 to 2 r is an integer from 0 to 6; s is an integer from 0 to 3; and t is an integer from 0 to 3;
and the pharmaceutically acceptable salts thereof.
In a third embodiment of the invention is a method of eliciting an ctvβ3 antagonizing effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound of the formula
Figure imgf000032_0001
wherein X is selected from
NTR1 NR2
-C-NR1H2 — NRl-C-NR1R2
a 5- or 6-membered monocyclic aromatic or nonaromatic ring system containing 0, 1, 2, 3 or 4 heteroatoms selected from N, O or S wherein the 5- or 6-membered ring system is either unsubstituted or substituted on a carbon atom with R 1 and R2, or
a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1, 2, 3 or 4 heteroatoms selected from N, O or
S, and wherein the polycyclic ring system is either unsubstituted or substituted on a carbon atom with Rl and R2;
Y is selected from - (CH2)- ,
Figure imgf000033_0001
Figure imgf000033_0002
Z is a 5-1 1 membered aromatic or nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups independently selected from R4, R5, R6 and R7; provided that Z is not a 6-membered monocyclic aromatic ring system; preferably Z is selected from
Figure imgf000033_0003
Figure imgf000034_0001
Figure imgf000034_0002
Rl, R2, R4, R5, Rl3 and Rl4 are each independently selected from hydrogen, halogen, Ci-io alkyl, C3- cycloalkyl, aryl, aryl Cl -8 alkyl, amino, amino Cl- alkyl, Cl -3 acylamino, Cl-3 acylamino Cl-8 alkyl, Cl-6 alkylamino, Cl -6 alkylamino- Cl -8 alkyl, Cl-6 dialkylamino, Cl-6 dialkylamino Cl-8 alkyl, Ci-4 alkoxy, Cl-4 alkoxy Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl-6 alkyl, Cl-3 alkoxycarbonyl, Cl-3 alkoxycarbonyl Cl-6 alkyl, hydroxycarbonyl- Ci-6 alkyloxy, hydroxy, hydroxy Cl -6 alkyl, Cl-6 alkyloxy- Cl -6 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, Cl-8 alkyl-S(0)q, Cl-8 aminocarbonyl, Cl-8 dialkylaminocarbonyl, Cl-8 alkyloxycarbonylamino, Cl-8 alkylaminocarbonyloxy or Cl -8alkylsulfonylamino;
selected from hydrogen, aryl,
-(CH2)p-aryl, hydroxyl, Cl-5 alkoxycarbonyl, aminocarbonyl,
C3-8 cycloalkyl, amino Cl -6 alkyl, arylaminocarbonyl, aryl Cl -5 alkylaminocarbonyl, hydroxycarbonyl Cl -6 alkyl,
Cl-8 alkyl, aryl Cl_6 alkyl,
Cl -6 alkylamino Cl-6 alkyl, aryl Cl-6 alkylamino Cl-6 alkyl,
Cl-6 dialkylamino Cl-6 alkyl,
Cl-8 alkylsulfonyl,
Cl-8 alkoxycarbonyl, aryloxy carbonyl, aryl Cl -8 alkoxycarbonyl,
Cl-8 alkylcarbonyl, arylcarbonyl, aryl Cl -6 alkylcarbonyl,
Cl -8 alkylaminocarbonyl, aminosulfonyl,
Cl-8 alkylaminosulfonyl, arylaminosulfonylamino, aryl Cl-8 alkylaminosulfonyl, Cl-6 alkylsulfonyl, arylsulfonyl, aryl Cl-6 alkylsulfonyl, aryl Cl-6 alkylcarbonyl,
Cl-6 alkylthiocarbonyl, arylthiocarbonyl, or aryl Cl-6 alkylthiocarbonyl, wherein any of the alkyl groups may be unsubstituted or substituted with Rl and Rl4;
R6, R7, R8? R9? RIO ancj R1 1 are each independently selected from hydrogen, aryl,
-(CH2)p-aryl, halogen, hydroxyl,
Cl -8 alkylcarbonylamino, aryl Cl-5 alkoxy,
Cl-5 alkoxycarbonyl, aminocarbonyl, Cl-8 alkylaminocarbonyl,
Cl-6 alkylcarbonyloxy,
C3-8 cycloalkyl, oxo, amino, Cl-6 alkylamino, amino Cl-6 alkyl, arylamino carbonyl, aryl Cl-5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cl -6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl -6 alkyl,
Cl-8 alkyl, either unsubstituted or substituted, with one or more groups selected from: halogen, hydroxyl,
Cl-5 alkylcarbonylamino, aryl Cl-5 alkoxy, Cl-5 alkoxycarbonyl, aminocarbonyl, Cl-5 alkylaminocarbonyl, Cl-5 alkylcarbonyloxy, C3-8 cycloalkyl, oxo, amino, Cl -3 alkylamino, amino Cl-3 alkyl, arylamino- carbonyl, aryl Cl-5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cl -4 alkyl, hydroxycarbonyl, or hydroxycarbonyl Cl -5 alkyl,
-(CH2)s C≡CH,
-(CH2)s C≡C-C 1-6 alkyl, -(CH2)s G≡C-C3-7 cycloalkyl,
-(CH2)s C≡C-aryl,
-(CH2)s C≡C-Cl -6 alkylaryl,
-(CH2)s CH=CH2,
-(CH2)s CH=CH Cl-6 alkyl, -(CH2)s CH=CH-C3-7 cycloalkyl,
-(CH2)s CH=CH aryl,
-(CH2)s CH=CH Cl -6 alkylaryl,
-(CH2)s S02C 1-6 alkyl,
-(CH2)s S02Cl-6 alkylaryl, Ci-6 alkoxy, aryl Cl-6 alkoxy, aryl Cl-6 alkyl,
Cl-6 alkylamino Cl-6 alkyl, arylamino, arylamino Cl-6 alkyl, aryl Cl -6 alkylamino, aryl Cl -6 alkylamino Cl-6 alkyl, arylcarbonyloxy, aryl Cl-6 alkylcarbonyloxy, Cl-6 dialkylamino,
Cl-6 dialkylamino Cl-6 alkyl,
Cl-6 alkylaminocarbonyloxy,
Cl-8 alkylsulfonylamino, Cl-8 alkylsulfonylamino C l -6 alkyl, arylsulfonylamino Cl-6 alkyl, aryl Cl-6 alkylsulfonylamino, aryl Cl-6 alkylsulfonylamino Cl-6 alkyl,
Cl-8 alkoxycarbonylamino, Cl-8 alkoxycarbonylamino Cl-8 alkyl, aryloxycarbonylamino Cl-8 alkyl, aryl Cl-8 alkoxycarbonylamino, aryl Cl-8 alkoxycarbonylamino Cl-8 alkyl,
Cl-8 alkylcarbonylamino, Cl-8 alkylcarbonylamino Cl-6 alkyl, arylcarbonylamino Cl-6 alkyl, aryl Cl-6 alkylcarbonylamino, aryl Cl-6 alkylcarbonylamino Cl-6 alkyl, aminocarbonylamino Cl-6 alkyl, Cl-8 alkylaminocarbonylamino,
Cl-8 alkylaminocarbonylamino Cl-6 alkyl, arylaminocarbonylamino Cl-6 alkyl, aryl Cl-8 alkylaminocarbonylamino, aryl Cl-8 alkylaminocarbonylamino Cl-6 alkyl, aminosulfonylamino Cl-6 alkyl,
Cl-8 alkylaminosulfonylammo,
Cl-8 alkylammosulfonylammo Cl-6 alkyl, arylaminosulfonylamino Cl-6 alkyl, aryl Cl-8 alkylaminosulfonylammo, aryl Cl-8 alkylaminosulfonylammo Cl-6 alkyl,
Cl-6 alkylsulfonyl,
Cl-6 alkylsulfonyl Cl-6 alkyl, arylsulfonyl Cl-6 alkyl, aryl Cl-6 alkylsulfonyl, aryl Cl -6 alkylsulfonyl Cl-6 alkyl,
Cl-6 alkylcarbonyl,
Cl-6 alkylcarbonyl Cl -6 alkyl, arylcarbonyl Cl-6 alkyl, aryl Cl -6 alkylcarbonyl, aryl Cl-6 alkylcarbonyl Cl-6 alkyl,
Cl-6 alkylthiocarbonylamino,
Cl -6 alkylthiocarbonylamino Cl -6 alkyl, arylthiocarbonylamino Cl -6 alkyl, aryl Cl -6 alkylthiocarbonylamino, aryl Cl-6 alkylthiocarbonylamino Cl -6 alkyl,
Cl -8 alkylaminocarbonyl Cl-6 alkyl, arylaminocarbonyl Cl-6 alkyl, aryl Cl-8 alkylaminocarbonyl, or aryl Cl -8 alkylaminocarbonyl Cl-6 alkyl, wherein any of the alkyl groups may be unsubstituted or substituted with Rl3 and R^4; and provided that the carbon atom to which R& and R^ are attached is itself attached to no more than one heteroatom; and provided further that the carbon atom to which RΪO and R11 are attached is itself attached to no more than one heteroatom;
R 2 is selected from hydrogen,
Cl-8 alkyl, aryl, aryl Cl-8 alkyl, hydroxy,
Cl-8 alkoxy, aryloxy, aryl Cl -6 alkoxy,
Cl-8 alkylcarbonyloxy Cl -4 alkoxy, aryl Cl -8 alkylcarbonyloxy Cl-4 alkoxy,
Cl-8 alkylaminocarbonylmethyleneoxy, or
Cl-8 dialkylaminocarbonylmethyleneoxy; m is an integer from 0 to 3; n is an integer from 1 to 3; p is an integer from 1 to 4; q is an integer from 0 to 2; r is an integer from 0 to 6; and s is an integer from 0 to 3;
and the pharmaceutically acceptable salts thereof. Illustrating the invention is the method wherein the αvβ3 antagonizing effect is selected from inhibition of bone resoφtion, inhibition of restenosis, inhibition of angiogenesis, inhibition of diabetic retinopathy, inhibition of macular degeneration, inhibition of atherosclerosis, inflammation or inhibition of tumor growth. Preferably, the ocvβ3 antagonizing effect is the inhibition of bone resoφtion.
An illustration of the invention is a compound of the formula
Figure imgf000040_0001
wherein X is a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1, 2, 3 or 4 heteroatoms selected from N, O or S, and wherein the polycyclic ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups chosen from Rl , R2, R ! 5 or Rl6;
Y is selected from R^ O
I II
— (CH2)-N-(CH2) m (CH2)r-c-(CH2^ ,
o II o I I
■(CH2)—C-N- (CH2) m — (CH2)rN-C-(CH2)s- R3 R3
■ (CH2)-S(0)2-N- (CH2)- t (CH2) — S(0)2-(CH2);
R ,3 R3
— (CH2)-S(0)q-(CH2)^ , — (CH2) O-(CH2)^ or - (CH2)r-;
Z is a 5-11 membered aromatic or nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups independently selected from R4, R5, R6 and R7; provided that Z is not a 6-membered monocyclic aromatic ring system, an isoxazoline ring or an isoxazole ring;
R1 , R2, R4, R5, Rl3, R14? R15 and R!6 are each independently selected from hydrogen, halogen, Ci -10 alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, C3-8 cycloalkyl Cl -6 alkyl,
C3-8 cycloheteroalkyl Cl -6 alkyl, aryl, aryl Cl-8 alkyl, amino, amino Cl-8 alkyl, Cl-3 acylamino, Cl-3 acylamino Cl -8 alkyl, (Cl -6 alkyOqamino, (Cl-6 alkyOqamino Cl-8 alkyl, Cl-4 alkoxy, Cl-4 alkoxy Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl-6 alkyl, Cl -3 alkoxycarbonyl,
Cl-3 alkoxycarbonyl Cl -6 alkyl, hydroxycarbonyl- Cl-6 alkyloxy, hydroxy, hydroxy Cl-6 alkyl, Cl -6 alkyloxy- Cl -6 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, Cl -8 alkyl-S(0)q, (Cl -8 alkyOqaminocarbonyl, Cl-8 alkyloxycarbonylammo, (Cl -8 alkyOqaminocarbonyloxy, oxo, (aryl Cl -8 alkyOqamino, (aryl)qamino, aryl Cl-8 alkylslfonylamino or Cl-8 alkylsulfonylamino;
elected from hydrogen, aryl, aryl-(CH2)p-, hydroxyl,
Cl -5 alkoxy, aminocarbonyl,
C3-8 cycloalkyl, amino Cl-6 alkyl, (aryOqaminocarbonyl,
(aryl Cl -5 alkyOqaminocarbonyl, hydroxycarbonyl Cl -6 alkyl,
Cl-8 alkyl, aryl Cl-6 alkyl, (Cl -6 alkyOqamino Cl -6 alkyl,
(aryl Cl -6 alkyOqamino Cl -6 alkyl,
Cl-8 alkylsulfonyl,
Cl-8 alkoxycarbonyl, aryloxycarbonyl, aryl Cl -8 alkoxycarbonyl,
Cl-8 alkylcarbonyl, arylcarbonyl, aryl Cl -6 alkylcarbonyl,
(Cl-8 alkyOqaminocarbonyl, aminosulfonyl,
Cl -8 alkylaminosulfonyl,
(aryl)qaminosulfonylamino,
(aryl Cl-8 alkyOqaminosulfonyl,
Cl-6 alkylsulfonyl, arylsulfonyl, aryl Cl -6 alkylsulfonyl, aryl Cl-6 alkylcarbonyl,
Cl-6 alkylthiocarbonyl, arylthiocarbonyl, or aryl Cl-6 alkylthiocarbonyl, wherein any of the alkyl groups may be unsubstituted or substituted with R l and Rl4;
R6, R7, R R9? RIO and R11 are each independently selected from hydrogen, aryl, aryl-(CH2)p-, aryl-(CH2)n-0-(CH2)m-, aryl-(CH2)n-S(0)q-(CH2)m-, aryl-(CH2)n-C(0)-(CH2)m-, aryl-(CH2)n-C(0)-N(R3)-(CH2)m-, aryl-(CH2)n-N(R3)-C(0)-(CH2)m-, aryl-(CH2)n-N(R3)-(CH2)m-, halogen, hydroxyl,
Cl-8 alkylcarbonylamino, aryl Cl -5 alkoxy,
Cl-5 alkoxycarbonyl, (Cl-8 alkyOqaminocarbonyl,
Cl-6 alkylcarbonyloxy,
C3-8 cycloalkyl, oxo,
(Cl-6 alkyOqamino, amino Cl -6 alkyl, arylaminocarbonyl, aryl Cl-5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl-6 alkyl,
Cl-8 alkyl, either unsubstituted or substituted, with one or more groups selected from: halogen, hydroxyl, Cl-5 alkylcarbonylamino, aryl Cl-5 alkoxy,
Cl-5 alkoxycarbonyl, aminocarbonyl, (Cl -5 alkyOqaminocarbonyl, Cl-5 alkylcarbonyloxy, C3-8 cycloalkyl, oxo, (Cl -3 alkyOqamino, amino Cl -3 alkyl, (aryl)qaminocarbonyl, (aryl Cl -5 alkyOqaminocarbonyl, aminocarbonyl, aminocarbonyl Cl -4 alkyl, hydroxycarbonyl or hydroxycarbonyl Cl-5 alkyl,
CH≡C-(CH2)s-,
Cl-6 alkyl-C≡C-(CH2)s-,
C3-7 cycloalkyl-C≡C-(CH2)s-, aryl-C≡C-(CH2)s-,
Cl-6 alkylaryl-C≡C-(CH2)s-,
CH2=CH-(CH2)s-,
Cl-6 alkyl-CH=CH-(CH2)s-,
C3-7 cycloalkyl-CH=CH-(CH2)s-, aryl-CH=CH-(CH2)s-,
Cl-6 alkylaryl-CH=CH-(CH2)s-,
Cl-6 alky l-Sθ2-(CH2)s-,
Cl -6 alkylaryl-Sθ2-(CH2)s-,
Cl -6 alkoxy, aryl Cl-6 alkoxy, aryl C 1-6 alkyl,
(Cl -6 alkyOqamino Cl-6 alkyl,
(aryl)qamino,
(aryl)qamino Cl-6 alkyl, (aryl Cl -6 alkyOqamino,
(aryl Cl -6 alkyOqamino Cl -6 alkyl, arylcarbonyloxy, aryl Cl -6 alkylcarbonyloxy,
(Cl-6 alkyOqaminocarbonyloxy, Cl-8 alkylsulfonylamino, arylsulfonylamino,
Cl -8 alkylsulfonylamino Cl -6 alkyl, arylsulfonylamino Cl-6 alkyl, aryl Cl-6 alkylsulfonylamino, aryl Cl_6 alkylsulfonylamino Cl-6 alkyl,
Cl -8 alkoxycarbonylamino,
Cl -8 alkoxycarbonylamino Cl-8 alkyl, aryloxycarbonylamino Cl-8 alkyl, aryl Cl-8 alkoxycarbonylamino, aryl Cl -8 alkoxycarbonylamino Cl -8 alkyl,
Cl -8 alkylcarbonylamino,
Cl -8 alkylcarbonylamino Cl-6 alkyl, arylcarbonylamino Cl-6 alkyl, aryl Cl -6 alkylcarbonylamino, aryl Cl -6 alkylcarbonylamino Cl -6 alkyl, aminocarbonylamino Cl-6 alkyl,
(Cl -8 alkyOqaminocarbonylamino,
(C] -8 alkyOqaminocarbonylamino Cl-6 alkyl, (aryOqaminocarbonylamino Cl-6 alkyl,
(aryl Cl -8 alkyOqaminocarbonylamino,
(aryl Cl-8 alkyOqaminocarbonylamino Cl -6 alkyl, aminosulfonylamino Cl -6 alkyl,
(Cl -8 alkyOqaminosulfonylamino, (Cl-8 alkyOqaminosulfonylamino Cl-6 alkyl,
(aryl)qaminosulfonylamino Cl -6 alkyl,
(aryl Cl-8 alkyOqaminosulfonylamino,
(aryl Cl- alkyOqaminosulfonylamino Cl-6 alkyl,
Cl-6 alkylsulfonyl, Cl-6 alkylsulfonyl Cl-6 alkyl, arylsulfonyl Cl-6 alkyl, aryl Cl-6 alkylsulfonyl, aryl Cl-6 alkylsulfonyl Cl-6 alkyl,
Cl-6 alkylcarbonyl, Cl -6 alkylcarbonyl Cl -6 alkyl, arylcarbonyl Cl -6 alkyl, aryl Cl -6 alkylcarbonyl, aryl Cl-6 alkylcarbonyl Cl-6 alkyl, Cl -6 alkylthiocarbonylamino,
Cl -6 alkylthiocarbonylamino Cl-6 alkyl, arylthiocarbonylamino Cl -6 alkyl, aryl Cl-6 alkylthiocarbonylamino, aryl Cl-6 alkylthiocarbonylamino Cl -6 alkyl, (Cl -8 alkyOqaminocarbonyl Cl -6 alkyl,
(aryl)qaminocarbonyl Cl -6 alkyl,
(aryl Cl-8 alkyOqaminocarbonyl, or
(aryl Cl-8 alkyOqaminocarbonyl Cl-6 alkyl, wherein any of the alkyl groups may be unsubstituted or substituted with Rl and R ^4; and provided that the carbon atom to which R^ and R9 are attached is itself attached to no more than one heteroatom; and provided further that the carbon atom to which RlO and R ^ are attached is itself attached to no more than one heteroatom;
R1 is selected from hydrogen,
Cl-8 alkyl, aryl, aryl Cl -8 alkyl, Cl-8 alkylcarbonyloxy Cl -4 alkyl, aryl Cl -8 alkylcarbonyloxy Cl-4 alkyl,
Cl-8 alkylaminocarbonylmethylene, or
Cl -8 dialkylaminocarbonylmethylene;
m, s and t are each independently an integer from 0 to 3; n is an integer from 1 to 3; p is an integer from 1 to 4; q is an integer from 0 to 2; r is an integer from 0 to 6; and the pharmaceutically acceptable salts thereof.
Particularly illustrative of the invention is the compound wherein Z is a 5-1 1 membered nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups independently selected from R4, R^, R6 and R7; and all other variables are as defined above. Exemplifying the invention is the compound wherein
Z is selected from
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000048_0002
and the pharmaceutically acceptable salts thereof. Preferably Z is selected from
Figure imgf000048_0003
Figure imgf000049_0001
An example of the invention is the compound of the formula
Figure imgf000050_0001
wherein X is selected from
Figure imgf000050_0002
Y is selected from -(CH2)r- or -(CH2)m-NR3-(CH2)t-; R is selected from hydrogen, aryl-(CH2)p-, Cl- alkoxycarbonyl,
C3- cycloalkyl,
(aryl)qaminocarbony 1 ,
(aryl Cl-5 alkyOqaminocarbonyl,
Ci-8 alkyl, aryl Cl-6 alkyl,
Cl -8 alkylsulfonyl, arylsulfonyl, aryl Cl-6 alkylsulfonyl,
Cl-8 alkoxycarbonyl, aryloxycarbonyl, aryl Cl-8 alkoxycarbonyl,
Ci- alkylcarbonyl, arylcarbonyl, aryl Cl-6 alkylcarbonyl, (Cl -8 alkyOqaminocarbonyl,
Cι _6 alkylsulfonyl, or aryl Cl - alkylcarbonyl, wherein any of the alkyl groups may be unsubstituted or substituted with R13 and R14;
R4 is selected from hydrogen, Cl-6 alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl,
C3-8 cycloalkyl Cl -6 alkyl, C3-8 cycloheteroalkyl Cl -6 alkyl, aryl or aryl Cl -8 alkyl,
R is selected from hydrogen, aryl, aryl-(CH2)p-, CH≡C-(CH2)s-, Cl-6 alkyl-C≡C-(CH2)s-, C3-7 cycloalkyl-C≡C-(CH2)s-, aryl-C≡C-(CH2)s-, Cl-6 alkylaryl-C≡C-(CH2)s-, CH2=CH-(CH2)s-, Cl-6 alkyl-CH=CH-(CH2)s-, C3-7 cycloalkyl-CH=CH-(CH2)s-, aryl-CH=CH-(CH2)s-, Cl-6 alkylaryl-CH=CH-(CH2)s-, Cl-6 alky l-S02-(CH2)s-, Cl-6 alkylaryl-Sθ2-(CH2)s-; and
r is an integer from 0 to 3; wherein all other variables are as defined above; and the pharmaceutically acceptable salts thereof.
Further illustrating the invention is the compound of the formula
Figure imgf000051_0001
wherein Z is selected from
Figure imgf000052_0001
R8 is selected from hydrogen,
Figure imgf000052_0002
indolyl-(CH2)p-,
CH≡C-(CH2)s-,
Cl-6 lkyl-C≡C-(CH2)s-,
C3-7 cycloalkyl-C≡C-(CH2)s-, aryl-C≡C-(CH2)s-,
Cl -6 alkylaryl-C≡C-(CH2)s-,
CH2=CH-(CH2)s-,
Ci-6 alkyl-CH=CH-(CH2)s-,
C3-7 cycloalkyl-CH=CH-(CH2)s-, aryl-CH=CH-(CH2)s-, Cl-6 alkylaryl-CH=CH-(CH2)s-,
Ci-6 alkyl-S02-(CH2)s-,
Cl-6 alkylaryl-S02-(CH2)s-; and
Rl2 is selected from hydrogen or Cl-8 alkyl; and s is an integer from 0 to 3; and all other variables are as defined above; and the pharmaceutically acceptable salts thereof.
Further exemplifying the invention is the compound selected from
2-Oxo-3-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2-yl)ethyl]piperidin- 1 -yl-acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-3-[2-(5,6,7,8-tetrahydroll,8]-naphthyridin-2-yl)ethyllpiperin- 1 -yl-acetyl-3(S)-pyridin-3-yl-β-alanine trifluoroacetate;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l -yl)acetyI-3(S)-alkynyl-β-alanine ethyl ester;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- y l)ethy ljpyrrolidin- 1 -yl)acetyi-3(S)-alkynyl-β-alanine;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2-yl)ethyl]- pyrrolidin-l -yl)acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- y l)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-alkyny 1-β-alanine ethyl ester;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- y l)ethy l]pyrrolidin- 1 -yl)acety l-3(S)-alkynyl-β-alanine; 2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[ l ,8]-naphthyridin-2-yl)ethyl]- pyπOlidin-l -yl)acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- yl)ethyl]pyπOlidin-l-yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
Ethyl 2-oxo-3-12-(5,6,7,8-tetrahydro[l ,8]naphthyridin-2-yl)ethyll- tetrahydroρyrimidin-l-yl-acetyl-3(S)-ρyridin-3-yl-β-alanine;
2-Oxo-3-[2-(5,6,7,8-tetrahydro[l ,8]naphthyridin-2-yl }ethyl]- tetrahydropyrimidin-l -yl-acetyl-3(S)-pyridin-3-yl-β-alanine;
Ethyl 2-oxo-3-[2-(5,6,7,8-tetrahydrof 1 ,8]naphthyridin-2- yOe yl]imidazolidin-l-yl-acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3-[2-(5,6,7,8-tetrahydro[l ,8)naphthyridin-2-yl}ethyl]- imidazolidin- 1 -yl-acetyI-3(S)-pyridin-3-yl-β-alanine;
Ethyl 2-oxo-3(R)-f 2-(5,6,7,8-tetrahydro[ 1 ,8]naphthyridin-2- yl)ethyl]pyπOlidin-l-yl)acetyl-3(R)-(2-ethylindol-3-yl)-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[l ,8]naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(R)-(2-ethylindol-3-yl)-β-alanine;
Ethyl 3-(2-{2-oxo-3(S)-[(5,6,7,8-tetrahydro-ri ,8]naphthyridin-2- ylmethyl)-aminol-pyrrolidin-l -yl } -acetylamino)-3-(S)-pyridin-3-yl- propionic acid;
3-(2-{ 2-Oxo-3(S)-[(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-ylmethyO- amino]pyrrolidin-l-yl }-acetylamino)-3-(S)-pyridin-3-yl-propionic acid; 3- {2-[6-Oxo-l-(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-ylmethy0- hexahydro-(3aS, 6aS)pyrrolo[3,4-b]pyrrol-5-yl]-acetylamino}-3-(S)- pyridin-3-yl-propionic acid;
3-{2-[6-Oxo-l -(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-ylmethy0- hexahydro-(3aR, 6aR)ρyrrolo[3,4-b]pyrrol-5-yl]-acetylamino } -3-(S)- pyridin-3-yl-propionic acid;
2-Oxo-5(R)-methyl-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2-y0- ethyl]pyrrolidin-l-yl)acetyl-3(S)-alkynyl-β-alanine ethyl ester;
2-Oxo-5(R)-methyl-3(S)-[2-(5,6,7,8-tetrahydro[l,8]-naρhthyridin-2- y l)ethy l]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-5(S)-benzyl-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2-y0- ethyljpyrrolidin- 1 -yl)acety l-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-5(S)-benzyl-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- y l)ethy l]pyrrolidin- 1 -y l)acetyl-3(S)-pyridin-3-yl-β-alanine;
5(R)-Methyl-2-oxo-3(S)-r2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- y lmethyO-aminolpyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine ethyl ester;
5(R)-Methyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydrol 1 ,8J-naphthyridin-2- ylmethyl)-aminolpyrrolidin-l-yl)acetyl-3(S)-alkynyl-β-alanine;
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-{ 2-oxo-3(S)-[2-(5,6,7,8- tetrahydro-[ 1 ,81naphthyridin-2-yl)-ethyl]-pyrrolidin- 1 -yl } - acetylamino)-propionic acid ethyl ester; or
3(5)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-{2-oxo-3(S)-[2-(5,6,7,8- tetrahydro-11 ,8 |naphthyridin-2-yl)-ethyl]-pyrrolidin- 1 -yl } - acetylamino)-propionic acid; and the pharmaceutically acceptable salts thereof.
Preferably, the compound is selected from
2-Oxo-3-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2-yl)ethyl]piperin- 1 -yl-acetyl-3(S)-pyridin-3-yl-β-alanine trifluoroacetate;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydrofl ,8]-naphthyridin-2- yl)ethyI]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-3(R)-r2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- yOethyllpyrrolidin- 1 -yl)acetyI-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3-[2-(5,6,7,8-tetrahydro[l,8]naphthyridin-2-yl}ethyl]- imidazolidin-l-yl-acetyl-3-(S)-pyridin-3-yl-β-alanine;
2-Oxo-3-[2-(5 ,6,7,8-tetrahydro[ 1 ,8]naphthy ridin-2-yl } ethyl] - tetrahydropyrimidin-l-yl-acetyl-3-(S)-pyridin-3-yl-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydrofl ,8]naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(R)-(2-ethylindol-3-yl)-β-alanine;
3-(2-{2-Oxo-3(S)-[(5,6,7,8-tetrahydro-f l ,8]naphthyridin-2-ylmethy0- amino]pyrrolidin- 1 -yl } -acetylamino)-3-(S)-pyridin-3-yl-propionic acid;
3-{ 2-[6-Oxo-l-(5,6,7,8-tetrahydro-[l,8]naphthyridin-2-ylmethy0- hexahydro-(3aS, 6aS)pyrrolo[3,4-b]pyrrol-5-yl]-acetylamino } -3-(S)- pyridin-3-yl-propionic acid; or 3-{2-[6-Oxo-l -(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-ylmethy0- hexahydro-(3aR, 6aR)pyrroIof3,4-b]pyrrol-5-yI]-acetylamino }-3-(S)- pyridin-3-yl-propionic acid;
2-Oxo-5(R)-methyl-3(S)-[2-(5,6,7,8-tetrahydroll ,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -y l)acety l-3(S)-alkynyl-β-alanine;
2-Oxo-5(S)-benzyl-3(S)-[2-(5,6,7,8-tetrahydro[ l ,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l -yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
5(R)-Methyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- ylmethyO-aminojpyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine; or
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-{2-oxo-3(S)-[2-(5,6,7,8- tetrahydro-r 1 ,8]naphthyridin-2-yl)-ethyl]-pyπolidin- 1 -yl } - acetylamino)-propionic acid;
and the pharmaceutically acceptable salts thereof. An additional example of the invention is a compound of the formula
Figure imgf000057_0001
wherein X is a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1 , 2, 3 or 4 heteroatoms selected from N, O or S, and wherein the polycyclic ring system is either unsubstituted or substituted on a carbon atom with RΪ and R2;
Y is selected from R3 R3 ° O
-N-(CH2)— , -(CH^ - _c-(CH2)^ , -C- -(CH2)- ,
O -N-C-(CH2)- -S(0)q-(CH2fc , - 0-(CH2fe or - (CH2)r- ; R3
Z is a 5-1 1 membered aromatic or nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups independently selected from R4, R5, R6 and R7; provided that Z is not a 6-membered monocyclic aromatic ring system; preferably, Z is selected from
Figure imgf000058_0001
Figure imgf000059_0001
R1 , R2, R3, R4, R5, R 13 and R14 are each independently selected from hydrogen, halogen, Cl-lO alkyl, C3-8 cycloalkyl, aryl, aryl Cl -8 alkyl, amino, amino Cl-8 alkyl, Cl-3 acylamino, Cl -3 acylamino Cl-8 alkyl, Cl-6 alkylamino, Cl-6 alkylamino- Cι_8 alkyl, Cl-6 dialkylamino, Cl-6 dialkylamino Cl- alkyl, Cl-4 alkoxy, Cl-4 alkoxy Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl-6 alkyl, Cl _3 alkoxycarbonyl, Cl-3 alkoxycarbonyl Cl-6 alkyl, hydroxycarbonyl- Cl-6 alkyloxy, hydroxy or hydroxy Cl -6 alkyl;
R6> R7, R8? R9 R IO nd R1 1 are each independently selected from hydrogen, aryl,
-(CH2)p-aryl, halogen, hydroxyl,
Cl -8 alkylcarbonylamino, aryl Cl -5 alkoxy,
Cl-5 alkoxycarbonyl, aminocarbonyl, Cl-8 alkylaminocarbonyl,
Cl-6 alkylcarbonyloxy,
C3-8 cycloalkyl, oxo, amino, Cl-6 alkylamino, amino Cl-6 alkyl, arylaminocarbonyl, aryl Cl-5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cl -6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl -6 alkyl,
Cl-8 alkyl, either unsubstituted or substituted, with one or more groups selected from: halogen, hydroxyl, Cl-5 alkylcarbonylamino, aryl Cl -5 alkoxy,
Cl-5 alkoxycarbonyl, aminocarbonyl, Cl -5 alkylaminocarbonyl, Cl-5 alkylcarbonyloxy, C3-8 cycloalkyl, oxo, amino, Cl-3 alkylamino, amino Cl-3 alkyl, arylaminocarbonyl, aryl Cl -5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cl -4 alkyl, hydroxycarbonyl, or hydroxycarbonyl Cl-5 alkyl, -(CH2)s C≡CH, -(CH2)s C≡C-C 1-6 alkyl, -(CH2)s C≡C-C3-7 cycloalkyl,
-(CH2)s C≡C-aryl, -(CH2)s C≡C-C 1 -6 alkylaryl,
-(CH2)s CH=CH2,
-(CH2)s CH=CH Ci-6 alkyl, -(CH2)s CH=CH-C3-7 cycloalkyl,
-(CH2)s CH=CH aryl,
-(CH2)s CH=CH Cl -6 alkylaryl,
-(CH2)s S02Ci-6 alkyl, or
-(CH2)s S02Cl-6 alkylaryl; Cl -6 alkoxy, aryl Cl -6 alkoxy, aryl Cl-6 alkyl,
Cl-6 alkylamino Cl-6 alkyl, arylamino, arylamino Cl-6 alkyl, aryl Cl-6 alkylamino, aryl Cl -6 alkylamino Cl-6 alkyl, arylcarbonyloxy, aryl Cl-6 alkylcarbonyloxy, Cl-6 dialkylamino,
Cl-6 dialkylamino Cl-6 alkyl,
Cl -6 alkylaminocarbonyloxy,
Cl-8 alkylsulfonylamino,
Cl-8 alkylsulfonylamino Cl-6 alkyl, arylsulfonylamino Cl-6 alkyl, aryl Cl-6 alkylsulfonylamino, aryl Cl-6 alkylsulfonylamino Cl-6 alkyl,
Cl-8 alkoxycarbonylamino,
Cl -8 alkoxycarbonylamino Cl-8 alkyl, aryloxycarbonylamino Cl-8 alkyl, aryl Cl-8 alkoxycarbonylamino, aryl Cl-8 alkoxycarbonylamino Cl-8 alkyl, Cl-8 alkylcarbonylamino, Cl-8 alkylcarbonylamino Cl-6 alkyl, arylcarbonylamino Cl-6 alkyl, aryl Cl-6 alkylcarbonylamino, aryl Cl-6 alkylcarbonylamino Cl-6 alkyl, aminocarbonylamino Cl-6 alkyl, Cl-8 alkylaminocarbonylamino,
Cl-8 alkylaminocarbonylamino Cl-6 alkyl, arylaminocarbonylamino Cl-6 alkyl, aryl Cl-8 alkylaminocarbonylamino, aryl Cl-8 alkylaminocarbonylamino Cl-6 alkyl, aminosulfonylamino Cl-6 alkyl,
Cl-8 alkylaminosulfonylammo, Cl-8 alkylaminosulfonylammo Cl-6 alkyl, arylaminosulfonylamino Cl-6 alkyl, aryl Cl-8 alkylaminosulfonylammo, aryl Cl-8 alkylammosulfonylammo Cl-6 alkyl,
Cl-6 alkylsulfonyl, Cl-6 alkylsulfonyl Cl-6 alkyl, arylsulfonyl Cl-6 alkyl, aryl Cl-6 alkylsulfonyl, aryl C 1 -6 alkylsulfonyl C 1 -6 alkyl,
Cl-6 alkylcarbonyl, Cl-6 alkylcarbonyl Cl-6 alkyl, arylcarbonyl Cl-6 alkyl, aryl Cl-6 alkylcarbonyl, aryl Cl-6 alkylcarbonyl Cl-6 alkyl,
Cl-6 alkylthiocarbonylamino, Cl-6 alkylthiocarbonylamino Cl-6 alkyl, arylthiocarbonylamino Cl-6 alkyl, aryl Cl-6 alkylthiocarbonylamino, aryl Cl -6 alkylthiocarbonylamino Cl -6 alkyl,
Cl-8 alkylaminocarbonyl Cl-6 alkyl, arylaminocarbonyl Cl -6 alkyl, aryl Cl-8 alkylaminocarbonyl, or aryl Cl-8 alkylaminocarbonyl Cl -6 alkyl, wherein any of the alkyl groups may be unsubstituted or substituted with R l and R^4; and provided that the carbon atom to which R$ and R9 are attached is itself attached to no more than one heteroatom; and provided further that the carbon atom to which RlO and R11 are attached is itself attached to no more than one heteroatom;
Rl^ is selected from hydrogen, Cl-8 alkyl, aryl, aryl Cl-8 alkyl, hydroxy, Cl-8 alkoxy, aryloxy, aryl Cl -6 alkoxy,
Cl- alkylcarbonyloxy Cl-4 alkoxy, aryl Cl -8 alkylcarbonyloxy Cl -4 alkoxy, Cl -8 alkylaminocarbonylmethyleneoxy, or Cl-8 dialkylaminocarbonylmethyleneoxy;
m is an integer from 0 to 3; n is an integer from 1 to 3; p is an integer from 1 to 4; q is an integer from 0 to 2; r is an integer from 0 to 6; and s is an integer from 0 to 3; and the pharmaceutically acceptable salts thereof.
An additional illustration of the invention is a compound of the formula
Figure imgf000064_0001
wherein X is a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1 , 2, 3 or 4 heteroatoms selected from N, O or
S, and wherein the polycyclic ring system is either unsubstituted or substituted on a carbon atom with R and R2;
Y is selected from
R3 R3 fi O
-N-(CH2)— , _(CH2)-N- . -C-fCHafcr , -C-N-(CH2)~ ,
R3 O _N_C_ (CH2)- -S(0)q-(CH2)^ , - 0-(CH2fcr or - (CH2)r- ; R3
Z is a 5-11 membered aromatic or nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted on a carbon or nitrogen atom with one or more groups independently selected from R4, R5, R6 and R ; provided that Z is not a 6-membered monocyclic aromatic ring system; preferably, Z is selected from 63 -
Figure imgf000065_0001
Rl , R2, R4, R5, R13 and R^4 are each independently selected from hydrogen, halogen, Cl -10 alkyl, C3-8 cycloalkyl, aryl, aryl Cl-8 alkyl, amino, amino Cl-8 alkyl, Cl -3 acylamino,
Cl-3 acylamino Cl-8 alkyl, Cl-6 alkylamino, Cl-6 alkylamino- Ci-8 alkyl, Cl-6 dialkylamino, Cl -6 dialkylamino Cl-8 alkyl, Cl-4 alkoxy, Cl-4 alkoxy Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl -6 alkyl, Cl -3 alkoxycarbonyl, Cl-3 alkoxycarbonyl Cl-6 alkyl, hydroxycarbonyl-
Cl-6 alkyloxy, hydroxy, hydroxy Cl-6 alkyl, Cl-6 alkyloxy- Cl -6 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, Cl-8 alkyl-S(0)q, Cl-8 aminocarbonyl, Cl -8 dialkylaminocarbonyl, Cl-8 alkyloxycarbonylammo, Cl-8 alkylaminocarbonyloxy or Cl -8 alkylsulfonylamino;
R3 is selected from hydrogen, aryl, -(CH )p-aryl, hydroxyl, Cl-5 alkoxycarbonyl, aminocarbonyl,
C3-8 cycloalkyl, amino Cl-6 alkyl, arylaminocarbonyl, aryl Cl-5 alkylaminocarbonyl, hydroxycarbonyl Cl -6 alkyl,
Cl-8 alkyl, aryl Cl-6 alkyl, Cl -6 alkylamino Cl-6 alkyl, aryl Cl-6 alkylamino Cl-6 alkyl,
Cl -6 dialkylamino Cl-6 alkyl,
Cl -8 alkylsulfonyl,
Cl-8 alkoxycarbonyl, aryloxycarbonyl, aryl Cl-8 alkoxycarbonyl,
Cl-8 alkylcarbonyl, aryl carbonyl, aryl Cl-6 alkylcarbonyl, Cl -8 alkylaminocarbonyl, aminosulfonyl,
Cl -8 alkylaminosulfonyl, arylaminosulfonylamino, aryl Cl-8 alkylaminosulfonyl, Cl -6 alkylsulfonyl, arylsulfonyl, aryl Cl-6 alkylsulfonyl, aryl Cl-6 alkylcarbonyl,
Cl-6 alkylthiocarbonyl, arylthiocarbonyl, or aryl Cl -6 alkylthiocarbonyl, wherein any of the alkyl groups may be unsubstituted or substituted with Rl3 and Rl4; R6, R75 R8} R9? IO nd R^ are each independently selected from hydrogen, aryl,
-(CH2)p-aryl, halogen, hydroxyl,
Cl -8 alkylcarbonylamino, aryl Cl-5 alkoxy, Cl-5 alkoxycarbonyl, aminocarbonyl,
Cl -8 alkylaminocarbonyl, Cl-6 alkylcarbonyloxy, C3-8 cycloalkyl, oxo, amino,
Cl-6 alkylamino, amino Cl-6 alkyl, arylaminocarbonyl, aryl Cl-5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl -6 alkyl,
Cl-8 alkyl, either unsubstituted or substituted, with one or more groups selected from: halogen, hydroxyl,
Cl-5 alkylcarbonylamino, aryl Cl-5 alkoxy, Cl-5 alkoxycarbonyl, aminocarbonyl, Cl -5 alkylaminocarbonyl, Cl-5 alkylcarbonyloxy, C3-8 cycloalkyl, oxo, amino, Cl -3 alkylamino, amino Cl -3 alkyl, arylamino- carbonyl, aryl Cl-5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cl-4 alkyl, hydroxycarbonyl, or hydroxycarbonyl Cl -5 alkyl, -(CH2)s OCH, -(CH2)s C≡C-C 1-6 alkyl, -(CH2)s C≡C-C3-7 cycloalkyl,
-(CH2)s G≡C-aryl,
-(CH2)s C≡C-Cl -6 alkylaryl,
-(CH2)s CH=CH2, -(CH2)s CH=CH Cl -6 alkyl,
-(CH2)s CH=CH-C3-7 cycloalkyl,
-(CH2)s CH=CH aryl,
-(CH2)s CH=CH Cl-6 alkylaryl,
-(CH2)s S02Ci-6 alkyl, or -(CH2)s S02C1-6 alkylaryl;
Cl -6 alkoxy, aryl Cl-6 alkoxy, aryl Cl-6 alkyl,
Cl -6 alkylamino Cl-6 alkyl, arylamino, arylamino Cl-6 alkyl, aryl Cl -6 alkylamino, aryl Cl-6 alkylamino Cl-6 alkyl, arylcarbonyloxy, aryl Cl-6 alkylcarbonyloxy,
Cl-6 dialkylamino,
Cl -6 dialkylamino Cl -6 alkyl,
Cl -6 alkylaminocarbonyloxy,
Cl-8 alkylsulfonylamino, Cl-8 alkylsulfonylamino Cl -6 alkyl, arylsulfonylamino Cl-6 alkyl, aryl Cl-6 alkylsulfonylamino, aryl Cl-6 alkylsulfonylamino Cl-6 alkyl,
Cl -8 alkoxycarbonylamino, Cl-8 alkoxycarbonylamino Cl-8 alkyl, aryloxycarbonylamino Cl -8 alkyl, aryl Cl -8 alkoxycarbonylamino, aryl Cl -8 alkoxycarbonylamino Cl -8 alkyl,
Cl -8 alkylcarbonylamino, Cl-8 alkylcarbonylamino Cl-6 alkyl, arylcarbonylamino Cl -6 alkyl, aryl Cl-6 alkylcarbonylamino, aryl Cl -6 alkylcarbonylamino Cl -6 alkyl, aminocarbonylamino Cl-6 alkyl,
Cl -8 alkylaminocarbonylamino, Cl -8 alkylaminocarbonylamino Cl - alkyl, arylaminocarbonylamino Cl-6 alkyl, aryl Cl-8 alkylaminocarbonylamino, aryl Cl -8 alkylaminocarbonylamino Cl -6 alkyl, aminosulfonylamino Cl -6 alkyl, Cl-8 alkylaminosulfonylammo, Cl -8 alkylaminosulfonylammo Cl-6 alkyl, arylaminosulfonylamino Cl-6 alkyl, aryl Cl-8 alkylaminosulfonylammo, aryl Cl-8 alkylaminosulfonylammo Cl-6 alkyl,
Cl -6 alkylsulfonyl,
Cl-6 alkylsulfonyl Cl-6 alkyl, arylsulfonyl Cl-6 alkyl, aryl Cl -6 alkylsulfonyl, aryl Cl-6 alkylsulfonyl Cl-6 alkyl, Cl -6 alkylcarbonyl, Cl-6 alkylcarbonyl Cl -6 alkyl, arylcarbonyl Cl-6 alkyl, aryl Cl-6 alkylcarbonyl, aryl Cl-6 alkylcarbonyl Cl-6 alkyl, Cl -6 alkylthiocarbonylamino, Cl -6 alkylthiocarbonylamino Cl-6 alkyl, arylthiocarbonylamino Cl-6 alkyl, aryl Cl -6 alkylthiocarbonylamino, aryl Cl-6 alkylthiocarbonylamino Cl -6 alkyl, Cl -8 alkylaminocarbonyl Cl-6 alkyl, arylaminocarbonyl Cl-6 alkyl, aryl Cl-8 alkylaminocarbonyl, or aryl Cl -8 alkylaminocarbonyl Cl-6 alkyl, wherein any of the alkyl groups may be unsubstituted or substituted with Rl and R 4; and provided that the carbon atom to which R^ and R^ are attached is itself attached to no more than one heteroatom; and provided further that the carbon atom to which R1^ and Rl 1 are attached is itself attached to no more than one heteroatom;
R! is selected from hydrogen, Cl-8 alkyl, aryl, aryl Cl-8 alkyl, hydroxy,
Cl-8 alkoxy, aryloxy, aryl Cl-6 alkoxy,
Cl -8 alkylcarbonyloxy Cl -4 alkoxy, aryl Cl-8 alkylcarbonyloxy Cl -4 alkoxy,
Cl-8 alkylaminocarbonylmethyleneoxy, or Cl-8 dialkylaminocarbonylmethyleneoxy;
m is an integer from 0 to 3; n is an integer from 1 to 3; p is an integer from 1 to 4; q is an integer from 0 to 2; r is an integer from 0 to 6; and s is an integer from 0 to 3; and the pharmaceutically acceptable salts thereof.
More particularly illustrating the invention is a pharmaceutical composition comprising any of the compounds described above and a pharmaceutically acceptable carrier. Another example of the invention is a pharmaceutical composition made by combining any of the compounds described above and a pharmaceutically acceptable carrier. Another illustration of the invention is a process for making a pharmaceutical composition comprising combining any of the compounds described above and a pharmaceutically acceptable carrier.
Further illustrating the invention is a method of treating and/or preventing a condition mediated by antagonism of a vitronectin receptor in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds described above. Preferably, the condition is selected from bone resoφtion, osteoporosis, restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, cancer and tumor growth. More preferably, the condition is selected from osteoporosis and cancer. Most preferably, the condition is osteoporosis. More specifically exemplifying the invention is a method of eliciting a vitronectin antagonizing effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above. Preferably, the vitronectin antagonizing effect is an αvβ3 antagonizing effect; more specifically the αvβ3 antagonizing effect is selected from inhibition of bone resorption, inhibition of restenosis, inhibition of atherosclerosis, inhibition of angiogenesis, inhibition of diabetic retinopathy, inhibition of macular degeneration, inhibition of inflammation or inhibition of tumor growth. Most preferably, the αvβ3 antagonizing effect is inhibition of bone resorption. Altematively, the vitronectin antagonizing effect is an αvβ5 antagonizing effect or a dual αvβ3/ocvβ5 antagonizing effect. Examples of αvβ5 antagonizing effects are inhibition of: restenosis, atherosclerosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation or tumor growth. Examples of dual αvβ3/αvβ5 antagonizing effects are inhibition of: bone resorption, restenosis, atherosclerosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation or tumor growth.
Additional examples of the invention are methods of inhibiting bone resorption and of treating and/or preventing osteoporosis in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions decribed above.
Further exemplifying the invention is any of the compositions described above, further comprising a therapeutically effective amount of a second bone resoφtion inhibitor; preferably, the second bone resoφtion inhibitor is alendronate.
More particularly illustrating the invention is any of the methods of treating and/or preventing osteoporosis and/or of inhibiting bone resoption described above, wherein the compound is administered in combination with a second bone resoφtion inhibitor; preferably, the second bone resoφtion inhibitor is alendronate.
Additional illustrations of the invention are methods of treating hypercalcemia of malignancy, osteopenia due to bone metastases, periodontal disease, hypeφarathyroidism, periarticular erosions in rheumatoid arthritis, Paget's disease, immobilization-induced osteopenia, and glucocorticoid treatment in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above. More particularly exemplifying the invention is the use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of osteoporosis in a mammal in need thereof. Still further exemplifying the invention is the use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of: bone resoφtion, tumor growth, cancer, restenosis, atherosclerosis, diabetic retinopathy, macular degeneration, inflammation and/or angiogenesis.
Additional illustrations of the invention are methods of treating tumor growth in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound described above and one or more agents known to be cy to toxic or antiproliferative, e.g., taxol and doxorubicin. DETAILED DESCRIPTION OF THE INVENTION
Representative compounds of the present invention are integrin antagonists which display submicromolar affinity for the human vβ3 receptor. Compounds of this invention are therefore useful for treating mammals suffering from a bone condition caused or mediated by increased bone resoφtion, who are in need of such therapy. Pharmacologically effective amounts of the compounds, including pharamaceutically acceptable salts thereof, are administered to the mammal, to inhibit the activity of mammalian osteoclasts. The compounds of the present invention are administered in dosages effective to antagonize the αvβ3 receptor where such treatment is needed, as, for example, in the prevention or treatment of osteoporosis. For use in medicine, the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts." Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts include the following:
Acetate, Benzenesulfonate, Benzoate, Bicarbonate, Bisulfate, Bitartrate, Borate, Bromide, Calcium, Camsylate, Carbonate, Chloride, Clavulanate, Citrate, Dihydrochloride, Edetate, Edisylate, Estolate, Esylate, Fumarate, Gluceptate, Gluconate, Glutamate, GlycoUylarsanilate, Hexylresorcinate, Hydrabamine, Hydrobromide, Hydrochloride, Hydroxynaphthoate, Iodide, Isothionate, Lactate, Lactobionate, Laurate, Malate, Maleate, Mandelate, Mesylate, Methylbromide, Methylnitrate, Methylsulfate, Mucate, Napsylate, Nitrate, N-methylglucamine ammonium salt, Oleate, Oxalate, Pamoate (Embonate), Palmitate, Pantothenate, Phosphate/diphosphate,
Polygalacturonate, Salicylate, Stearate, Sulfate, Subacetate, Succinate, Tannate, Tartrate, Teoclate, Tosylate, Triethiodide and Valerate. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.
The compounds of the present invention, may have chiral centers and occur as racemates, racemic mixtures, diastereomeric mixtures, and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention. Therefore, where a compound is chiral, the separate enantiomers, substantially free of the other, are included within the scope of the invention; further included are all mixtures of the two enantiomers. Also included within the scope of the invention are polymoφhs and hydrates of the compounds of the instant invention.
The present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985. Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu.
The term "therapeutically effective amount" shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician.
The term "vitronectin receptor antagonist," as used herein, refers to a compound which binds to and antagonizes either the αvβ3 receptor or the vβ5 receptor, or a compound which binds to and antagonizes both the ocvβ3 and αvβ5 receptors (i.e., a dual αvβ3/αvβ5 receptor antagonist).
The term "bone resoφtion," as used herein, refers to the process by which osteoclasts degrade bone. The term "alkyl" shall mean straight or branched chain alkanes of one to ten total carbon atoms, or any number within this range (i.e., methyl, ethyl, 1-propyl, 2-propyl, n-butyl, s-butyl, t-butyl, etc.).
The term "alkenyl" shall mean straight or branched chain alkenes of two to ten total carbon atoms, or any number within this range.
The term "alkynyl" shall mean straight or branched chain alkynes of two to ten total carbon atoms, or any number within this range. The term "cycloalkyl" shall mean cyclic rings of alkanes of three to eight total carbon atoms, or any number within this range (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl).
The term "cycloheteroalkyl," as used herein, shall mean a 3- to 8-membered fully saturated heterocyclic ring containing one or two heteroatoms chosen from N, O or S. Examples of cycloheteroalkyl groups include, but are not limited to piperidinyl, pyrrolidinyl, azetidinyl, moφholinyl, piperazinyl.
The term "alkoxy," as used herein, refers to straight or branched chain alkoxides of the number of carbon atoms specified (e.g., Cl-5 alkoxy), or any number within this range (i.e., methoxy, ethoxy, etc.).
The term "aryl," as used herein, refers to a monocyclic or polycyclic system composed of 5- and 6-membered fully unsaturated or partially unsaturated rings, such that the system comprises at least one fully unsaturated ring, wherein the rings contain 0, 1 , 2, 3 or 4 heteroatoms chosen from N, O or S, and either unsubstituted or substituted with one or more groups independently selected from hydrogen, halogen, Cl-10 alkyl, C3- cycloalkyl, aryl, aryl Cl -8 alkyl, amino, amino Cl -8 alkyl, Cl-3 acylamino, Cl -3 acylamino Cl -8 alkyl, Cl -6 alkylamino, C] -6 alkylamino Cl -8 alkyl, Cl-6 dialkylamino, Cl-6 dialkylamino-Ci-8 alkyl, Cl-4 alkoxy, Cl -4 alkoxy Cl -6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl-6 alkyl, Cl -5 alkoxycarbonyl, Cl-3 alkoxycarbonyl Cl -6 alkyl, hydroxycarbonyl Cl-6 alkyloxy, hydroxy, hydroxy Cl-6 alkyl, cyano, trifluoromethyl, oxo or Cl-5 alkylcarbonyloxy. Examples of aryl include, but are not limited to, phenyl, naphthyl, pyridyl, pyrazinyl, pyrimidinyl, imidazolyl, benzimidazolyl, indolyl, thienyl, furyl, dihydrobenzofuryl, benzo(l,3) dioxolane, oxazolyl, isoxazolyl and thiazolyl, which are either unsubstituted or substituted with one or more groups independently selected from hydrogen, halogen, Cl -10 alkyl, C3-8 cycloalkyl, aryl, aryl Cl -8 alkyl, amino, amino Cl-8 alkyl, Cl-3 acylamino, Cl -3 acylamino Cl-8 alkyl, Cl-6 alkylamino, Cl-6 alkylamino-Cl-8 alkyl, Cl -6 dialkylamino, Cl-6 dialkylamino Cl-8 alkyl, Cl-4 alkoxy, Cl-4 alkoxy Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl -6 alkyl, Cl-5 alkoxycarbonyl, Cl-3 alkoxycarbonyl Cl -6 alkyl, hydroxycarbonyl Cl- 6 alkyloxy, hydroxy, hydroxy Cl -6 alkyl, cyano, trifluoromethyl, oxo or Cl -5 alkylcarbonyloxy. Preferably, the aryl group is unsubstituted, mono-, di-, tri- or tetra-substituted with one to four of the above-named substituents; more preferably, the aryl group is unsubstituted, mono-, di- or tri-substituted with one to three of the above-named substituents; most preferably, the aryl group is unsubstituted, mono- or di-substituted with one to two of the above-named substituents. Whenever the term "alkyl" or "aryl" or either of their prefix roots appear in a name of a substituent (e.g., aryl Q)-8 alkyl) it shall be inteφreted as including those limitations given above for "alkyl" and "aryl." Designated numbers of carbon atoms (e.g., Cl-10) shall refer independently to the number of carbon atoms in an alkyl or cyclic alkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.
The terms "arylalkyl" and "alkylaryl" include an alkyl portion where alkyl is as defined above and to include an aryl portion where aryl is as defined above. The Cθ-m or Cl-m designation where m may be an integer from 1-10 or 2-10 respectively refers to the alkyl component of the arylalkyl or alkylaryl unit. Examples of arylalkyl include, but are not limited to, benzyl, fluorobenzyl, chlorobenzyl, phenylethyl, phenylpropyl, fluorophenylethyl, chlorophenylethyl, thienylmethyl, thienylethyl, and thienylpropyl. Examples of alkylaryl include, but are not limited to, toluene, ethylbenzene, propylbenzene, methylpyridine, ethylpyridine, propylpyridine and butylpyridine.
When substituent R1 , R2, R3, R4, R5, R6, R7, R8, R9, R!0, Rl 1 , Rl , Rl3 or R*4 includes the definition Co (e.g., aryl Cθ-8 alkyl), the group modified by Co is not present in the substituent.
Similarly, when any of the variables m, q, r or s is zero, then the group modified by the variable is not present; for example, when s is zero, the group "-(CH2)s C≡CH" is "-C≡CH". In addition, the substituent "(Cl -6 alkyOqamino" where q is zero, one or two, refers to an amino, Cl-6 alkylamino and Cl-6 dialkylamino group, respectively. When a Cl -6 dialkylamino substituent is intended, the Cl-6 alkyl groups can be the same (e.g., dimethylamino) or different (e.g., N(CH3)(CH2CH3)). Similarly, the substituent "(aryl)qamino" or ["(aryl Cl -6 alkyOqamino"], where q is zero, one or two, refers to an amino, arylamino and diarylamino group, [or an amino, aryl Cl-6 alkylamino or di-(aryl Cl -6 alkyl)amino] respectively, where the aryl [or aryl Cl -6 alkyl] groups in a diarylamino [or di-(aryl Cl-6 alkyl)aminol substituent can be the same or different.
The term "halogen" shall include iodine, bromine, chlorine and fluorine.
The term "oxy" means an oxygen (O) atom. The term "thio" means a sulfur (S) atom. The term "oxo" shall mean =0.
The term "substituted" shall be deemed to include multiple degrees of substitution by a named substitutent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the (two or more) substituents can be the same or different. Under standard nonmenclature used throughout this disclosure, the terminal portion of the designated side chain is described first, followed by the adjacent functionality toward the point of attachment. For example, a Cl -5 alkylcarbonylamino Cl-6 alkyl substituent is equivalent to
O
II -C1 -6 alkyl-NH-C-C^s alkyl .
The present invention is also directed to combinations of the compounds of the present invention with one or more agents useful in the prevention or treatment of osteoporosis. For example, the compounds of the instant invention may be effectively administered in combination with effective amounts of other agents used in the treatment of osteoporosis such as bisphosphonate bone resoφtion inhibitors; preferably, the bone resoφtion inhibitor is the bisphosphonate alendronate, now sold as FOSAMAX®. Preferred combinations are simultaneous or alternating treatments of an αvβ3 receptor antagonist of the present invention and FOSAMAX®.
In addition, the integrin (αvβ3) antagonist compounds of the present invention may be effectively administered in combination with a growth hormone secretagogue in the therapeutic or prophylactic treatment of disorders in calcium or phosphate metabolism and associated diseases. These diseases include conditions which can benefit from a reduction in bone resoφtion. A reduction in bone resoφtion should improve the balance between resoφtion and formation, reduce bone loss or result in bone augmentation. A reduction in bone resoφtion can alleviate the pain associated with osteolytic lesions and reduce the incidence and/or growth of those lesions. These diseases include: osteoporosis (including estrogen deficiency, immobilization, glucocorticoid induced and senile), osteodystrophy, Paget's disease, myositis ossificans, Bechterew's disease, malignant hypercalcemia, metastatic bone disease, periodontal disease, cholelithiasis, nephrolithiasis, urolithiasis, urinary calculus, hardening of the arteries (sclerosis), arthritis, bursitis, neuritis and tetany. Increased bone resoφtion can be accompanied by pathologically high calcium and phosphate concentrations in the plasma, which would be alleviated by this treatment. Similarly, the present invention would be useful in increasing bone mass in patients with growth hormone deficiency. Thus, preferred combinations are simultaneous or alternating treatments of an vβ3 receptor antagonist of the present invention and a growth hormone secretagogue, optionally including a third component comprising FOSAMAX®.
In addition, the vitronectin receptor antagonist compounds of the present invention may be effectively administered in combination with one or more agents known to be cytoxic or antiproliferative, e.g, taxol and doxorubicin.
In accordance with the method of the present invention, the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be inteφreted accordingly. It will be understood that the scope of combinations of the compounds of this invention with other agents useful for treating ocvβ3 related conditions includes in principle any combination with any pharmaceutical composition useful for treating osteoporosis.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
The compounds of the present invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixers, tinctures, suspensions, syrups and emulsions. Likewise, they may also be administered in intravenous (bolus or infusion), intraperitoneal, topical (e.g., ocular eyedrop), subcutaneous, intramuscular or transdermal (e.g., patch) form, all using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as an vβ3 inhibitor. The dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician, veterinarian or clinician can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
Oral dosages of the present invention, when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, preferably 0.01 to 10 mg/kg/day, and most preferably 0.1 to 5.0 mg/kg/day. For oral administration, the compositions are preferably provided in the form of tablets containing 0.01 , 0.05, 0.1 , 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. A medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably, from about 1 mg to about 100 mg of active ingredient. Intravenously, the most preferred doses will range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion. Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittant throughout the dosage regimen.
In the methods of the present invention, the compounds herein described in detail can form the active ingredient, and are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as 'carrier' materials) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices. For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incoφorated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta- lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcho lines.
Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxy- ethylaspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polyactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
In the schemes and examples below, various reagent symbols and abbreviations have the following meanings:
Figure imgf000083_0001
Figure imgf000084_0001
The novel compounds of the present invention were prepared according to the procedure of the following schemes and examples, using appropriate materials and are further exemplified by the following specific examples. The most preferred compounds of the invention are any or all of those specifically set forth in these examples. These compounds are not, however, to be construed as forming the only genus that is considered as the invention, and any combination of the compounds or their moieties may itself form a genus. The following examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless otherwise noted. The following Schemes and Examples describe procedures for making representative compounds of the present invention. Moreover, by utilizing the procedures described in detail in PCT International Application Publication Nos. WO95/32710, published 7 December 1995, and W095/17397, published 29 June 1995, in conjunction with the disclosure contained herein, one of ordinary skill in the art can readily prepare additional compounds of the present invention claimed herein.
More specifically, procedures for preparing the N-terminus of the compounds of the present invention are described in WO
95/32710. Additionally, for a general review describing the synthesis of β-alanines which can be utilized as the C-terminus of the compounds of the present invention, see Cole, D.C., Recent Stereoselective Synthetic Approaches to β-Amino Acids, Tetrahedron, 1994, 50, 9517-9582; Juaristi, E, et al., Enantiose lee five Synthesis of β-Amino Acids,
Aldrichemica Ada, 1994, 27, 3. In particular, synthesis of the 3-methyl β-alanine is taught in Duggan, M.F. et al., J. Med. Chem., 1995, 38, 3332-3341 ; the 3-ethynyl β-alanine is taught in Zablocki, J.A., et al., J. Med. Chem., 1995, 38, 2378-2394; the 3-pyrid-3-yl β-alanine is taught in Rico, J.G. et al., J. Org. Chem., 1993, 58, 7948-7951 ; and the 2- amino and 2-toslylamino β-alanines are taught in Xue, C-B, et al., Biorg. Med. Chem. Letts., 1996, 6, 339-344.
SCHEME 1
EDA, THF, -78°C
Figure imgf000086_0001
1 -3
1-4 L-proline, ethaπol, reflux
Figure imgf000086_0002
Figure imgf000086_0003
NaN(TMS)2, DMF, ethyl bromoacetate
Figure imgf000086_0004
SCHEME 1 (CONT'D)
Figure imgf000087_0001
10%Pd/C, EtOAc, H2
Figure imgf000087_0002
1-10, R = Et
6NHCI 1-11, R = H 2-Oxo-3-(3-oxobutyl)piperidine (1 -3)
A stirred solution of TMEDA (3.0 g, 20 mmol), 0.5 M LDA (6 mL, in THF), and THF (10 mL) at -78°C was treated with hi (1.7 g, 10 mmol) (for preparation, see: JOC, 1990, 55, 3682) to effect an orange solution.
After 1 h, the iodide hi (2.4 g, 10 mmol) (J. Org. Chem., 1983, 48, 5381) was added to the orange solution and the resulting solution stirred for 2 h at -78°C, 3 h at -15°C and then 16 h at ambient temperature. The reaction mixture was concentrated and then treated with IN HC1 (30 mL). The mixture was then basified with IN
NaOH/brine followed by extraction with EtOAc (3x). The combined extracts were dried (MgSθ4) and concentrated to give a yellow oil. Flash chromatography (silica, EtOAc → 10% CH3θH/EtOAc) gave hi as a colorless solid. TLC Rf 0.42 (silica, 10% CH3θH/EtOAc)
!H NMR (300 MHz, CDC13) δ 5.75 (bs, 1H), 3.28 (m, 2H), 2.64 (t, 7Hz, 2H), 2.30-1.50 (m, 7H), 2.16 (s, 3H).
2-Oxo-3-r2-(ri .8]-naphthyridin-2-yl)ethvnpiperidine (l-5) A solution of hi (0.25 g, 1.5 mmol), L-proline (85 mg,
0.75 mmol), J 4 (0.18 g, 1.5 mmol) (for preparation see: Synth.
Commun. 1987, J_7, 1695), and ethanol (10 mL) was refluxed for 24 hr.
The cooled solution was concentrated and the residue purified by flash chromatography (silica, EtOAc → 20% CH3θH/EtOAc) to give 1 -5 as a solid.
TLC Rf = 0.32 (silica, 20% CH3θH/EtOAc)
! H NMR (300 MHz, CDCI3) δ 9.08 (m, 1H), 8.16 (m, 1H), 8.10 (d,
J=8Hz, 1H), 7.50 (d, J=8Hz, 1H), 7.45 (m, 1H), 5.64 (bs, 1H), 3.31 (m,
2H), 3.18 (m, 2H), 2.50-1.60 (m, 7H).
Ethyl 2-Oxo-3-[2-([l ,8]-naphthyridin-2-yl)ethyl]piperidin-l-yl-acetate
Ii 6)
A solution of hi (0.28 g, 1.1 mmol) and DMF (10 mL) at -15°C was treated with NaN(TMS)2 (1.2 mL, 1.2 mmol, 1M in hexanes) to give a red solution. After 30 min, the red solution was treated with ethyl bromoacetate (128 μL, 1.2 mmol), followed by continued stirring for 1 h. The reaction mixture was then quenched with sat. NH4CI and then extracted with EtOAc (3x). The combined extracts were washed with brine, dried (MgSθ4), and concentrated. Flash chromatography (silica, 10% CH3θH/EtOAc) gave h . as a yellow gum. TLC Rf = 0.50 (silica, 10% CH3θH/EtOAc) iH NMR (300 MHz, CDCI3) δ 9.07 (m, 1H), 8.16 (m, 1H), 8.10 (d, J=8Hz, IH), 7.50 (d, J=8Hz, IH), 7.44 (m, IH), 4.30-3.90 (m, 4H), 3.50-3.30 (m, 2H), 3.17 (m, 2H), 2.46 (m, 2H), 2.20-1.70 (m, 5H), 1.28 (t, J=7Hz, 3H).
Ethyl 2-Oxo-3-[2-(5,6,7,8-tetrahydro-[l,8]-naphthyridin-2- yPethy llpiperidin- 1 -yl-acetate (1-7) A mixture of ή (102 mg, 0.3 mmol), 10% Pd/C (50 mg), and EtOAc (25 mL) was stirred under a hydrogen atmosphere (1 arm) for 24 h. The catalyst was then removed by filtration through celite and the filtrate concentrated. Flash chromatography (silica, 20% CH3θH/EtOAc) gave hi as a yellow gum. TLC Rf = 0.45 (silica, 30% CH3θH/EtOAc) iH NMR (300 MHz, CDCI3) δ 7.05 (d, J=6Hz, IH), 6.41 (d, J=6Hz, IH), 4.80 (bs, IH), 4.18 (q, J=7Hz, 2H), 4.08 (m, 2H), 3.37 (m, 4H), 2.80-1.60 (m, 13H), 1.26 (t, 7Hz, 3H).
2-Oxo-3-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2-yl)ethyl]piperidin-
1-yl-acetic acid (1-8)
A solution of hi (71 mg, 0.21 mmol) and 6N HC1 (15 mL) was stirred at 55°C for 2h, followed by concentration to give _U8 as a pale yellow gum. TLC Rf = 0.09 (silica, 20% CH3θH/EtOAc) 2-Oxo-3-[2-(5,6,7,8-tetrahydro-[ l ,8]-naphthyridin-2-yl)ethyl]piper-idiri: l -yl-acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester (1-10)
A stiπed mixture of 1^ (71 mg, 0.20 mmol), J _9 (59 mg, 0.22 mmol) (Rico et al, J. Org. Chem., 1993, 58, 7948), NMM (88 μL, 0.8 mmol), and CH3CN (25 mL) was treated with BOP (97 mg, 0.22 mmol). After 24h, the reaction mixture was concentrated to dryness, dissolved in EtOAc, and then washed with H2O, dried (MgSθ4), and concentrated. Flash chromatography (silica, 10% (NH3/EtOH/EtOAc) gave 1-10 as a colorless gum. TLC Rf = 0.9 (silica, 10% (NH3/EtOH)/EtOAc)
ΪH NMR (300 MHz, CD3OD) δ 8.55 (m, IH), 8.43 (m, IH), 7.83 (m, IH), 7.40 (m, IH), 7.1 1 (m, IH), 6.37 (m, IH), 5.38 (m, IH), 4.08 (q, J=7Hz, 2H), 4.00 (m, 2H), 3.37 (m, 4H), 2.90 ( , IH), 2.70-1.60 (m, 14H), 1.14 (t, J=7Hz, 3H).
2-Oxo-3-[2-(5,6,7,8-tetrahydro-[l ,8]-naphthyridin-2-yl)ethyl]piperin- l -yl-acetyl-3(S)-pyridin-3-yl-β-alanine trifluoroacetate (1-11)
A stirred solution of 1 -1 1 (52 mg, 0.10 mmol) and 6N HC1 (10 mL) was heated at 55°C for 2 h, followed by concentration. Preparative HPLC (VYDAC Cl8 semiprep column, gradient elution: [95:5 (0.1% TFA/H2θ/0.1 % TFA/CH3CN) to 50:50
(0.1% TFA/H20/0.1 % TFA/CH3CN) 80 min] gave hll as a colorless solid.
*H NMR (300 MHz, CD3OD) δ 8.90 (s, IH), 8.74 (d, J=5Hz, IH), 8.61 (d, J=8Hz, IH), 8.03 (m, IH), 7.56 (d, J=7Hz, IH), 6.59 (d, J=7Hz, I H), 5.43 (m, IH), 4.03 (m, 2H), 3.40 (m, 5H), 3.00 (m, 2H), 2.78 (m, 4H), 2.40-1.60 (m, 12H). SCHEME 2
2-3 ,
Figure imgf000091_0002
2-4 pTSA, acetone, reflux
Figure imgf000091_0003
2-5 SCHEME 2 (CONT'D)
Figure imgf000092_0001
2-5
1-4 proline, ethanol, reflux
Figure imgf000092_0002
Figure imgf000092_0003
10% Pd/C, H2, ethanol
Figure imgf000092_0004
6N HCI, 50°C
Figure imgf000092_0005
2-8 SCHEME 2 (CONT'D)
Figure imgf000093_0001
2-8
Figure imgf000093_0002
2-11 , R = -C≡CH 2-12, R= 3-pyridyl
1 N NaOH, ethanol
Figure imgf000093_0003
2-13, R = -C≡CH 2-14, R= 3-pyridyl (2-Oxo-3-(3-(ethylendioxy)butyl)pyrrolidin- 1 -vPbenzyl (2-2)
To a stirred solution of 2=1 (5.3 g, 30 mmol) and THF (100 mL) at -78°C was added LDA (17.5 mL, 35 mmol, 2.0 M in hexanes) dropwise over a 10 minute period. After 30 min, hi (5.0 g, 21 mmol) was added followed by removal of the cooling bath. After 1 h, the reaction was quenched with AcOH (10 mL) and then diluted with EtOAc, washed with sat. NaHCθ3 and brine, dried (MgS04) and concentrated. Flash chromatography (silica, 25% — > 75% EtOAc/hexanes) gave 2=2 as an oil. TLC Rf = 0.38 (silica, EtOAc) H NMR (300 MHz, CDC13) δ 7.25 (m, 5H), 4.48 (d, J=15Hz, IH), 4.40 (d, J=15Hz, IH), 3.94 (s, 4H), 3.18 (m, 2H), 2.44 (m, IH), 2.30-1.30 (m, 9H).
2-Oxo-3-(3-(ethylendioxy)butyl)pyrrolidine (2-3)
To a stirred solution of 2=2 (4-l g, l4-2 mmol) in THF
(100 mL) at -78°C was added a solution of Li 4,4'-di-tert-butylbiphenyl
(188 mL, 0.5 M in THF) in 4 portions. After 1 h, the reaction was quenched with AcOH (25 mL). The resulting mixture was diluted with EtOAc and then washed with H2θ, sat. NaHC03, and brine, dried
(MgSθ4) and concentrated. Flash chromatography (silica, EtOAc — >
10% CH3θH/EtOAc) gave 2=2 as a yellow oil.
TLC Rf = 0.1 (silica, EtOAc) iH NMR (300 MHz, CDCI3) δ 6.23 (bs, IH), 3.94 (s, 4H), 3.30 (m, 2H), 2.70 (m, 2H), 2.10-1.30 (m, 9H).
Ethyl (2-Oxo-3-(3-(ethylendioxy)butyl)pyrrolidin-l -vDacetate (2-4)
To a rapidly stirred solution of 2=2 (0.86 g, 4.3 mmol) and THF (25 mL) at -78°C was added NaN(TMS)2 (5.2 mL, 5.2 mmol, 1.0 M in THF). After 20 min, ethyl bromoacetate (0.58 mL, 5.2 mmol) was added followed by removal of the cooling bath. After 1 h, the reaction mixture was diluted with EtOAc and then washed with H2O, sat. NaHCθ3 and brine, dried (MgSθ4), and concentrated to give 2=4 as a yellow oil. TLC Rf = 0.53 (silica, EtOAc) iH NMR (300 MHz, CDC13) δ 4.18 (q, J=7Hz, 2H), 4.04 (m, 2H), 3.93
(s, 4H), 3.39 (m, 2H), 2.44 (m, IH), 2.23 (m, IH), 2.00-1.30 (m, 9H),
1.25 (t, J=7H, 3H).
Ethyl (2-Oxo-3-(3-oxobutyl)pyrrolidin-l -yl)acetate (2-5)
A solution of 2=4 (1.1 g, 3.9 mmol), p-TSA (5 mg) and acetone (50 mL) was heated at reflux for 1 hr. The cooled reaction mixture was diluted with EtOAc and then washed with sat. NaHC03 and brine, dried (MgSθ4), and concentration to afford 2zl as a yellow oil.
TLC Rf = 0.48 (silica, EtOAc) iH NMR (300 MHz, CDCI3) δ 4.18 (q, J=7Hz, 2H), 4.01 (s, 2H), 3.40
(m, 2H), 2.67 (t, J=7Hz, 2H), 2.48 (m, IH), 2.30-1.60 (m, 4H), 2.15 (s,
3H), 1.25 (t, J=7Hz, 3H).
Ethyl (2-Oxo-3-(2-([ 1 ,8]naphthyridin-2-yI)ethyl)pyrrolidin- 1 -yl)-acetate
(2-6)
A mixture of 2=5 (0.77 g, 3.0 mmol), i=4 (0.55 g, 4.5 mmol, for preparation see Het, 1993, 36, 2513), L-proline (0.17 g, 1.5 mmol) and ethanol (25 mL) was heated at reflux for 20 hr. The cooled reaction mixture was concentrated and the residue purified by flash chromatography (silica, EtOAc → 5% CH3θH/EtOAc) to give 2-6 as a yellow oil.
TLC Rf = 0.13 (silica, 10% CH3θH/EtOAc) iH NMR (300 MHz, CDCI3) δ 9.08 (m, IH), 8.17 (m, IH), 8.12 (d,
J=8Hz, IH), 7.49 (d, J=8Hz, IH), 7.46 (m, IH), 4.15 (q, J=7Hz, 2H),
4.04 (m, 2H), 3.42 (m, 2H), 3.21 (t, J=8Hz, 2H), 2.60-1.80 (m, 5H),
1.25 (t, J=7Hz, 3H).
Ethyl (2-Oxo-3-(2-(5,6,7,8-tetrahydro-[l ,8]-naphthyridin-2- vPethvPpyrrolidin-1 -vPacetate (2-7) _____
A mixture of 2=6 (0.87 g, 2.6 mmol), 10% Pd/C (0.5 g), and CH3OH (25 mL) was stirred under a hydrogen atmosphere (1 atm) for 2 hr. The catalyst was then removed by filtration through a celite pad followed by concentration of the filtrate. Flash chromatogφhy (silica, EtOAc → 5% CH3θH/EtOAc) gave 2=2 as a yellow oil. TLC Rf = 0.18 (silica, 5% CH3θH/EtOAc) iH NMR (300 MHz, CDCI3) δ 7.05 (d, J=7Hz, IH), 6.40 (d, J=7Hz, IH), 4.83 (bs, IH), 4.17 (q, J=7Hz, 2H), 4.03 (m, 2H), 3.40 (m, 4H), 2.80-1.60 (m, 11H), 1.27 (t, J=7Hz, 3H).
(2-Oxo-3-(2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2-yl)ethyl)pyrro- lidin-1 -vPacetic acid hydrochloride (2-8) A stirred mixture of 2=1 (0.45 g, 1.4 mmol) and 6N HCI
(10 mL) was heated at 50°C for 1 h, followed by concentration to give 2-8 as a yellow oil. iH NMR (300 MHz, CD3OD) δ 7.60 (d, J=7Hz, IH), 6.66 (d, J=7Hz, IH), 4.05 (s, 2H), 3.50 (m, 4H), 2.83 (m, 4H), 2.54 (m, IH), 2.32 (m, IH), 2.10 (m, IH), 2.00-1.75 (m, 4H).
(2-Oxo-3-(2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2-yl) lidin-l -yl)acetyl-3(S)-ethvnyl-β-alanine ethyl ester (2-1 1)
To a stirred solution of 2=8 (50 mg, 0.15 mmol), 2__ (29 mg, 0.17 mmol) (Zablocki et al., J. Med Chem., 1995, 38, 2378), NMM (83 μL, 0.75 mmol), and CH3CN (1 mL) was added BOP (74 mg, 0.17 mmol). After 20 h, the reaction mixture was diluted with EtOAc and then washed with sat. NaHCθ3, H2O and brine, dried (MgSθ4), and concentrated to give 2-11 as a yellow oil. TLC Rf = 0.24 (silica, 10% CH3θH/EtOAc).
(2-Oxo-3-(2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2-yl)ethyl)pyrro- lidin-l -yl)acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester (2-12)
To a stirred solution of 2_ (50 mg, 0.15 mmol), 2-10 (44 mg, 0.17 mmol) (Rico et al., J. Org. Chem., 1993, 58, 7948), NMM (83 μL, 0.75 mmol), and CH3CN (1 mL) was added BOP (74 mg, 0.17 mmol). After 20 h, the reaction mixture was diluted with EtOAc and then washed with sat. NaHCθ3, H2O and brine, dried (MgSθ4), and concentrated to give 2-12 as a brown oil. TLC Rf = 0.24 (silica, 20% CH3θH/EtOAc).
(2-Oxo-3-(2-(5,6,7,8-tetrahydro[ l,8]-naphthyridin-2- yl)ethyl)pyrrolidin-l -yl)acetyl-3(S)-ethvnyl-β-alanine (2-13) A mixture of 2_i (0.1 g, 0.15 mmol), IN NaOH (300 μL, and ethanol (1 mL) was stirred at ambient temperature for 1 hr. Concentration and then flash chromagraphy (silica, 25:10:1 :1 — > 15:10:1 : 1 EtOAc/EtOH/NH4θH/H2θ) gave 2=12 as a white solid. TLC Rf = 0.18 (silica, 10:10:1 : 1 EtOAc/EtOH/NH4θH/H2θ) J H NMR (300 MHz, CD3OD) δ 7.45 (m, IH), 6.50 (m, IH), 4.53 (m, IH), 3.80-3.30 (m, 5H), 3.05 (m, IH), 2.80-2.15 (m, 9H), 2.00-1.75 (m, 4H).
(2-Oxo-3-(2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2-yl)ethyl)pyrro- lidin-1 -yl)acetyl-3(S)-pyridin-3-yl-β-alanine (2-14)
A mixture of 2=12 (0.1 g, 0.15 mmol), IN NaOH (300 μL) and ethanol (1 mL) was stirred at ambient temperature for 1 hr.
Concentration and the flash chromatography (silica, 25:10:1 :1 →
15:10:1 :1 EtOAc/EtOH/NH4θH/H2θ) gave 2=14 as a white solid. TLC Rf = 0.10 (silica, 10:10: 1 :1 EtOAc/EtOH/NH4θH/H2θ)
*H NMR (300 MHz, CD3OD) δ 8.57 (m, IH), 8.40 (m, IH), 7.86 (m,
IH), 7.40 (m, 2H), 6.50 (m, IH), 5.28 (m, IH), 4.65-4.40 (m, IH),
3.90-1.80 (M, 19H).
SCHEME 3
Figure imgf000098_0001
Figure imgf000098_0002
-97-
SOHFME 3 (cont'd
Figure imgf000099_0001
SCHEME 3 (cont'd)
Figure imgf000100_0001
EDC, HOBT NMM
Figure imgf000100_0002
4-(Propyl-2-ene)butyric acid (3-2)
To a stirred suspension of of methyltriphenylphosphonium bromide (67.7 g, 190 mmol) in 1 L THF at 0° C was added a solution of sodium bis(trimethylsilyl)amide (190 mL, 190 mmol, IM THF) . After an additional 30 minutes, 2=1 ethyl 4-acetylbutyrate (Aldrich Chemical Co.)(25.0 g, 158 mmol) was added, and the mixture sthred for 18 h. The mixture was filtered, and the filtrate concentrated. The residue was triturated with hexanes, and then filtered. Following evaporative removal of the solvent, the residue was chromatographed on silica gel, eluting with 10% ethyl acetate/hexanes to give the olefin as a colorless oil. TLC Rf = 0.52 (10% ethyl acetate/hexanes). !H NMR (300 MHz, CHC13) δ 4.71 (d, 2H, J-13 Hz), 4.13 (q, 2H, J=7 Hz), 2.29 (t, 2H, J=7 Hz), 2.05 (t, 2H, J= 8 Hz), 1.77 (m, 2H), 1.72 (s, 3H), 1.26 (t, 3H, J=7Hz).
A solution of the above olefin (15.4 g, 98.6 mmol), 1 N NaOH (150 mL), and EtOH (300 mL) was stirred at ambient temperature for 2 h. Following acidification with 1 N HCI, the mixture was extracted with ether. The ether layer was washed with brine, dried over magnesium sulfate, and concentrated to give 2=2 as a colorless oil. iH NMR (300 MHz, CHCI3) δ 4.70 (d, 2H, J=13 Hz), 2.27 (t, 2H, J=7 Hz), 2.06 (t, 2H, J= 7 Hz), 1.72 (m, 5H).
(4-(Propyl-2-ene)butanoyl)-4(R)-benzyl-2-oxazolidinone (3-3)
To a solution of 2=2 (6.0 g , 46.8 mmol) in THF (200 ml) at -78° C was added triethylamine (7.19 mL , 51.5 mmol) followed by pivaloyi chloride (6.35 mL , 51.5 mmol). The mixture was warmed to 0°C for 1 h, then recooled to -78° C. In a separate flask, of (R)-(+)-4- benzyl-2-oxazolidinone (9.15 g, 51.5 mmol) was dissolved in THF (100 mL), cooled to -78° C, and n-BuLi (32.3 mL, 51.5 mmol; 1.6 M hexanes) was added drop wise. After 10 minutes, the lithium oxazolidinone was added to the pivalic anhydride. After 10 minutes, the mixture was warmed to 0° C for 1.5 h. The mixture was then poured into ethyl acetate, washed with aqueous sodium bicarbonate, and dried over magnesium sulfate. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, dichloromethane) to give 3-3 as a slightly yellow oil. TLC Rf = 0.8 (CH2C12). iH NMR (300 MHz, CHCI3) δ 7.40-7.18 (m, 5H), 4.80-4.60 (m, 3H), 4.18 (m, 2H), 3.30 (dd, IH, J=3.2, 13.2 Hz), 2.95 (m, 2H), 2.76 (dd, IH, J=9.5, 13.1 Hz), 2.11 (t, 2H, J=7.5 Hz), 1.87 (m, 2H), 1.74 (s, 3H). 2-Chloroethyltriflate (3-4)
To a solution of 1.67 mL (24.8 mmol) of 2-chloroethanol and 3.47 mL (29.8 mmol) of 2,6-lutidine in 20 mL of dichloromethane at 0° C was added 4.59 mL (27.3 mmol) of triflic anhydride. After 1 h, the mixture was diluted with hexanes, washed with ice-cold IN HCI, and dried over sodium sulfate. The solvents were evaporated to give 3-4 as a pink oil. iH NMR (300 MHz, CHC13) δ 4.69 (t, 2H, J=5.3 Hz), 3.78 (t, 2H, J=5.6 Hz).
2(S)-Chloroethyl-4-(propyl-2-ene)butanoyl-(4(R)-benzyl-2- oxazolidinone) (3-5)
To a solution of 2=2 (1 0 g, 38.3 mmol) in THF (60 mL) at -78° C was added a solution of sodium bis(trimethylsilyl)amide (42.1 mL, 42.1 mmol; 1M THF). After 20 min, 2=4 (16.2 ml, 115 mmol) was added over 5 min, and the resulting mixture stirred for 1.5 h at -78° C, then 2 h at -15° C. The mixture was diluted with hexanes, washed with sat. ammonium chloride, and dried over sodium sulfate. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 14% ethyl acetate/hexanes) to give 2=5 as a colorless oil. TLC Rf = 0.5 (20% ethyl acetate/hexanes).
!H NMR (300 MHz, CHCI3) δ 7.30-7.18 (m, 5H), 4.67 (m, 3H), 4.19 (m, 2H), 3.99 (m, IH), 3.58 (m, 2H), 3.33 (dd, IH, J=3.2, 12.0 Hz), 2.75 (dd, IH, J=9.7, 13.5 Hz), 2.23 (m, IH), 2.18-1.82 (m, 4H), 1.77- 1.60 (m, IH), 1.71 (s, 3H).
Ethyl 2-oxo-3(S)-(3-methylenebutyl)pyrrolidine (3-6)
A mixture of 3_ (8.15 g, 23.3 mmol) and NaN3 (4.54 g, 69.8 mmol) in DMSO (120 mL) was heated at 75° C for 2 h. After cooling, the mixture was diluted with ether and hexanes, washed with water, and dried over sodium sulfate. Evaporative removal of the solvent gave the azide as a colorless oil. TLC Rf = 0.5 (20% ethyl acetate/hexanes). iH NMR (300 MHz, CHCI3) δ 7.30-7.22 (m, 5H), 4.69 (m, 3H), 4.17 (d, 2H, J=5.1 Hz), 3.89 (m, IH), 3.38 (m, 3H), 2.74 (m, IH), 2.13-1.63 (m, 6H), 1.71 (s, 3H).
To a solution of of this azide (8.0 g , 22.4 mmol) in THF (250 mL) and water (40 mL) was added triphenylphosphine (8.24 g , 31.4 mmol) in 4 portions over 5 minutes. This mixture was heated at reflux for 2 h, cooled, and evaporated. The residue was chromatographed (silica gel, 10% chloroform/ethyl acetate) to give 3_3 as a colorless oil. TLC Rf = 0.40 (20% chloroform/ethyl acetate). iH NMR (300 MHz, CHCI3) δ 6.47 (br s, IH), 4.73 (m, 2H), 3.31 (m, 2H), 2.33 (m, 2H), 2.08 (m, 3H), 1.81 (m, IH), 1.74 (s, 3H), 1.44 (s, IH).
Ethyl 2-oxo-3(S)-(3-methylenebutyl)pyπolidin-l -yl)acetate (3-7)
To a solution of 2_ (2.50 g, 16.3 mmol) in THF (40 mL) at -78° C was added sodium bis(trimethylsilyl)amide (17.1 mL, 17.1 mmol; IM/ THF) dropwise. After an additional 20 min, ethyl bromoacetate (2.17 mL, 19.6 mmol) was added dropwise over 3 min. After an additional 20 min, 20 mL sat. aqueous NH4CI was added, and the cooling bath removed. The layers were separated, the aqueous layer washed with ether, and the combined organic extracts were dried over sodium sulfate. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 40% ethyl acetate/hexanes) to give 3 7 as a colorless oil.
TLC Rf = 0.85 (50% chloroform/ethyl acetate). iH NMR (300 MHz, CHCI3) δ 4.73 (m, 2H), 4.18 (q, 2H, J=7.1Hz), 4.06 (dd, 2H, J=17.6, 20.8 Hz), 3.42 (m, 2H), 2.44 (m, IH), 2.27 (m, IH), 2.12 (m, 3H), 1.75 (m, IH), 1.74 (s, 3H), 1.50 (m, IH), 1.28 (t, 3H, J=7.3 Hz).
Ethyl 2-oxo-3(S)-(3-oxo-butyl)pyrrolidin-l-yl)acetate (3-8)
To a solution of 2=2 (3.35 g,14.0 mmol) and N- methylmorpholine-N-oxide (3.27 g, 28.0 mmol) in THF (10 mL) and water (1 mL) was added Osθ4 (5.7 mL, 0.56 mmol; 2.5 % t-butanol). After 1 h, NaIθ4 (5.99 g , 28 mmol) in warm water (30 mL) was added over 2 min, and the resulting mixture stirred for 1 h. Water was then added, and the aqueous layer washed with ether and ethyl acetate, and the combined organic extracts were dried over sodium sulfate.
Evaporative removal of the solvent gave 2=8. as a dark oil containing residual Osθ4.
TLC Rf = 0.78 (70:20:10 chloroform/ethyl acetate/MeOH). lH NMR (300 MHz, CHC13) δ 4.19 (m, 2H, J=7.2 Hz), 4.03 (s, 2H), 3.41 (m, 2H), 2.68 (t, 2H, J=9.4 Hz) 2.45 (m, IH), 2.27 (m, IH), 2.17 (s, 3H), 1.97 (m, IH), 1.78 (m, 2H), 1.28 (t, 3H, J=7.2 Hz).
Ethyl 2-oxo-3(S)-[2-([l,8]-naphthyridin-2-yl)ethyl]pyrrolidin-l- vPacetate (3-9) A mixture of 3_ (3.25 g, 13.5 mmol), 1 -4. 2-amino-3- formylpyridine (2.2 g, 18.2 mmol; for preparation see Synth. Commun. 1987, 17, 1695) and proline (0.62 g, 5.39 mmol) in absolute ethanol (45 mL) was heated at reflux for 15 h. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 70:25:5 chloroform/ethyl acetate MeOH to give 2=9 as a colorless oil. TLC Rf = 0.24 (70:25:5 chloroform/ethyl acetate/MeOH). JH NMR (300 MHz, CHCI3) δ 9.08 (m, IH), 8.16 (m, 2H), 7.47 (m, 2H), 4.17 (m, 4H), 3.42 (m, 2H), 3.21 (t, 2H, J=6.0 Hz), 2.56 (m, IH), 2.39 (m, 2H), 2.08 (m, IH), 1.87 (m, IH), 1.27 (t, 3H, J=7.1 Hz).
Ethyl 2-oxo-3(S)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- vPethyllpyrrolidin-1-yPacetate (3-10)
A mixture of 2=2 (3.33 g, 10.2 mmol) and 10% Pd/carbon (1.5 g) in EtOH (50 mL) was stirred under a balloon of hydrogen for 13 h. Following filtration and evaporative removal of the solvent, the residue was chromatographed (silica gel, 70:20:10 chloroform/ethyl acetate/MeOH to give 3-10 as a colorless oil. TLC Rf - 0.20 (70:20:10 chloroform/ethyl acetate/MeOH). iH NMR (300 MHz, CHCI3) δ 7.05 (d, IH, J=7.3 Hz), 6.38 (d, IH, J=7.3 Hz), 4.88 (br s, IH), 4.17 (dd, 2H, J=7.0, 14.4 Hz), 4.04 (dd, 2H, J-17.6, 27.3 Hz), 3.40 (m, 4H), 2.69 (m, 4H), 2.51 (m, IH), 2.28 (m, 2H), 1.90 (m, 2H), 1.78 (m, 2H), 1.27 (t, 3H, J=6.9 Hz).
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- vPethyllpyrrolidin-1-vPacetic acid (3-11)
A mixture of 2=1Q (0.60 g, 1.81 mmol) and 6N HCI (25 mL) was heated at 60° C for 1 h. Evaporative removal of the solvent gave 3-1 1 as a yellow oil. H NMR (300 MHz, DMSO-d6) δ 8.4 (br s, IH), 7.60 (d, IH, J=7.3 Hz), 6.63 (d, IH, J=7.3 Hz), 3.92 (dd, 2H, J=17.6, 25.9 Hz), 3.43 (m, 2H), 3.35 (m, 2H), 2.74 (m, 4H), 2.28 (m, 2H), 2.03 (m, IH), 1.82 (m, 2H), 1.67 (m, 2H).
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- yl)ethyllpyrrolidin-l-vPacetyl-3(S)-alkynyl-β-alanine ethyl ester (3-12)
A mixture of 3-11 (0.20 g, 0.588 mmol), 2_ (0.157 g, 0.882 mmol), EDC (0.147 g, 0.765 mmol), HOBT (0.095 g, 0.706 mmol) and NMM (0.453 mL, 4.12 mmol) in CH3CN (3 mL) and DMF (2 mL) was stirred for 20 h. The mixture was diluted with ethyl acetate, washed with water, brine, and dried over sodium sulfate. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 70:20:10 chloroform/ethyl acetate/MeOH to give 3-12 as a colorless foam.
TLC Rf = 0.44 (70:20:10 chloroform/ethyl acetate/MeOH). iH NMR (300 MHz, CHCI3) δ 7.06 (d, IH, J=7.3 Hz), 6.39 (d, IH, J=7.3 Hz), 5.07 (m, IH), 4.94 (br s, IH), 4.18 (q, 2H, J=6.1 Hz), 3.95 (q, 2H, J=16.1 Hz), 3.39 (m, 4H), 2.90 (s, IH), 2.68 (m, 6H), 2.50 (m, IH), 2.27 (m, 3H), 1.82 (m, 4H), 1.27 (t, 3H, J=7.1 Hz).
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2-yl)ethyl]- yrrolidin-l-yl)acetyl-3(S)-alkvnyl-β-alanine (3-13) To a solution of 2_2 (0.050 g, 0.1 17 mmol) in EtOH (1 mL) was added IN NaOH (0.164 ml, 0.164 mmol). After stirring for 2 h, the solvents were evaporated and the residue was chromatographed (silica gel, 25:10:1:1 ethyl acetate/EtOH/water/NH40H to give 3-13 as a colorless foam.
TLC Rf = 0.26 (25: 10:1 :1 ethyl acetate/EtOH/water/NH4θH). ΪH NMR (300 MHz, DMSO-d6) δ 7.75 (br s, IH), 7.14 (d, IH, J=7.3 Hz), 6.31 (d, IH, J=7.3 Hz), 4.74 (m, IH), 3.90 (d, IH, J=16.6 Hz), 3.67 (d, IH, J-16.6 Hz), 3.23 (m, 4H), 2.57 (m, 7H), 2.30 (m, IH), 2.1 1 (m, 2H), 1.73 (m, 2H), 1.59 (m, 2H).
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- pyrrolidin-l -yl)acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester (3-14) A mixture of 3_i (0.30 g, 0.882 mmol), 2=iQ (0.354 g, 1.32 mmol) , EDC (0.220 g (1.15 mmol), HOBT (0.143 g, 1.05 mmol) and NMM (0.680 mL (6.18 mmol) in CH3CN (5 mL) and DMF (3 mL) at 0° C was stirred for 10 min, then allowed to warm and stir for 20 h. The mixture was diluted with ethyl acetate, washed with water, brine, and dried over sodium sulfate. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 70:20:10 chloroform/ethyl acetate/MeOH to give 3-14 as a colorless foam. TLC Rf = 0.31 (70:20:10 chloroform/ethyl acetate/MeOH). iH NMR (300 MHz, CHCI3) δ 8.55 (d, IH, J=2.2 Hz), 8.50 (dd, IH, J= 1.5, 4.6 Hz), 7.64 (m, 2H), 7.23 (m, IH), 7.05 (d, IH, J=7.3 Hz), 6.38 (d, IH, J=7.3 Hz), 5.40 (m, IH), 4.98 (br s, IH), 4.01 (m, 4H), 3.39 (m, 4H), 2.85 (m, 2H), 2.68 (m, 4H), 2.49 (m, IH), 2.25 (m, 2H), 1.83 (m, 4H), 1.16 (t, 3H, J=7.2 Hz).
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- yl)ethyllpyrrolidin-l -yPacetyl-3(S)-pyridin-3-yl-β-alanine (3-15) To a solution of 3_14. (0.049 g, 0.102 mmol) in THF (1 mL) and water (0.3 mL) at 0° C was added IM LiOH (0.112 ml, 0.112 mmol). After warming to ambient temperature and stirring for 2 h, the solvents were evaporated and the residue was chromatographed (silica gel, 25:10:1 :1 ethyl acetate/EtOH/water/NH4θH to give 2=15 as a colorless foam.
TLC Rf = 0.15 (25: 10:1 :1 ethyl acetate/EtOH/water/NH4θH). iH NMR (300 MHz, DMSO-d6) δ 8.74 (d, IH, J=8.3 Hz), 8.51 (m, IH),
8.42 (m, 2H), 7.70 (d, IH, J=8.1 Hz), 7.33 (m, IH), 7.21 (d, IH, J=7.3
Hz), 6.36 (d, IH, J=7.3 Hz), 5.14 (m, IH), 4.00 (d, IH, J-16.8 Hz), 3.70
(d, IH, J-16.6 Hz), 3.30 (m, 4H), 2.68 (m, 7H), 2.20 (m, 3H), 1.71 (m,
4H).
SCHEME 4
Figure imgf000107_0001
EDC, HOBT NMM
Figure imgf000107_0002
NaOH
Figure imgf000107_0003
SCHEME 4 /cont'd)
Figure imgf000108_0001
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[ l,8]-naphthyridin-2- yl)ethyllpyrrolidin-l -yl)acetyl-3(S)-alkvnyl-β-alanine ethyl ester (4-2)
Prepared from 4_ (prepared by the method used to prepare 3-11. utilizing (S)-(-)-4-benzyl-2-oxazolidinone) and 2_, by the method used to prepare 3-12. iH NMR (300 MHz, CHCI3) δ 7.06 (d, IH, J=7 Hz), 6.39 (d, IH), J=7 Hz), 5.06 (m, IH), 4.84 (br s, IH), 4.16 (q, 2H, J=6 Hz), 3.93 (m, 2H), 3.38 (m, 4H), 2.68 (m, 6H), 2.52 (m, IH), 2.25 (m, 2H), 1.90 (m, 2H), 1.78 (m, 2H), 1.26 (t, 3H, J=7Hz).
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- yl)ethyl1pyrrolidin-l -yl)acetyl-3(S)-alkvnyl-β-alanine (4-3)
Prepared from 4_2 (0.05 g, 0.1 1 mmol) by the method used to prepare 3-13. iH NMR (300 MHz, CD3OD, 1 drop IN NaOD) δ 7.1 1 (d, IH, J=7 Hz), 6.40 (d, IH, J=7 Hz), 4.90 (m, IH), 3.94 (q, 2H, J= 17 Hz), 3.39 (m, 4H), 2.69 (d, 2H, J= 6 Hz), 2.60 (m, 2H), 2.52 (d, J=7 Hz), 2.49 (m, IH), 2.27 (m, IH), 2.13 (m, IH), 1.85 (m, 4H), 1.68 (m, IH).
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2-yl)ethyl]- pyrrolidin-l -yPacetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester (4-4)
Prepared from 4_ (0.35 g, 1.0 mmol) and 2_l_ (0.33 g, 1.2 mmol) by the method used to prepare 3-14. iH NMR (300 MHz, CHCI3) δ 8.55 (d, IH, J= 2 Hz), 8.55 (dd, IH, J= 2 , 5 Hz), 7.61 (m, IH), 7.54 (m, IH), 7.06 (d, IH), 6.38 (d, IH, J=7 Hz), 5.40 (m, IH), 4.90 (br s, IH), 4.05 (q, 2H, J=7 Hz), 3.95 (m, 2H), 3.42 (m, 4H), 2.85 (dd, 2H, J=2, 6 Hz), 2.67 (m, 4H), 2.53 (m, IH), 2.27 (m, 2H), 1.90 (m, 2H), 1.78 (m, 2H), 1.16 (m, 3H, J=7 Hz).
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro-[ 1 ,8]-naphthyridin-2- vPethyllpyrrolidin-l -yl)acetyl-3(S)-ρyridin-3-yl-β-alanine (4-5)
Prepared from 4_4 (0.16 g, 0.33 mmol) by the method used to prepare 3-15. iH NMR (300 MHz, CD3OD) δ 8.57 (s, IH), 8.42 (m, IH), 7.86 (d, IH, J=6 Hz), 7.43 (m, 2H), 6.51 (d, IH, J=7 Hz), 5.28 (m, IH), 4.63 (d, IH, J=17 Hz), 3.60 (m, 2H), 3.47 (d, IH, J= 17 Hz), 3.35 (m, 3H), 3.14 (td, IH, J=5, 13 Hz), 2.75 (m, 5H), 2.42 (m, IH), 2.23 (m, IH), 1.90 (m, 4H). __EME_
Figure imgf000110_0001
5-1 5-2
Figure imgf000110_0002
5-5 SCHFME 5 (confd)
Figure imgf000111_0001
EDC, HOBT, NMM, DMF, 1-9
Figure imgf000111_0002
1.3-Di-tert-buyloxycarbonyl-tetrahydropyrimidine (5-2)
A heterogeneous mixture of ___ (10.0 g, 100 mmol), BOC20 (48 g, 220 mmol), DMAP (20 mg), and CH3CN (500 mL) was heated for 40 hr at 65°C followed by addition of DMF (100 mL) and then continued heating for 24 hr. The cooled reaction mixture was diluted with EtOAc and then washed with H2O, sat. NaHCθ3, IN HCI, and brine, dried (MgS04), and concentrated. The residue was triturated with hexanes to give 5_2 as a yellow solid. TLC RF = 0.93 (EtOAc); JHNMR (300 MHz, CDCI3) δ 3.68 (t, J = 7 Hz, 4H), 2.00 (m, 2H), 1.48 (s, 18 H).
Tert-Butyloxycarbonyl-tetrahydropyrimidine (5-3)
A solution of 5_ (19.0 g, 63 mmol), Mg(Clθ4)2 (2.8 g, 12.7 mmol), and CH3CN was heated at 50 °C for 2 hr. The cooled solution was diluted with CHCI3 and then washed with IN HCI, sat.
NaHCθ3, and brine, dried (MgSθ4), and concentrated. Flash chromatography (silica, 75% EtOAc/ hexanes — EtOAc) gave 5_ as a brown solid. TLC RF = 0.26 (silica, EtOAc);
*HNMR (300 MHz, CDCI3) δ 5.50 (bs, IH), 3.70 (m, 2H), 3.29 (m,
2H), 1.97 (m, 2H), 1.48 (s, 9H).
Tert-Butyloxycarbonyl-2-oxo-3-(3-ethylene glycolbutyl)- tetrahvdropyrimidine (5-4)
To a stirred solution of 5__3 (3.2g, 16.1 mmol) and DMF
(50 mL) was added LiN(TMS)2 (21 mL, lM/hexanes). After 20 minutes, the iodide J_2 (8.6 g, 35.2 mmol) in DMF (10 mL) was added and the reaction mixture heated at 50 °C for 2 hours. The cooled solution was diluted with CHCI3 and then washed with H2O and brine, dried (MgSθ4), and concentrated. Flash chromatography (silica, 60% to 75% EtOAc/hexanes) gave 5_4 as an orange oil.
TLC RF = 0.74 (silica, 70:15:15 CHCl3/EtOAc/CH3θH); - I l l -
*H NMR (300 MHz, CDCI3) δ 3.93 (s, 4H), 3.66 (t, J= 6Hz, 2H), 3.,44 (m, 2H), 3.30 (m, 2H), 1.96 (m, 2H), 1.48 (s, 9H), 1.32 (s, 3H).
l -Oxo-2-(3-ethylene glvcol-butyl) tetrahydro-pyrimidine (5-5) A mixture of 5=4 (3.0 g, 9.5 mmol), TFA (1.5 mL, and toluene (30 mL) was stirred at ambient temperature for 20 minutes, concentrated and the residue azeotroped with toluene to remove excess TFA. The residue was then dissolved in toluene (30 mL) and treated with NaHCθ3 (3g), filtered, and the filtrate concentrated to give a yellow oil. Flash chromatography (silica, 70: 15:15 CHCl3/EtO Ac/ CH3OH) gave 5_5 as a yellow oil.
TLC RF = 0.63 (silica, 70:15:15 CHCl3/EtOAc/CH3θH); lH NMR (300 MHz, CDCI3) δ 5.16 (bs, IH), 3.94 (s, 4H), 3.40 (m,
2H), 3.24 (m, 4H), 1.90 (m, 2H), 1.34 (s, 3H).
Ethyl 2-oxo-3-[3-ethylene glycol-butyl]tetrahydropyrimidin-l-yl- acetate (5-6)
To a stirred solution of 5_5 (2.0 g, 9.3 mmol) and DMF (50 mL) was added LiN(TMS)2 (12.1 mL, 1.0 M/THF). After 20 min, ethyl iodoacetate (1.66 mL, 14.0 mmol) was added followed by heating at 60°C for 1 hr. The cooled solution was diluted with EtOAc and then washed with H2O, sat. NaHC03, and brine, dried (MgS04), and concentrated. Flash chromatography (silica, 50% to 75% EtOAc/hexanes) gave 5_6 as a colorless oil. TLC RF = 0.72 (silica, 70:15:15 CHCl3/EtOAc/CH3θH); lH NMR (300 MHz, CDCI3) δ 4.18 (q, J=7Hz, 2H), 3.93 (s, 4H), 3.42 (m, 2H), 3.34 (m, 4H), 1.98 (m, 2H), 1.92 (m, 2H), 1.34 (s, 3H), 1.25 (t, J=7Hz, 3H).
Ethyl 2-oxo-3-r3-oxo-butylltetrahvdro-pyrimidin-l -yl-acetate (5-7)
A solution of 5_6 (750 mg, 2.5 mmol), p-TSA (10 mg), and acetone (30 mL) was refluxed for 1 hr. The cooled solution was diluted with CHCI3 and then washed with sat. NaHC03 and brine, dried (MgSθ4), and concentrated to give 5_7 as a yellow oil. TLC RF = 0.36 (silica, 10% CH3θH/EtOAc);
*H NMR (300 MHz, CDCI3) δ 4.17 (q, J=7Hz, 2H), 3.56 (m, 2H), 3.34 (m, 4H), 2.76 (t, J=7Hz, 2H), 2.17 (s, 3H), 2.00 (m, 2H), 1.27 (t, J=7Hz, 3H).
Ethyl 2-oxo-3-[2-naphthyridin-2-yl)ethyl]-tetrahydropyrimidin-l-yl- acetate (5-8)
A mixture of 5_7 (600 mg, 2.3 mmol), j_4 (343 mg, 2.8 mmol), L-proline (175 mg), and ethanol (25 mL) was heated at reflux for 18 hr. The cooled reaction mixture was concentrated and the residue purified by flash chromatography (silica, 10% CH3θH/EtOAc) gave 5_8 as a yellow solid.
TLC RF = 0.21 (silica, 10% CH3θH/EtOAc); lH NMR (300 MHz, CDCI3) δ 9.10 (m, IH), 8.19 (m, IH), 8.14 (d, J=8Hz, IH), 7.52 (d, J=8Hz, IH), 7.44 (m, IH), 4.18 (q, J=7Hz, 2H), 3.83 (m, 2H), 3.32 (m, 6H), 1.93 (m, 2H), 1.24 (t, J=7Hz, 3H).
Ethyl 2-oxo-3-[2-(5,6,7,8-tetrahydro-[l ,8]-naphthyridine-2-yl)ethyl] tetrahvdropyrimidine-1 -yl-acetate (5-9) A mixture of 5_8 (600 mg, 1.75 mmol), 10% Pd/C (300 mg), and ethanol (10 mL) was stirred at ambient temperature under a hydrogen atmosphere (1 atm) for 20 hr. The catalyst was removed by filtration through a celite pad and the filtrate concentrated to give 5_ as a yellow oil. ]H NMR (300 MHz, CDCI3) δ 7.04 (d, J=8Hz, IH), 6.42 (d, J=8Hz,
IH), 4.80 (bs, IH), 4.22-4.03 (m, 4H), 3.60 (m, 2H), 2.78 (m, 2H), 2.66 (m, 2H), 1.96 (m, 4H), 1.24 (t, J=7Hz, 3H).
2-Oxo-3-[2-(5,6,7,8-tetrahydro-[ l ,8]naphthridin-2-yl)tetrahydro- pyrimidin-1-yl-acetic acid (5-10)
A solution of 5_9 (600 mg, 1.73 mmol) and 6N HCI (20 mL) was heated at 50°C for 2 hr. The solution was concentrated followed by azeotropic removal of H2O with CH3CN to give 5-10 as a yellow solid. *H NMR (300 MHz, CD3OD) δ 7.58 (d, J=8Hz, IH), 6.63 (d, J=8Hz, IH), 3.98 (s, 2H), 3.62 (t, J=7Hz, 2H), 3.50 (m, 2H), 3.36 (m, 4H), 2.93 (m, 2H), 2.80 (m, 2H), 2.00 (m, 4H).
Ethyl 2-oxo-3-[2-(5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl)ethyl]- tetrahvdropyrimidin-l-yl-acetyl-3(S)-pyridin-3-yl-β-alanine (5-11) To a stirred solution of 5=10 (250 mg, 0.70 mmol), _9 (210 mg, 0.77 mmol), EDC (148 mg, 0.77 mmol), HOBT (95 mg, 0.70 mmol), CH3CN (2 mL), and DMF (2 mL) was added NMM (542 μL, 4.9 mmol). After stirring at ambient temperature for 20 hr, the reaction mixture was diluted with EtOAc and then washed with H2O, sat. NaHCθ3, brine, dried (MgSθ4), and concentrated. Flash chromatography (silica, 70:15: 15 CHCl3/EtOAc/CH3θH) gave 5=11 as a colorless oil. TLC RF = 0.31 (silica, 70: 15:15 CHCI3/ EtOAc/CH3θH);
*H NMR (300 MHz, CDCI3) δ 8.58 (m, IH), 8.50 (m, IH), 7.94 (m, IH), 7.66 (m, IH), 7.22 (m, IH), 7.05 (d, J=8Hz, IH), 6.40 (d, J=8Hz, IH), 5.43 (m, IH), 4.06 (q, J=7Hz, 2H), 4.02 (m, IH), 3.90 (m, IH), 3.60 (m, 2H), 3.39 (m, 2H), 3.29 (m, 2H), 3.19 (m, 2H), 2.88 (m, 2H), 2.77 (m, 2H), 2.70 (m, 2H), 1.90 (m, 4H), 1.16 (t, J=7Hz, 3H).
2-Oxo-3-[2-(5,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl }ethyl]- tetrahvdropyrimidin-l -yl-acetyl-3-(S)-pyridin-3-yl-β-alanine (5-12) A mixture of 5_H (100 mg, 0.22 mmol), IN NaOH (300 μL), and ethanol (1 mL) was stirred at ambient temperature for 1 hr, followed by concentration. Flash chromatography (silica, 25:10: 1 : 1 to 15:10:1 : 1 EtOAc/EtOH/NH4θH/H2θ) gave __2 as a white solid. TLC RF = 0.22 (silica, 10:10:1 :1 EtOAc/ethanol/NH4θH, H2O); l NMR (300 MHz, CD3OD) δ 8.66 (m, IH), 8.39 (m, IH), 7.95 (m, IH), 7.53 (d, J=8Hz, IH), 7.40 (m, IH), 6.66 (d, J=8Hz, IH), 5.18 (m, IH), 4.27 (d, J=7Hz, IH), 4.16 (m, IH), 3.64 (d, J=7Hz, IH), 3.50-3.10 (m, 8H), 3.00-2.65 (m, 6H), 1.95 (m, 4H). SCHEMES
Figure imgf000116_0001
6-1
6-2
Figure imgf000116_0002
6-6
6-5 SCHEME 6 (cont'd)
Figure imgf000117_0001
1.3-Di-tert-buyloxycarbonyl-imidazolidin-2-one (6-2)
A heterogeneous mixture of 6-1 (10.0 g, 116 mmol), BOC20 (56 g, 255 mmol), DMAP (20 mg), and CH3CN (400 mL) was heated for 18 hr at 60°C. The cooled reaction mixture was diluted with EtOAc and then washed with H2O, sat. NaHCθ3, IN HCI, and brine, dried (MgSθ4), and concentrated. The residue was triturated with hexanes to give 6-2 as a white solid. TLC RF = 0.91 (EtOAc);
]H NMR (300 MHz, CDCI3) δ 3.73 (s, 4H), 1.53 (s, 18 H).
Tert-Butyloxycarbonyl-imidazolidin-2-one (6-3)
A solution of 6-2 (28.0 g, 98 mmol), Mg(Clθ4)2 (4.3 g, 20 mmol), and CH3CN (400 mL) was heated at 50 °C for 3 hr. The cooled solution was diluted with CHCI3 and then washed with IN HCI, sat. naHC03, and brine, dried (Mg SO4), and concentrated. Flash chromatography (silica, 50% EtOAc/ hexanes — >EtOAc) gave 6-3 as a yellow solid.
TLC RF = 0.31 (silica, EtOAc); lH NMR (300 MHz, CDCI3) δ 6.27 (bs, IH), 3.86 (m, 2H), 3.47 (m, 2H), 1.50 (s, 9H).
l -Tert-Butyloxycarbonyl-3-(3-ethylene glycol-butyl)imidazolidin-2-one
(6-4)
To a stirred solution of 6-3 (4.5 g, 24 mmol) and DMF (50 mL) was added LiN(TMS)2 (26.6 mL, IM/hexanes). After 20 minutes, the iodide 1-2 (8.6 g, 35.2 mmol) in DMF (10 mL) was added and the reaction mixture heated at 60 °C for 4 hours. The cooled solution was diluted with CHCI3 and then washed with H2O and brine, dried (MgS04), and concentrated. Flash chromatography (silica, 75% EtOAc/hexanes) gave 6-4 as an yellow solid.
TLC RF = 0.71 (silica, 70:15:15 CHCI3/E1OAC/CH3OH);
XH NMR (300 MHz, CDCI3) δ 3.93 (s, 4H), 3.75 (m, 2H), 3.36 (m, 4H), 1.90 (m, 2H), 1.53 (s, 9H), 1.34 (s, 3H). l-(3-Ethylene glvcol-butyl)imidazoIidin-2-one (6-5)
A mixture of 6-4 (4.0 g, 13.3 mmol), TFA (3 mL, and toluene (60 mL) was stirred at 50°C for 60 minutes, concentrated and the residue azeotroped with toluene to remove excess TFA. The residue was then dissolved in toluene (30 mL) and treated with NaHC03 (3g), filtered, and the filtrate concentrated to give a yellow oil. Flash chromatography (silica, 70:25:5 CHCl3/EtOAc/CH3θH) gave 6-5 as a white solid. TLC RF = 0.58 (silica, 70:15:15 CHCl3/EtOAc/CH3θH); lH NMR (300 MHz, CDCI3) δ 4.25 (bs, IH), 3.94 (s, 4H), 3.44 (m, 4H), 3.32 (m, 2H), 1.90 (m, 2H), 1.35 (s, 3H).
Ethyl 2-oxo-3-[3-ethylene glvcol-butyllimidazolidin-1 -yl-acetate (6-6) To a stirred solution of 6-5 (2.0 g, 10 mmol) and DMF (50 mL) was added LiN(TMS)2 (11 mL, 1.0 M/THF). After 20 min, ethyl iodoacetate (3.5 mL, 30 mmol) was added at ambient temperature. After 3 hr the solution was diluted with EtOAc and then washed with H2O, sat. NaHCθ3, and brine, dried (MgSθ4), and concentrated. Flash chromatography (silica, 50% to 75% EtOAc/hexanes) gave 6-6 as a colorless oil.
TLC RF = 0.71 (silica, 70:15:15 CHCl3/EtOAc/CH3θH);
*H NMR (300 MHz, CDCI3) δ 4.18 (q, J=7Hz, 2H), 3.93 (s, 4H), 3.91
(m, 2H), 3.50-3.30 (m, 6H), 1.90 (m, 2H), 1.92 (m, 2H), 1.35 (s, 3H),
1.25 (t, J=7Hz, 3H).
Ethyl 2-oxo-3-r3-oxo-butyl]imidazolidin-l-yl-acetate (6-7)
A solution of 6-6 (1.4 g, 4.9 mmol), p-TSA (10 mg), and acetone (30 mL) was refluxed for 1 hr. The cooled solution was diluted with CHCI3 and then washed with sat. NaHCθ3 and brine, dried (MgS04), and concentrated to give 6-7 as a yellow oil.
TLC RF = 0.34 (silica, EtOAc); l NMR (300 MHz, CDCI3) δ 4.17 (q, J=7Hz, 2H), 3.94 (s, 2H),
3.48 (m, 2H), 3.42 (m, 4H), 2.72 (t, J=7Hz, 2H), 2.17 (s, 3H),
1.27 (t, J=7Hz, 3H). Ethyl 2-oxo-3-r2-naρhthyridin-2-yl)ethyl]imidazolidin-l-yl-acetate (6-8)
A mixture of 6-7 (1.0 g, 4.1 mmol), 1-4 (604 mg, 4.9 mmol), L-proline (238 mg), and ethanol (50 mL) was heated at reflux for 20 hr. The cooled reaction mixture was concentrated and the residue purified by flash chromatography (silica, 70:25:5 CHCl3/EtOAc/CH30H) gave 6-8 as a yellow oil. TLC RF = 0.42 (silica, 70:15:15 CHCl3/EtOAc/CH3θH);
J H NMR (300 MHz, CDCI3) δ 9.10 (m, IH), 8.19 (m, IH), 8.14 (d, J=8Hz, IH), 7.52 (d, J=8Hz, IH), 7.44 (m, IH), 4.17 (q, J=7Hz, 2H)„ 3.81 (m, 2H), 3.42 (m, 4H), 3.32 (m, 4H), 1.24 (t, J=7Hz, 3H).
Ethyl 2-oxo-3-[2-(5,6,7,8-tetrahydro-[ 1 ,8]-naphthyridine-2- vPethyllimidazolidin-1 -yl-acetate (6-9) A mixture of 6-8 (1.1 g, 3.35 mmol), 10% Pd/C (500 mg), and ethanol (30 mL) was stirred at ambient temperature under a hydrogen atmosphere (1 atm) for 20 hr. The catalyst was removed by filtration through a celite pad and the filtrate concentrated to give 6-9 as a colorless oil. TLC RF = 0.1 1 (silica, 70:25:5 CHCl3/EtOAc/CH3θH); lH NMR (300 MHz, CDCI3) δ 7.04 (d, J=8Hz, IH), 6.42 (d, J=8Hz, IH), 4.80 (bs, IH), 4.22-4.03 (m, 4H), 3.96 (s, 2H), 3.55 (m, 2H), 3.40 (m, 2H), 2.78 (m, 2H), 2.68 (m, 2H), 1.90 (m, 2H), 1.24 (t, J=7Hz, 3H).
2-Oxo-3-[2-(5,6,7,8-tetrahydro-[ 1 ,8]naphthridin-2-yl)imidazolidin-l-yl- acetic acid (6-10)
A solution of 6-9 (1.0 g, 3.0 mmol) and 6N HCI (40 mL) was heated at 60°C for 1 hr. The solution was concentrated followed by azeotropic removal of H2O with CH3CN to give 6-10 as a yellow solid. *H NMR (300 MHz, CD3OD) δ 7.58 (d, J=8Hz, IH), 6.63 (d, J=8Hz, IH), 3.98 (s, 2H), 3.50 (m, 4H), 3.36 (m, 4H), 2.93 (m, 2H), 2.82 (m, 2H), 1.97 (m, 4H). Ethyl 2-oxo-3-[2-(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2- yl)ethvnimidazolidin-l-yl-acetyl-3(S)-pyridin-3-yl-β-alanine (6-11 ) To a stirred solution of 6-10 (240 mg, 0.70 mmol), 1-9 (207 mg, 0.77 mmol), EDC (269 mg, 1.4 mmol), HOBT (95 mg, 0.70 mmol), and CH3CN (3 mL) was added NMM (619 μL, 5.6 mmol). After stirring at ambient temperature for 20 hr, the reaction mixture was diluted with EtOAc and then washed with H2O, sat. NaHCθ3, brine, dried (MgSθ4), and concentrated. Flash chromatography (silica, 70: 15:15 CHCl3/EtOAc/CH3θH) gave 6-1 1 as a colorless oil. TLC RF = 0.41 (silica, 70: 15:15 CHCI3/ EtOAc/CH3θH);
*H NMR (300 MHz, CDCI3) δ 8.58 (m, IH), 8.50 (m, IH), 7.94 (m, IH), 7.66 (m, IH), 7.22 (m, IH), 7.05 (d, J=8Hz, IH), 6.40 (d, J=8Hz, IH), 5.43 (m, IH), 4.06 (q, J=7Hz, 2H), 3.85 (m, IH), 3.55 (m, 2H), 3.40 (m, 2H), 3.33 (m, 4H), 2.90 (m, 2H), 2.77 (m, 2H), 2.70 (m, 2H), 1.90 (m, 2H), 1.77 (m, 2H), 1.18 (t, J=7Hz, 3H).
2-Oxo-3-[2-(5,6,7,8-tetrahydro-[l,8]naphthyridin-2-yl}ethyl]- imidazolidin-1 -yl-acetyl-3-(S)-pyridin-3-yl-β-alanine (6-12)
A mixture of 6-11 (160 mg, 0.33 mmol), IN NaOH (500 μL), and ethanol (1 mL) was stirred at ambient temperature for 1 hr, followed by concentration. Flash chromatography (silica, 25:10: 1 :1 to 15:10:1:1 EtOAc/EtOH/NH4θH/H2θ) gave 6-12 as a white solid. TLC RF = 0.21 (silica, 10:10:1 :1 EtOAc/ethanol/NH4θH, H2O);
JH NMR (300 MHz, CD3OD) δ 8.66 (m, IH), 8.39 (m, IH), 7.95 (m, IH), 7.53 (d, J=8Hz, IH), 7.40 (m, IH), 6.66 (d, J=8Hz, IH), 5.22 (m, IH), 3.93 (d, J-17 Hz, IH), 3.74 (d, J=17Hz, IH), 4.00-3.20 (m, 9H), 3.00-2.65 (m, 6H), 1.89 (m, 4H). SCHEME 7
Figure imgf000122_0001
4-1 »Et
HOH2N'
7-1
Figure imgf000122_0002
7-2
Figure imgf000122_0003
7-3 Ethyl 2-oxo-3(R)-[2-(5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2- yl)ethyllpyrrolidin-l-yl)acetyl-3(R)-(2-ethylindol-3-yl)-β-alanine (7-2)
To a stirred solution of 4_ (175 mg, 0.52 mmol), 7_ (214 mg, 0.72 mmol; for preparation see US 5,321,034), EDC (197 mg, 1.0 mmol), HOBT (70 mg, 0.52 mmol), and CH3CN (3 mL) was added NMM (498 μL, 4.1 mmol). After stirring at ambient temperature for 20 hr, the reaction mixture was diluted with EtOAc and then washed with H2O, sat. NaHCθ3, brine, dried (MgS04), and concentrated. Flash chromatography (silica, 70:25:5 CHCl3/EtOAc/CH3θH) gave 7^2 as a white solid.
TLC RF = 0.11 (silica, 70:25:5 CHCI3/ EtOAc/CH3θH); H NMR (300 MHz, CDCI3) δ 8.29 (bs, IH), 7.55 (d, J = 7 Hz, IH), 7.36 (d, J = 7 Hz, IH), 7.20-7.00 (m, 3H), 6.63 (d, J = 7 Hz, IH), 6.39 (d, J = 7 Hz, IH), 4.30 (m, IH), 4.10 (q, J=7Hz, 2H), 3.94 (d, J = 17 Hz, IH), 3.83 (d, J = 17 Hz, IH), 3.36 (m, 4H), 2.80 (m, 2H), 2.69 (m, 3H), 2.53 (d, J= 6 Hz, 2H), 2.50 (m, IH), 2.24 (m, 2H), 1.93 (m, 4H), 1.75 (m, 2H), 1.18 (t, J=7Hz, 3H).
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2- yl)ethyllpyrrolidin-l-yl)acetyl-3(R)-(2-ethylindol-3-yP-β-alanine (7-3) A mixture of 7_2 (60 mg, 0.11 mmol), IN NaOH (132 μL), and ethanol (1 mL) was stirred at ambient temperature for 1 hr, followed by concentration. Flash chromatography (silica, 25:10: 1 :1 to 15:10:1:1 EtOAc/EtOH/NH4θH/H2θ) gave 7=2 as a white solid. TLC RF = 0.12 (silica, 10:10:1 :1 EtOAc/ethanol/NH4θH/H2θ);
*H NMR (300 MHz, CD3OD) δ 7.52 (d, J = 7 Hz, IH), 7.43 (d, J = 7 Hz, IH), 7.30 (d, J = 8 Hz, IH), 7.05 (m, 2H), 6.92 (m, IH), 6.48 (d, J = 7 Hz, IH), 4.54 (d, J = 17 Hz, IH), 4.27 (m, IH), 3.50-1.70 (m, 22H). SCHEME 8 Synthesis of Radioligand for SPA Assay
Figure imgf000124_0001
8- 1
H, dioxane
Figure imgf000124_0002
Figure imgf000124_0003
SCHEME 8 (Cont'd)
Figure imgf000125_0001
__
Figure imgf000125_0002
Figure imgf000126_0001
N-(4-Iodo-phenylsulfonylamino)-L-asparagine (8-2)
To a stirred solution of acid 8_ (4.39 g, 33.2 mmol), NaOH (1.49 g, 37.2 mmol), dioxane (30 ml) and H2θ (30 ml) at 0°C was added pipsyl chloride (10.34 g, 34.2 mmol). After ~5 minutes, NaOH (1.49, 37.2 mmol) dissolved in 15 ml H2O, was added followed by the removal of the cooling bath. After 2.0 h, the reaction mixture was concentrated. The residue was dissolved in H2O (300 ml) and then washed with EtOAc. The aqueous portion was cooled to 0°C and then acidified with concentrated HCI. The solid was collected and then washed with Et2θ to provide acid Σ_2 as a white solid. iH NMR (300 MHz, D2θ) δ 7.86 (d, 2H, J=8HZ), 7.48 (d, 2H, J=8Hz) 3.70 (m, IH), 2.39 (m, 2H).
2(S)-(4-Iodo-phenylsulfonylamino)-β-alanine (8-3) To a stirred solution of NaOH (7.14 g, 181.8 mmol) and
H2O (40 ml) at 0°C was added Br2 (1.30 ml, 24.9 mmol) dropwise over a ten minute period. After ~5 minutes, acid _2 (9.9 g, 24.9 mmol), NaOH (2.00 g, 49.8 mmol) and H2O (35 ml) were combined, cooled to 0°C and then added in a single portion to the reaction. After stirring for 20 minutes at 0°C, the reaction was heated to 90°C for 30 minutes and then recooled to 0°C. The pH was adjusted to ~7 by dropwise addition of concentrated HCI. The solid was collected, washed with EtOAc, and then dried in vacuo to provide acid _2 as a white solid. iH NMR (300 MHz, D2θ) δ 8.02 (d, 2H, J=8Hz), 7.63 (d, 2H, J=8Hz), 4.36 (m, IH), 3.51 (dd, IH, J=5Hz, 13Hz) 3.21 (m, IH).
Ethyl 2(S)-(4-iodo-phenylsulfonylamino)-β-alanine-hvdrochloride (8-4)
HCI gas was rapidly bubbled through a suspension of acid 8-3 (4.0 g, 10.81 mmol) in EtOH (50 ml) at 0°C for 10 minutes. The cooling bath was removed and the reaction was heated to 60°C. After 18 h, the reaction was concentrated to provide ester _4 as a white solid. iH NMR (300 MHz, CD3OD) δ 7.98 (d, 2H, J=8Hz), 7.63 (d, 2H, J=8Hz), 4.25 (q, IH, J=5Hz), 3.92 (m, 2H), 3.33 (m, IH), 3.06 (m, I H), 1.01 (t, 3H, J=7Hz). Ethyl 4-r2-(2-Aminopyridin-6-yl)ethvnbenzoate (8-5)
A mixture of ester 8-5a (700 mg, 2.63 mmol), (for preparation, see: Scheme 29 of PCT International Application Publication No. WO 95/32710, published December 7, 1995) 10% Pd/C (350 mg) and EtOH were stirred under 1 atm H2. After 20 h, the reaction was filtered through a celite pad and then concentrated to provide ester _5 as a brown oil. TLC Rf = 0.23 (silica, 40% EtOAc/hexanes) iH NMR (300 MHz, CDCI3) δ 7.95 (d, 2H, J=8Hz), 7.26 (m, 3H), 6.43 (d, IH, J=7Hz), 6.35 (d, I H, J=8Hz), 4.37 (m, 4H), 3.05 (m, 2H), 2.91 (m, 2H), 1.39 (t, 3H, J=7Hz).
4-r2-(2-Aminopyridin-6-yl)ethyllbenzoic acid hvdrochloride (8-6) A suspension of ester _5 (625 mg, 2.31 mmol) in 6N HCI
(12 ml) was heated to 60°C. After ~20 h, the reaction was concentrated to give acid 8_3 as a tan solid. iH NMR (300 MHz, CD3OD) δ 7.96 (d, 2H, J=8Hz), 7.80 (m, IH), 7.33 (d, 2H, J=8Hz), 6.84 (d, IH, J=9Hz), 6.69 (d, IH, J=7Hz), 3.09 (m, 4H).
Ethyl 4-[2-(2-Aminopyridin-6-yl)ethyl]benzoyl-2(S)-(4-iodo- phenylsulfonylaminoVβ-alanine (8-7)
A solution of acid _6 (400 mg, 1.43 mmol), amine _4 (686 mg, 1.57 mmol), EDC (358 mg, 1.86 mmol), HOBT (252 mg, 1.86 mmol), NMM (632 μl, 5.72 mmol) and DMF (10 ml) was stirred for -20 h. The reaction was diluted with EtOAc and then washed with sat NaHCθ3, brine, dried (MgS04) and concentrated. Flash chromatography (silica, EtOAC — 5% isopropanol/EtOAc) provided amide _7 as a white solid. TLC Rf = 0.4 (silica, 10% isopropanol/EtOAc) iH NMR (300 MHz, CD3OD) δ 7.79 (d, 2H, J=9Hz) 7.61 (d, 2H, J=8Hz), 7.52 (d, 2H, J=9Hz), 7.29 (m, IH), 7.27 (d, 2H, J=8Hz), 4.20 (m, IH), 3.95 (q, 2H, J=7Hz), 3.66 (dd, IH, J=6Hz, 14Hz), 3.49 (dd, IH, J=8Hz, 13Hz), 3.01 (m, 2H), 2.86 (m, 2H), 1.08 (t, 3H, J=7Hz). 4-[2-(2-Aminopyridin-6-yl)ethyl]benzoyl-2(S)-(4-iodophenyl- sulfonylamino)-β-alanine (8-8)
A solution of ester _7 (200 mg, 0.3213 mmol) and 6N HCI (30 ml) was heated to 60°C. After ~20 h, the reaction mixture was concentrated. Flash chromatography (silica, 20:20: 1 : 1 EtOAc/EtOH/ NH4OH/H2O) provided acid _8 as a white solid. TLC Rf = 0.45 (silica, 20:20:1 : 1 EtOAc/EtOH/NH4θH/H2θ) ΪH NMR (400 MHz, DMSO) δ 8.40 (m, IH), 8.14 (Bs, IH), 7.81 (d, 2H, J=8Hz), 7.62 (d, 2H, J=8Hz), 7.48 (d, 2H, J=8Hz), 7.27 (m, 3H), 6.34 (d, IH, J=7Hz), 6.25 (d, IH, J=8Hz), 5.85 (bs, 2H), 3.89 (bs, IH), 3.35 (m, 2H), 2.97 (m, 2H), 2.79 (m, 2H).
4-[2-(2-Aminopyridin-6-yl)ethyl)benzoyl-2(S)-(4-trimethylstannyl- phenylsulfonylamino-β-alanine (8-9)
A solution of iodide _8 (70 mg, 0.1178 mmol), (CH3Sn)2 (49 μl, 0.2356 mmol), Pd(PPh3)4 (5 mg) and dioxane (7 ml) was heated to 90°C. After 2 h, the reaction was concentrated and then purified by prep HPLC (Delta-Pak Cl8 15 μM 100A°> 40 x 100 mm; 95:5 → 5:95 H2O/CH3CN) provided the trifluoroacetate salt. The salt was suspended in H2O (10 ml), treated with NH4OH (5 drops) and then lyophilized to provide amide 8_ as a white solid. iH NMR (400 MHz, DMSO) δ 8.40 (m, IH), 8.18 (d, IH, J=8Hz), 7.67 (m, 5H), 7.56 (d, 2H, J=8Hz), 7.29 (d, 2H, J=8Hz), 6.95-7.52 (m, 2H), 6.45 (bs, 2H), 4.00 (m, IH), 3.50 (m, IH), 3.33 (m, IH), 2.97 (m, 2H), 2.86 (m, 2H).
4-f 2-(2- Aminopyridin-6-yl)ethyl]benzoyl-2(S)-4- 125iodo- phenylsulfonylarnino-β-alanine (8-10) An iodobead (Pierce) was added to a shipping vial of 5 mCi of Nal25 (Amersham, IMS30) and stirred for five minutes at room temperature. A solution of 0.1 mg of 8_ in 0.05 mL of 10% H2Sθ4/MeOH was made and immediately added to the Nal25τ/iodobead vial. After stirring for three minutes at room temperature, approximately 0.04-0.05 mL of NH4OH was added so the reaction mixture was at pH 6-7. The entire reaction mixture was injected onto the HPLC for purification [Vydac peptide-protein C-18 column, 4.6 x 250 mm, linear gradient of 10% acetonitrile (0.1% (TFA):H2θ (0.1 % TFA) to 90% acetonitrile (0.1 % TFA):H2θ (0.1 % TFA) over 30 minutes, 1 mL/min]. The retention time of 8-10 is 17 minutes under these conditions. Fractions containing the majority of the radioactivity were pooled, lyophilized and diluted with ethanol to give approximately 1 mCi of 8-10. which coeluted on HPLC analysis with an authentic sample of 8-8.
Instrumentation: Analytical and preparative HPLC was carried out using a Waters 600E Powerline Multi Solvent Delivery System with 0.1 mL heads with a Rheodyne 7125 injector and a Waters 990 Photodiode Array Detector with a Gilson FC203 Microfraction collector. For analytical and preparative HPLC a Vydac peptide-protein C-18 column, 4.6 x 250 mm was used with a C-18 Brownlee modular guard column. The acetonitrile used for the HPLC analyses was Fisher Optima grade. The HPLC radiodetector used was a Beckman 170 Radioisotope detector. A Vydac C-18 protein and peptide column, 3.9 x 250 mm was used for analytical and preparative HPLC. Solutions of radioactivity were concentrated using a Speedvac vacuum centrifuge. Calibration curves and chemical concentrations were determined using a Hewlett Packard Model 8452A UV/Vis Diode Array Spectrophotometer. Sample radioactivities were determined in a Packard A5530 gamma counter.
SCHEME 9
Figure imgf000131_0001
Boc20, THF
Figure imgf000131_0002
SCHEME 9 (Cont'd)
Figure imgf000132_0001
£_2 Methyl (S)-(3-amino-2-oxo-pyrrolidin-l-yl)-acetic acid hvdrochloride(9-2)
A solution of 9_ (0.50 g, 1.84 mmol) (prepared as described by Freidinger, R. M.; Perlow, D. S.; Veber, D. F.; J. Org. Chem., 1982, 26, 104) in anhydrous ethyl acetate (50 mL) was cooled to 0°C and saturated with HCI gas, then stirred at 0°C for 2 h. The resulting colorless solution was concentrated at reduced pressure and the residue triturated with anhydrous diethyl ether giving _2 as a hygroscopic white solid. !H NMR (300 MHz, CD3OD) δ 4.16 (d, 2H); 4.2 (m, IH); 3.68 (s, 3H); 3.53 (m, 2H); 2.58 (m, IH); 2.09 (m, IH).
Methyl 2-oxo-3(S)-[l ,8]naphthyridin-2-ylmethyl)-aminol-pyrrolidin-l - yll -acetic acid (9-4) A solution of <_2 (232 mg, 1.11 mmol) and 9_3. (176 mg,
1.11 mmol) (prepared as reported by Weissenfels, M.; Ulrici, B.; Z.
Chem. 1978, 78, 20.) in anhydrous methanol (10 mL) was treated with NaOAc (91 mg, 1.1 1 mmol) , NaBH3CN (70 mg, 1.11 mmol) and powdered 4 A molecular sieves (450 mg). The resulting mixture was stirred at 0° for 3.5 h, then concentrated and the residue subjected to flash chromatography on silica gel (95:4.5:0.5 CH2Cl2/MeOH/NH4θH) to afford _4 as a colorless glass.
FAB MS (315, M+ ;
Η NMR (300 MHz, CD3OD) δ 9.04 (d, IH); 8.41 (dd, IH); 8.38(d, IH); 7.72 (d, IH); 7.62 (dd, IH); 4.31 (d, 2H); 4.21 (m, 2H); 3.68 (s,
3H);3.63 (m, IH); 3.53 (m, 2H); 2.52 (m, IH); 1.95 (m, IH).
Methyl [3(S)-[ erf-butoxycarbonyl-[ 1 ,8]naphthyridin-2-ylmethyl)- aminol-2-oxo-pyrrolidin-l -yll-acetic acid (9-5) A solution of amine 9_4 (69 mg, 0.22 mmol) in THF (5 mL) was treated with B0C2O (83 mg, 0.24 mmol) and stirred at room temperature for 18 h. The solvent was removed in vacuo and the resulting residue isolated by chromatography on silica gel (5% MeOH/CH2Cl2) to afford 9_5 as a yellow glass. FAB MS (415, M+ ;
Η NMR (300 MHz, CD3OD) δ 9.04 (d, IH); 8.20 (m, 2H); 7.88 (d, 0.5H (rotamer a)); 7.82 (d, 0.5H (rotamer b)); 7.46(m, IH); 5.1-4.3 (m, 5H); 3.81 (m, 2H); 3.72 (s, 3H); 3.41 (m, 2H); 2.36 (m, 2H); 1.47 (s, 4.5 H (rotamer a)); 1.30 (s, 4.5 H , (rotamer b)).
Methyl 3(S)-[ter/-butoxycarbonyl-(5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin- 2-ylmethyl)-aminol-2-oxo-pyrrolidin-l -yl1-acetic acid (9-6) A solution of 9_5 (40 mg, 0.097mmol) in EtOH (5 mL) was treated with 10% Pd on C (8 mg) and then stirred under a H2 filled balloon for 16 h. The catalyst was removed by filtration through celite and the filtrate concentrated to afford 9_ as a colorless glass. *H NMR (300 MHz, CD3OD) δ 7.10 (d, IH) 6.78 (d, 0.5H (rotamer a)); 6.62 (d, 0.5H (rotamer b)); 4.8-3.9 (m, 5H); 3.81 (m, 2H); 3.72 (s, 3H); 3.38 (m, 2H); 2.36 (m, 2H); 1.21 (s, 4.5 H (rotamer a)); 1.15 (s, 4.5 H , (rotamer b)).
3(S)-[fe -butoxycarbonyl-(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2- ylmethyl)-amino]-2-oxo-pyrrolidin-l -vn-acetic acid (9-7)
A solution of _6 (38 mg, 0.091 mmol) in 50 % aqueous THF (2 mL) was treated with 1.0 N NaOH (95 mL, 0.095 mmol) and stirred at room temperature for 2 h. The reaction was nuetralized with IN HCI, evaporated, and the residue dissolved in MeOH (2.5 mL), filtered and evaporated to afford <__ as a colorless glass. iH NMR (300 MHz, CD3OD) δ 7.31 (d, IH) 6.78 (br, d, IH); 4.8-3.9 (m, 5H); 3.81 (m, 2H); 3.38 (m, 2H); 2.36 (m, 2H); 1.21 (s, 4.5 H (rotamer a)); 1.15 (s, 4.5 H , (rotamer b)).
Ethyl 3-(2-{2-oxo-3(S)-[(5,6,7,8-tetrahydro-[l ,8)naphthyridin-2- ylmethyl)-amino]-pyrrolidin-l -yl } -acetylamino)-3-(S)-pyridin-3-yl- propionic acid (9-8)
9-7 (43 mg, 0.093 mmol), 1 -9 (25 mg, 0093 mmol), EDC (18 mg, 0.093 mmol), HOBT (13 mg, 0.093 mmol), and N-methyl mo holine (31 mL, 0.28 mmol) in anhydrous DMF (5 mL) was stirred at room temperature for 18 h, then concentrated in vacuuo and the residue chromatographed on silica gel using 5% MeOH/CH2θ2 as eluent affording _8 as a colorless glass. JH NMR (300 MHz, CDC13) δ 8.61 (s, IH); 8.45 (d, IH); 8.00 (m, IH);
7.68, (d, IH); 7.21 (m, IH); 7.17 (d, IH); 5.56 (m, IH); 4.75 (s, 2H);
4.45 (m, 2H); 4.05 (q, 2H); 3.95 (m, IH); 3.5-3.3 (m, 4H); 2.92 (m,
I H); 2.87 (m, IH); 2.74 (m, 2H); 2.35 (m, 2H); 1.92 (m, 2H); 1.36 (s,
9H); 1.21 (t, 3H).
3-(2- { 2-oxo-3(S)-[(5,6,7,8-tetrahydro-f 1 ,8]naphthyridin-2-ylmethyl)- amino]-pyrrolidin- 1 -yl } -acetylamino)-3-(S)-pyridin-3-y 1-propionic acid (9-9)
9-8 (25 mg, 0.043 mmol) was dissolved in 6 N HCI (2 mL) and stirred at room temperature for 16 h, then evaporated to afford f_9 as a pale yellow solid.
FAB MS (453, M+*); iH NMR (300 MHz, CD3OD) δ 9.00 (s, IH); 8.81 (d, IH); 8.79(m, IH);
8.10 (m, IH); 7.71 (d, IH); 7.01 (m, IH); 5.56 (m, IH); 4.75 (s, 2H); 4.61 (m, IH); 4.50 (m, IH); 4.35 (m, IH); 4.10 (s, 2H); 3.62 (m, 4H);
3.4 -3.0 (m, 2H); 2.8 (m, 2H); 2.70 (m, IH); 2.45 (m IH);
1.98 (m, 2H).
Following the procedure described in Scheme 10, bicyclic compounds such as 10-6 are readily prepared by one of ordinary skill in the art.
SCHEME 1Q
Figure imgf000136_0001
10-2
10-1 (Fluka)
Figure imgf000136_0002
10-6 SCHEME 11
Figure imgf000137_0001
11-1 n_ 1-2
Figure imgf000137_0002
SCHEME 11 (CONT'D^
Figure imgf000138_0001
proline (cat.)
Figure imgf000138_0002
H2, Pd/C
Figure imgf000138_0003
SCHEME 11 (CONT'D)
Figure imgf000139_0001
EDC, HOBT NMM
Figure imgf000139_0002
11-13
NaOH
Figure imgf000139_0003
3(R)-phenyl-tetrahvdro-pyrrolor 1.2(S)-c1oxazol-5-one (11 -2)
A mixture of alcohol (S)-5-(hydroxymethyl)-2- pyrrolidinone (1 1 -1. Fluka) (5.0 g, 43.4 mmol), benzaldehyde (5.7 mL, 56.4 mmol), p-TSA (80 mg, 0.4340 mmol) and toluene (125 mL) was heated to reflux with azeotropic removal of water for 18 hours. The solution was concentrated. Flash chromatography (silica, 50% EtOAc/hexanes) gave 1 1 -2 as a yellow oil. TLC Rf = 0.21 (silica,50% EtOAc/hexanes) iH NMR (300 MHz, CDCI3) δ 7.29 → 7.46 (m, 5H), 6.34 (s,lH), 4.24 (m, IH), 4.16 (t, J=5.8 Hz, IH), 3.49 ((t, J=7.8 Hz, IH), 2.82 (m, IH), 2.55 (m, IH), 2.39 (m,lH), 1.97 (m,lH).
6(S)-[2-(2-methyl-[l,3]dioxolan-2-yl)-ethyl]-3(R)-phenyl-tetrahydro- pyrroloπ .2(S)-c1oxazol-5-one (1 1 -3) To a stirred solution of U_2 (7.0 g, 34.4 mmol), HMPA
(30.0 mL, 172 mmol) and THF (150 mL) at -78°C was added LDA (18.9 mL, 37.8 mmol, 2.0 M in heptane/THF). After 10 minutes, the reaction was warmed to -15°C. After 20 min, J_2 (8.3 g, 34.4 mmol), dissolved in 10 mL of THF, was added. After 2 h, the reaction was warmed to ambient temperature for 3.0 hours and then recooled to
-15°C for 18 hours. The reaction was warmed to ambient temperature for 2 hours and then diluted with Et20, washed with H20, dried (MgS04) and concentrated. Flash chromatography (silica, 40% → 60% EtOAc/hexanes) gave 1 1-3 as an oil. TLC Rf = 0.28 (silica,50% EtOAc/hexanes)
JH NMR (300 MHz, CDCI3) δ 7.25 → 7.46 (m, 5H), 6.33 (s,lH), 4.24 (m, IH), 4.11 (m, IH), 3.95 (s, 4H), 3.52 (t, J=7.3 Hz, IH), 2.87 (m, IH), 2.57 (m, IH), 2.10 (m,lH) 1.40 → 1.86 (m, 4H), 1.34 (s,3H).
1 -benzyl-5(S)-hydroxymethy l-3(S)-[2-(2-methyl-[ 1 ,3]dioxolan-2-yl)- ethyll-pyrrolidin-2-one (1 1 -4)
A mixture of 11 -3 (2.0 g, 6.30 mmol) and 10% Pd/carbon (2.0 g) in EtOH (30 mL) was stirred under a balloon of hydrogen for 1.0 h. Following filtration and evaporative removal of the solvent, the residue dissolved in benzene (30 mL), treated with TsOH (10 mg) and ethylene glycol (1.05 mL, 18.9 mmol) and then heated to reflux with azeotropic removal of water for 1 hour. The reaction was concentrated. Flash chromatography (silica, 70:23:7 CHCl3/EtOAc/MeOH) gave 1 1 -4 as an oil. iH NMR (300 MHz, CDC13) δ 7.30 (m, 5H), 4.64 (d, J=15 Hz, IH), 4.25 (d, J=15 Hz, IH ), 3.95 (s, 4H), 3.72 (m, IH), 3.49 (m, 2H), 2.46 (m, I H), 2.15 (m, 2H), 1.74 (m,2H), 1.53 (m,2H) 1.35 (s,3H).
l -benzyl-5(S)-iodomethyl-3(S)-[2-(2-methyl-[l ,3]dioxolan-2-yl)-ethyl]- pyrrolidin-2-one (1 1 -5)
To a stirred solution of 1 1 -4 (2.0 g, 6.26 mmol), PPh3 (2.63 g, 10.0 mmol), imidazole (725 mg, 10.6 mmol) and CH3CN (30 mL) at 0°C was added I2 (2.39 g, 9.39 mmol) in five portions over 15 minutes. After 20 minutes, the reaction was warmed to 50°C for 30 minutes and then poured into 200 mL 1 :1 EtOAc/ hexanes. The solution was washed with 10% sodium bisulfite, sat NaHC03, brine, dried (MgS04) and concentrated. Flash chromatography (silica, 40% EtOAc/hexanes) gave 11 -5 as an oil. TLC Rf = 0.27 (silica,50% EtOAc/hexanes)
!H NMR (300 MHz, CDCI3) δ 7.19 → 7.35 (m, 5H), 5.04 (d, J=15.1 Hz, IH), 3.96 (m, 5H), 3.30 (m IH), 3.19 (m, 2H), 2.50 (m, IH), 2.32 (m,lH), 2.12 (m,lH), 1.79 (m,2H), 1.58 (m,lH), 1.36 (m,4H).
l-benzyl-5(R)-methyl-3(S)-[2-(2-methyl-[l,3]dioxolan-2-yl)-ethyl]- pyrrolidin-2-one (1 1-6)
To a stirred solution of 1 1 -5 (900 mg, 6.26 mmol) and HMPA (30 mL) was added NaBH4 (156 mg, 4.20 mmol). After 45 minutes, the reaction was poured into 50 mL 1:1 Et20/ hexanes and then washed with H20, brine, dried (MgS04) and concentrated to provide Vh 6 as an oil. TLC Rf = 0.34 (silica,50% EtOAc/hexanes) iH NMR (300 MHz, CDCI3) δ 7.20 → 7.33 (m, 5H), 4.95 (d, J-15.1 Hz, 1H),4.03 (d, J=14.9Hz, IH), 3.95 (s 4H), 3.41 (m, IH), 2.38 (m, 2H), 2.10 (m,lH), 1.75 (m,2H), 1.48 (m,lH), 1.35 (s,3H), 1.16 (m,4H).
5(R)-methy l-3(S)-[2-(2-methyl-l 1 ,3]dioxolan-2-yl)-ethyl]-pyrrolidin-2- one (l l -7)
Into a 3-necked 500mL flask at -78°C was condensed 200 mL of ammonia. Lithium (64 mg, 9.25 mmol) was washed with MeOH, then THF and then added to the ammonia. After 20 minutes, 1 1-6 (560 mg, 1.85 mmol), dissolved in 25mL of THF, was added. After 30 minutes, the reaction was quenched with NH4C1; 200 mL of THF was added, the cooling bath was removed and the solution purged with argon for 30 minutes to remove the ammonia. The solution was dried (MgS04) and concentrated. Flash chromatography (silica, EtOAc — > 5% MeOH/ EtOAc) gave J__Z as an oil.
TLC Rf = 0.33 (silica, 10% MeOH/ EtOAc) iH NMR (300 MHz, CDCI3) δ 5.98 (br s, IH), 3.94 (s, 4H), 3.67 (m IH), 2.40 (m, 2H), 2.02 (m, IH), 1.70 (m,2H), 1.40 (m,lH), 1.33 (s,3H), 1.22 (m,4H).
{ 5(R)-methyl-3(S)-f 2-(2-methyl-[ 1 ,3]dioxolan-2-yl)-ethyl]-2-oxo- pyrrolidin-1 -yll -acetic acid ethyl ester (11-8)
To a stirred solution of 1 1 -7 (355 mg, 1.67 mmol) and THF (10 mL) at -78°C was added NaN(TMS)2 (1.83 mL, 1.83 mmol, 1.0 M in THF). After 20 min, ethyl bromoacetate (0.203 mL, 1.84 mmol) was added and the reaction was warmed to 0°C. After 30 minutes, the reaction mixture was diluted with EtOAc and then washed with H2O, brine, dried (MgSθ4), and concentrated to give 1 1-8 as a yellow oil. TLC Rf = 0.90 (silica, 10% MeOH/ EtOAc) iH NMR (300 MHz, CDCI3) δ 4.35 (d, J=17.6 Hz, IH), 4.18 (q, J=7.1 Hz, 2H), 3.94 (s, 4H), 3.74 (m, 3H), 2.44 (m, 2H), 2.05 (m, IH), 1.73 (m, 2H), 1.43 (m, IH), 1.33 (s,3H), 1.27 (t, J=7.1Hz, 3H), 1.20 (d, J=6.4 Hz, 3H). [5(R)-methyl-2-oxo-3(S)-(3-oxo-butyl)-pyrrolidin-l -yl]-acetic acid ethyl ester (11 -9)
A solution of 11 -10 (360 mg, 1.20 mmol), p-TSA (10 mg) and acetone (20 mL) was heated at reflux for 1 hr. The cooled reaction mixture was diluted with EtOAc and then washed with sat. NaHC03 and brine, dried (MgS04), and concentrated to afford 1 1 -9 as an oil. TLC Rf = 0.54 (silica, 75%EtOAc/hexanes) iH NMR (300 MHz, CDC13) δ 4.32 (d, J-17.6 Hz, IH), 4.18 (q, J=7.1Hz, 2H), 3.73 (m, 3H), 2.72 (m, 2H), 2.42 (m, IH), 2.16 (s, 3H), 1.99 (m, IH), 1.78 (m, IH), 1.27 (t, J=7.1Hz, 3H), 1.20 (d, J=6.1 Hz, 3H).
[5(R)-methyl-3(S)-(2-[ 1 ,8]naphthyridin-2-yl-ethyl)-2-oxo-pyrrolidin- 1 - yll -acetic acid ethyl ester (1 1-10)
A mixture of 1 1 -9 (220 mg, 0.8619 mmol), 1_, 2-amino-
3-formylpyridine (137 mg, 1.12 mmol) and proline (99 mg, 0.8619 mmol) in absolute ethanol (5 mL) was heated at reflux for 12 h.
Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 70:25:5 chloroform/ethyl acetate/MeOH) to give 1 1-10 as a yellow oil.
TLC Rf = 0.37 (70:25:5 chloroform/ethyl acetate/MeOH). iH NMR (300 MHz, CDCI3) δ 9.08 (m, IH), 8.16 (dd, J=2Hz, 6 Hz
IH), 8.12 (d,J=8Hz, IH), 7.46 (m, 2H), 4.33 (d, J-17.5 Hz, IH), 4.17 (m, 2H), 3.71 (m, 3H), 3.21 (t, J=8.0 Hz, 2H), 2.54 (m, 2H), 2.39 (m,
IH), 2.02 (m, IH), 1.35 (m, IH), 1.26 (t, J=7.1 Hz, 3H), 1.21 (d, J=6.3
Hz, 3H).
{ 5(R)-methyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2- vP-ethvn-pyrrolidin-1-yl l -acetic acid ethyl ester (1 1-11 )
A mixture of J_0 (250 mg, 0.7323 mmol) and 10% Pd/carbon (250 mg) in EtOH (5 mL) was stirred under a balloon of hydrogen for 20 h. Following filtration and evaporative removal of the solvent, the residue was chromatographed (silica gel, 70:25:5 chloroform/ethyl acetate/MeOH to give 1 1 -1 1 as a colorless oil. TLC Rf = 0.25 (70:25:5 chloroform/ethyl acetate/MeOH). iH NMR (300 MHz, CDC13) δ 7.05 (d, IH, J=7.3 Hz), 6.39 (d, IH, J=7.3 Hz), 4.77 (br s, I H), 4.17 (d, IH, J=17.5 Hz), 4.15 (m, 2H), 3.71 (m, 2H), 3.39 (m, 2H), 2.64 (m, 4H), 2.46 (m, 2H), 2.30 (m, IH), 1.91 (m, 2H), 1.88 (m, IH), 1.26(t, 3H, J=6.1 Hz) 1.23 (m,lH), 1.19 (d, J=6.4Hz, 3H).
{5(R)-methyI-2-oxo-3(S)-[2-(5,6,7,8-tetrahy yl)-ethyn-pyrrolidin-l -yl ) -acetic acid hydrochloride (11-12)
A mixture of 11 -1 1 (185 mg, 0.5356 mmol) and 6N HCI (10 mL) was heated at 60° C for 1 h. Evaporative removal of the solvent gave 1 1-12 as a yellow solid. iH NMR (300 MHz, CD3OD) δ 7.59 (d, IH, J=7.3 Hz), 6.66 (d, IH, J=7.3 Hz), 4.17 (d, 12H, J=17.8, Hz), 3.90 (d, IH, J=17.8, Hz), 3.77 (m, IH), 3.50 (t, J=5.4 Hz, 2H), 3.31 (m, 4H), 2.52 ( , 2H), 2.25 (m, IH), 1.95 (t, 2H, J=6.6 Hz), 1.80 (m, I H), 1.34 (m, IH), 1.25 (d, J=6.3 Hz, 3H)
2-Oxo-5(R)-methyl-3(S)-[2-(5,6,7,8-tetrahydro[ l ,8]-naphthyri ethvnpyrrolidin-l -yl)acetyl-3(S)-alkvnyl-β-alanine ethyl ester (1 1-13)
A mixture of 1 1 -12 (350 mg, 0.9892 mmol), 2_ (193 mg, 1.09 mmol), EDC (378 mg, 1.98 mmol), HOBT (134 mg, 0.9892 mmol) and NMM (1.10 mL, 7.91 mmol) in CH3CN (5 mL) was stirred for 20 h. The mixture was diluted with ethyl acetate, washed with sat. NaHC03, brine, and dried over MgS04. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 70:25:5 chloroform/ethyl acetate/MeOH to give 11-13 as a colorless foam. TLC Rf = 0.15 (70:25 :5 chloroform/ethyl acetate/MeOH). iH NMR (300 MHz, CDCI3) δ 7.05 (m, 2H), 6.39 (d, IH, J=7.3 Hz), 5.04 (m, IH), 4.16 (q, 2H, J=7.1Hz), 3.90 (s, 2H), 3.64 (m, 1H),3.39 (m, 2H), 2.69 (m, 6H), 2.47 (m, 2H), 2.30 ( , IH), 1.90 (m, 2H), 1.64 (m, 2H), 1.20 (m, 7H). 2-Oxo-5(R)-methyl-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- yl)ethyllpyrrolidin-l -yl)acetyl-3(S)-alkynyl-β-alanine (11-14)
To a solution of 1 1 -13 (70 mg, 0.1589 mmol) in EtOH (1 mL) was added IN NaOH (0.175 ml, 0.164 mmol). After stirring for 1 h, the solvents were evaporated and the residue was chromatographed (silica gel, 25:10:1 :1 to 15: 10:1 : 1 ethyl acetate/EtOH/water/NH40H to give 1 1 -14 as a colorless foam.
TLC Rf = 0.21 (10: 10: 1 :1 ethyl acetate/EtOH/water/NH4θH). iH NMR (300 MHz, CD3OD) δ 7.42 (d, IH, J=7.3 Hz), 6.49 (d, IH, J=7.3 Hz), 4.35 (d,J=17.1 Hz, IH), 3.64 (m, IH,), 3.50 (m, 3H,), 3.18 (m, 2H), 2.77 (t, J=5.6 Hz, 2H), 2.55 (m, 5H), 2.23 (m, IH), 1.91 (m, 4H), 1.41 (m, IH) 1.28 (d, J=6.3 Hz, 3H).
SCHEME 12
Figure imgf000146_0001
SCHEME 12 (CONT'D)
Figure imgf000147_0001
proline (cat.)
Figure imgf000147_0002
Figure imgf000147_0003
SCHEME 12 (CONT'D)
Figure imgf000148_0001
NaOH
Figure imgf000148_0002
l-benzyl-5(S)-methyl-p-toluenesulfonate-3(S)-[2-(2-methyl- π .31dioxolan-2-yl)-ethyll-pyrroIidin-2-one (12-1)
To a stirred solution of 1 1 -4 (1.8 g, 5.63 mmol) and THF (30 mL) at 0°C was added NaH (248 mg, 6.19 mmol). After 30 minutes, TosCl was added followed by the removal of the cooling bath. After 1.0 hour, the reaction was diluted with EtOAc and then washed with H20, sat NaHC03, brine, dried (MgS04) and concentrated. Flash chromatography (silica, 40 — » 60% EtOAc/hexanes) gave 12-1 as an oil. TLC Rf = 0.75 (silica, EtOAc) iH NMR (300 MHz, CDC13) δ 7.72 (d, J=8.30 Hz, 2H), 7.35 (d, J=7.3 Hz, 2H), 7.25 (m, 3H), 7.09 (m 2H), 4.94 (d, J=14.9 Hz, IH), 4.01 (m, IH), 3.94 (m,5H), 3.83 (d, J=15.1 Hz, IH), 3.54 (m,lH), 2.46 (s,3H), 2.42 (m,lH), 2.21 (m, IH), 2.01 (m, IH), 1.72 (M, 2H), 1.43 (m, 2H), 1.32 (s, 3H).
l-benzyl-5(S)-benzyl-3(S)-[2-(2-methyl-[l ,3]dioxolan-2-yl)-ethyl]- pyrrolidin-2-one (12-2)
To a stirred suspension of Cul (2.57 g, 13.5 mmol) and Et20 (10 mL) at 0°C was added PhLi (14.2 mL, 25.6 mmol, 1.8 M cyclohexane-ether) dropwise over a 1.0 hour period. After an additional hour, 12-1 (1.4 g, 2.96 mmol), dissolved in 10 mL Et20, was added. The reaction was stirred at -15°C for 96 hours. The reaction was diluted with EtOAc and then washed with sat NH4C1, sat NaHC03, brine, dried (MgS04) and concentrated. Flash chromatography (silica, 30 → 60% EtOAc/hexanes) gave 12-2 as an oil. TLC Rf = 0.29 (silica,50% EtOAc/hexanes) iH NMR (300 MHz, CDCI3) δ 7.13 → 7.36 (m, 8H), 7.02 (d, J=7.6Hz, 2H), 5.06 (d, J=14.9 Hz, IH), 4.14 (d, J=15.1 Hz, IH), 3.95 (m, 4H), 3.55 (m, IH), 3.18 (dd, J=4.2, 17.0 Hz,lH), 2.35 (m,2H), 2.04 (m,2H), 1.66 (m,2H), 1.32 (m,5H). 5(S)-benzyl-3(S)-[2-(2-methyl-f l,3]dioxolan-2-yl)-ethyl]-pyrrolidin-2- one (12-3)
Into a 3-necked 500mL flask at -78°C was condensed 100 mL of ammonia. Next, 12-2 (470 mg, 1.24 mmol), dissolved in 20mL of THF, was added. Lithium (19 mg, 2.48 mmol) was washed with
MeOH, then THF and then added to the ammonia. After 20 minutes, the reaction was quenched with NH4C1; 200 mL of THF was added, the cooling bath was removed and the solution purged with argon for 30 minutes to remove the ammonia. The solution was dried (MgS04) and concentrated. Flash chromatography (silica, EtOAc) gave 12-3 as an oil. TLC Rf = 0.22 (silica, EtOAc) iH NMR (300 MHz, CDCI3) δ 7.18 → 7.35 (m, 5H), 5.43 (br s, IH), 3.95 (s, 4H), 3.92 (m IH), 2.88 (dd, J=5.3, 18.6 Hz, IH), 2.41 (m, 2H), 2.03 (m,lH), 1.71 (m,2H), 1.43 (m,2H), 1.33 (s,3H).
{5(S)-benzyl-3(S)-[2-(2-me yl-[l ,3]dioxolan-2-yl)-ethyl]-2-oxo- pyrrolidin-1 -yl l -acetic acid ethyl ester (12-4)
To a stirred solution of 12-3 (210 mg, 0.7257 mmol) and THF (5 mL) at -78°C was added NaN(TMS)2 (0.943 mL, 0.943 mmol, 1.0 M in THF). After 30 min, ethyl bromoacetate (0.104 mL, 0.9434 mmol) was added and the reaction was warmed to 0°C. After 1.0 hour, the reaction mixture was diluted with EtOAc and then washed with sat NaHC03, brine, dried (MgSθ4), and concentrated to give 12-4 as a yellow oil.
TLC Rf = 0.64 (silica, EtOAc) iH NMR (300 MHz, CDCI3) δ 7.15 → 7.33 (m, 5H), 4.40
(d, J=17.8 Hz, IH), 4.15 (m, 2H), 3.93(m, 5H), 3.77 (d, J=17.8, IH),
3.07 (dd, J=5.0, 18.6 Hz, IH), 2.56 (m, IH), 2.39 (m, IH), 2.20 (m, IH), 2.05 (m,lH), 1.69 (m, 2H), 1.23 → 1.46 (m,8H).
r5(S)-benzyl-2-oxo-3(S)-(3-oxo-butyl)-pyrrolidin-l -yl]-acetic acid ethyl ester (12-5)
A solution of !2_ (260 mg, 0.6925 mmol), p-TSA (10 mg) and acetone (20 mL) was heated at reflux for 1 hr. NaHC03 was added to the cooled reaction mixture and then the mixture was concentrated. The residue was diluted with CHC13 and then washed with brine, dried (MgSθ4), and concentrated to afford 12-5 as an oil. TLC Rf = 0.66 (silica, 75%EtOAc/hexanes) iH NMR (300 MHz, CDCI3) δ 7.22 → 7.36 (m, 3H), 7.15 (d, J=6.5 Hz, 2H), 4.37 (d, J=17.6 Hz, IH), 4.18 (m, 2H), 3.97 (m, IH), 3.77 (d, J=17.8 Hz, IH), 3.06 (dd, J=5, 18 Hz, IH), 2.60 (m, 3H), 2.42 (m, I H), 2.17 (m, IH), 2.14 (s, 3H), 1.96 (m,lH), 1.74 (m, I H) 1.27 (m, 4H).
[5(S)-benzy l-3(S)-(2-[ 1 ,8]naphthyridin-2-yl-ethyl)-2-oxo-pyrrolidin- 1 - yll-acetic acid ethyl ester (12-6)
A mixture of 12-5 (230 mg, 0.6940 mmol), J_4, (2-amino- 3-formylpyridine, 110 mg, 0.9022 mmol) and proline (80 mg, 0.6940 mmol) in absolute ethanol (10 mL) was heated at reflux for 18 h. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 70:28:2 chloroform/ethyl acetate/MeOH) to give 12-6 as a yellow oil.
TLC Rf = 0.38 (70:25:5 chloroform/ethyl acetate/MeOH).
!H NMR (300 MHz, CDC13) δ 9.08 (m, IH), 8.16 (dd, J=2Hz, 10 Hz IH), 8.09 (d,J=8.3 Hz, IH), 7.44 (m, 2H), 7.28 (m, 2H), 7.16 (d, J=8Hz, 2H), 4.37 (d, J=17.6 Hz, IH), 4.16 (m, 2H), 3.96 (m, IH), 3.80 (d, J= 17.6 Hz, IH), 3.15 (m, 2H), 3.06 (dd, J=5.3, 18.5, IH), 2.26 → 2.63 (m, 4H), 1.97 (m, IH), 1.47 (m, IH), 1.25 (t, J=7.1 Hz, 3H).
{ 5(S)-benzyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl)- ethyll-pyrrolidin-1 -yl l-acetic acid ethyl ester (12-7)
A mixture of i__ (220 mg, 0.5270 mmol) and 10% Pd/carbon (100 mg) in EtOH (4 mL) was stirred under a balloon of hydrogen for 2 h. Following filtration and evaporative removal of the solvent, the residue was chromatographed (silica gel, 70:25:5 chloroform/ethyl acetate/MeOH to give 12-7 as a colorless oil. TLC Rf = 0.25 (70:25:5 chloroform/ethyl acetate/MeOH). iH NMR (300 MHz, CDCI3) δ 7.26 (m, 3H), 7.16 (d, J=8.1Hz, 2H), 7.04 (d, J=7.3 Hz, IH), 6.36 (d, J=7.3 Hz, IH), 4.74 (br s, IH), 4.39 (d, J-17.8 Hz, IH), 4.15 (m, 2H), 3.90 (m, IH), 3.77 (d, J-17.5 Hz, IH), 3.38 (m, 2H), 3.06 (dd, J=2.4, 18.8 Hz, IH), 2.65 (m, 5H), 2.43 (m, IH), 2.22 (m, 3H), 1.89 (m, IH) 1.36 (m,lH), 1.26 (t, J=7.1 Hz, 3H).
{ 5(s)-benzyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-yl)- ethyll-pyrrolidin-1 -yl l-acetic acid hvdrochloride (12-8)
A mixture of _2_7 (150 mg, 0.3559 mmol) and 6N HCI (10 mL) was heated at 60° C for 1 h. Evaporative removal of the solvent gave 12-8 as a yellow solid. iH NMR (300 MHz, CD3OD) δ 7.57 (d, J=7.3 Hz, IH), 7.24 (m, 5H), 6.60 (d, J=7.3 Hz, IH), 4.24 (d, J-17.8, Hz, IH), 4.03 (m, 2H), 3.49 (t, J=5.6 Hz, 2H), 3.15 (dd, J=4.4, 17.6 Hz, IH), 2.71 (m, 5H), 2.46 (m, IH), 2.21 (m, IH), 1.97 (m,3H), 1.64 (m, IH), 1.45 (m,lH)
2-Oxo-5(S)-benzyl-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2-yl)- ethyllpyrrolidin-l -yl)acetyl-3(S)-ρyridin-3-yl-β-alanine ethyl ester (12-9)
A mixture of 12__. (150 mg, 0.3559 mmol), 2_0 (60 mg, 0.2135 mmol), EDC (132 mg, 0.7118 mmol), HOBT (48 mg, 0.3559mmol) and NMM (0.4 mL, 2.85 mmol) in DMF (4 mL) was stirred for 20 h. The mixture was diluted with ethyl acetate, washed with sat. NaHC03, brine, and dried over MgS04. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 70:20:10 chloroform/ethyl acetate/MeOH to give 12-9 as a colorless foam. TLC Rf = 0.15 (70:25 :5 chloroform/ethyl acetate/MeOH).
!H NMR (300 MHz, CD3OD) δ 8.55 (s, IH), 8.44 (m, IH), 7.82 (m, IH), 7.6-7.1 (m, 7H), 6.33 (d, J=7.5 Hz, IH), 5.40 (t, J=8 Hz, IH), 4.2- 3.8 (m, 6H), 3.38 (m, IH), 3.17 (m, 2H), 2.90 (m, 2H), 2.67 (m, 2H), 2.54 (m, 2H), 2.12 (m, 2H),1.84 (m, 2H), 1.43 (m, 2H) 1.18 (m, 3H).
2-Oxo-5(S)-benzyl-3(S)-[2-(5,6,7,8-tetrahydroLl ,8]-naphthyridin-2- yl)ethyl1pyrrolidin-l -vPacetyl-3(S)-pyridin-3-yl-β-alanine (12-13)
To a solution of J2_ (70 mg, 0.1229 mmol) in EtOH (1 mL) was added IN NaOH (0.150 ml, 0.150 mmol). After stirring for 1.5 h, the solvents were evaporated and the residue was chromatographed (silica gel, 25:10:1:1 to 15:10:1:1 ethyl acetate/EtOH/water/NH4θH to give 12-10 as a colorless foam. TLC Rf = 0.21 (10:10:1:1 ethyl acetate/EtOH/water/NH40H). iH NMR (300 MHz, CD3OD) δ 8.62 (s, IH), 8.36 (m, IH), 7.92 (m, IH), 7.45-7.2 (m, 7H), 6.49 (d, J=7.1 Hz, IH), 5.27 (m, IH), 4.31 (d, J-17.3 Hz, IH), 3.93 (m, IH), 3.72 (d, J-17.5 Hz, IH), 3.30 (m, 3H), 2.92 -2.52 (m, 8H), 2.36 (m, 2H), 1.90 (m, 3H), 1.57 (m, IH).
SCHEME 13
Figure imgf000154_0001
__ 1_1
NaOEt
Figure imgf000154_0002
SCHFME 13. CONT'D
Figure imgf000155_0001
EDC, HOBT NMM
Figure imgf000155_0002
SCHEME 13 (CONT'D)
Figure imgf000156_0001
13-11
Figure imgf000156_0002
1 -benzyl-5(S)-hydroxymethyl-pyrrolidin-2-one (13-1 )
A mixture of 1_2 (5.0 g, 24.6 mmol), 10% Pd/C (2.5 g), and ethanol (80 mL) was stirred at ambient temperature under a hydrogen atmosphere (1 atm) for 5 hr. The catalyst was removed by filtration through a celite pad and the filtrate concentrated to give 13-1 as a colorless oil. TLC RF = 0.55 (silica, 70:20:10 CHCl3/EtOAc/CH3θH);
] H NMR (300 MHz, CDCI3) δ 7.29 (m, 5H), 4.83 (d, 2H, J-15H), 4.25 (d, IH, J-15Hz), 3.77 (m, IH), 3.51 (m, 2H), 2.54 (m, IH), 2.40 (m, IH), 1.92 (m, 2H).
1 -benzyl-5(S)-iodomethyl-pyrrolidin-2-one ( 13-2)
To a solution of 13_ (18.5 g, 90.1 mmol), triphenylphosphine (40.1 g, 153 mmol), and imidazole (11.03 g, 162 mmol) in 225 mL of acetonitrile and 150 mL of ether at 0°C was added iodine (34.3 g, 135 mmol) in 5 portions over 5 minutes. After 10 minutes, the reaction was heated to 50°C, and a stream of argon passed over the reaction to purge the evaporating ether. After an additional 30 minutes, the mixture was diluted with ether, the organic layer washed with NaHC03 (sat.) and brine, dried over K2C03, and the solvent evaporated. Flash chromatography of the residue (silica, 7-15% EtOAc/
CHC13) gave 13-2 as a yellow oil.
TLC Rf = 0.53 (silica, 30% EtOAc/CHCl3) iH NMR (300 MHz, CDCI3) δ 7.31 (m,5H), 5.05 (d, IH, J=15Hz), 3.92 (d, IH, J=15Hz), 3.41 (m, IH), 3.26 (m, 2H), 2.62 (m, IH), 2.43 (m,
IH), 2.16 (m, IH), 1.81 (m, IH).
1 -benzyl-5(R)- methyl-pyrrolidin-2-one (13-3)
To a solution of 13_2 (22.1 g, 70 mmol) in 200 mL of hexamethylphosphorous triamide at 0°C was added NaBH4 (5.25 g, 140 mmol) in 5 portions over 5 minutes. After 10 minutes, the reaction was allowed to warm to ambient temperature and stirred for 2 h. The mixture was diluted with 1:1 ether/hex anes, quenched by the careful addition of 300 mL 10% KHS04 (aq), separated, the organics dried over K2C03, and the solvent evaporated to give 13-2 as a yellow oil TLC Rf = 0.45 (silica, 30% EtOAc/CHCl3) iH NMR (300 MHz, CDC13) δ 7.32 (m, 5H), 4.95 (d, IH, J=15Hz), 4.00 (d, IH, J=15Hz), 3.52 (m, IH), 2.46 (m, 2H), 2.15 (m, IH), 1.60 (m, IH), 1.16 (d, 3H, J=6.0Hz)).
3(R)-azido- 1 -benzyl-5(R)-methyl-pyrrolidin-2-one ( 13-4)
To a solution of _3_i (2.2 g, 1 1.6 mmol) in THF (45 mL) at -78° C was added a solution of LDA (6.39 mL, 12.8 mmol;
2M/THF,ethylbenzene). The mixture was warmed to -15°C for 20 minutes, then recooled to -78°C, and 2,4,6-triisopropylbenzenesulfonyl azide (4.31 g, 13.9 mmol, prepared as described in Harmon, et al, J. Org. Chem. 1973, 38, 11 -16.) was added rapidly as a solution in 40 mL THF at -78°C. After 10 minutes, glacial acetic acid (2.67 mL, 47 mmol) was added, and the resultant viscous liquid mixture allowed to warm to ambient temperature and stir for 1 hour. The solvent was then evaporated, the residue dissolved in CHC13, washed with NaHC0 (sat.), and dried over magnesium sulfate. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 25% ethyl acetate/hexanes) to give 13-4 as a colorless oil. TLC Rf = 0.38 (25% ethyl acetate/hexanes). iH NMR (300 MHz, CHCI3) δ 7.32 (m, 5H), 5.00 (d, IH, J=15 Hz), 4.27 (t, IH, J=7.5 Hz), 3.98 (d, IH, J=15 Hz), 3.54 (m, IH), 1.97 (m, 2H), 1.16 (d, 3H, J=6.0 Hz).
3(S)-azido- 1 -benzy l-5(R)-methyl-pyrrolidin-2-one
To a solution of 1_ (2.17 g, 9.42 mmol) in EtOH (50 mL) was added a solution of NaOEt (3.52 mL, 9.42 mmol; 2.68 M/EtOH). The mixture was stirred for 90 minutes, then quenched by the addition of glacial acetic acid (3 mL). The solvent was then evaporated, the residue slurried in EtOAc, washed with NaHC03 (sat.), and dried over K2C03. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 17% ethyl acetate/hexanes) to give 13-5 as a colorless oil and 13-4 as a colorless oil. TLC Rf = 0.44 (25% ethyl acetate/hexanes). iH NMR (300 MHz, CHCI3) δ 7.32 (m, 5H), 4.97 (d,lH, J=15 Hz), 4.17 (t, IH, J=7.5 Hz), 4.05 (d, IH, J=15 Hz), 3.44 (m, IH), 2.48 (m, 2H), 1.50 (m, IH), 1.22 (d, 3H, J=6.6 Hz).
(l-benzyl-5(R)-methyl-2-oxo-pyrrolidin-3(S)-yl)-carbamic acid tert- butyl ester (13-6) A mixture of JLi_. (2.38 g, 10.3 mmol), 10% Pd/C (1.0 g),
TFA (10 mL), THF (80 mL) and methanol (100 mL) was stirred at ambient temperature under a hydrogen atmosphere (1 atm) for 3 hr. The catalyst was removed by filtration through a celite pad and the filtrate concentrated to give the intermediate amine salt as a colorless oil. To a solution of the crude amine salt in THF (50 mL) at 0°C was added NEt3 (2.88 mL, 20.7 mmol) and di-tert-butyl dicarbonate (2.59 g, 11.9 mmol). The mixture was allowed to warm to ambient temperature and stir for 4 hours. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 40% ethyl acetate/hexanes) to give 13-6 as a colorless oil.
TLC RF = 0.44 (silica, 40% ethyl acetate/hexanes); i H NMR (300 MHz, CHCI3) δ 7.31 (m, 5H), 5.17 (br s, IH), 4.94 (d, IH, J=15 Hz), 4.20 (m, IH), 4.07 (d, IH, J=15 Hz), 3.44 ( , IH), 2.77 (m, IH), 1.45 (s, 9H), 1.20 (d, 3H, J=7 Hz).
(5(R)-methyl-2-oxo-pyrrolidin-3(S)-yl)-carbamic acid tert-butyl ester i3_Q
To a blue solution of lithium metal (0.237 g,34.2 mmol) in NH3 (1) (200 mL) at -78°C was added a solution of _3_5 (2.60 g,8.54 mmol) in THF (15 mL). The mixture was stirred for 15 minutes, then quenched by the addition of ammonium chloride until the blue color dispersed. An additional 30 mL of THF was added, and the mixture warmed to 35°C to evaporate the ammonia. MgS04 was added,the mixture was filtered through a celite pad. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 70:20:10 chloroform/ethyl acetate/MeOH) to give 13-7 as a colorless oil TLC Rf = 0.45 (70:20:10 chloroform/ethyl acetate/MeOH). !H NMR (300 MHz, CHC13) δ 6.97 (br s, IH), 5.24 (d,lH, J=7.6 Hz), 4.32 (br s, IH), 3.66 (m, IH), 2.79 (m, IH), 1.45 (s, 9H), 1.25 (d, 3H, J=6.0 Hz).
(3(S)-tert-butoxycarbonylamino-5(R)-methyl-2-oxo-pyrrolidin-l -yl)- acetic acid ethyl ester (13-8) To a solution of 1_7 ( 1.83 g, 8.4 mmol) in THF (22 mL) at -78° C was added sodium bis(trimethylsilyl)amide (9.4 mL, 9.4 mmol; IM/ THF) dropwise. After an additional 20 min, ethyl bromoacetate (1.13 mL, 10.3 mmol) was added dropwise. After an additional 20 minutes, the mixture was allowed to warm to 0°C, and 20 mL sat. aqueous NH4CI was added. The layers were separated, the aqueous layer washed with EtOAc, and the combined organic extracts were dried over K2C03. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 40% ethyl acetate/hexanes) to give 13-8 as a colorless oil. TLC Rf = 0.39 (40% ethyl acetate/hexanes). H NMR (300 MHz, CHCI3) δ 5.20 (br s, IH), 4.38 (d,lH, J=18 Hz), 4.21 (m, 3H), 3.77 (m, 2H), 2.83 (m, IH), 1.44 (s, 9H), 1.23 (m, 6H).
(3(S)-/er -butoxycarbonylamino-5(R)-methyl-2-oxo-pyrrolidin-l -yl)- acetic acid (13-9)
To a solution 13-8 (527 mg, 1.75 mmol) in EtOH was added IN NaOH (1.93 mL, 1.925 mmol). After stirring for 1 h, the solvents were evaporated, the mixture was diluted with EtOAc, acidified with 10% KHSO4, washed with brine, dried over MgS04, and evaporated to give 13-9 as a white solid.
TLC Rf = 0.48 (silica,9.5/0.5/0.5 CH2Cl2/MeOH/AcOH) *H NMR (300 MHz, CD3OD) δ 4.21 (m, 2H), 3.85 (d, I H, J=18 Hz), 3.74 (m, IH), 2.58 (m, IH), 1.52 (m, IH), 1.44 (s, 9H), 1.25 (d, J=6.3 Hz, 3H). (3(S)- ^-butoxycarbonylamino-5(R)-methyl-2-oxo-pyπOlidin-l-yl)- acetyl-3(S)-alkynyl-β-alanine ethyl ester (13-10)
A mixture of IM (440 mg, 1.62 mmol), (290 mg, 1.62 mmol), EDC (373 mg, 1.94 mmol), HOBT (262 mg, 1.94 mmol) and NMM (1.20 mL, 11.34 mmol) in CH3CN (5 mL) was stirred for 20 h. The mixture was diluted with EtOAc, washed with sat. NaHC03, brine, and dried over MgS04. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, EtOAc) to give 13-10 as a colorless foam.
TLC Rf = 0.20 (silica, EtOAc). H NMR (300 MHz, CDCI3) δ 7.31 (bd, IH), 5.33 (bd, IH), 5.21 (m, IH), 4.16 (m, 5H), 3.64 (m, 2H), 2.72 (m, 2H), 2.45 (d, J=2.2 Hz, IH), 1.52 (m, IH), 1.46 (s, 9H), 1.27 (m, 6H).
(3(S)-amino-5(R)-methyl-2-oxo-pyrrolidin-l -yl)-acetyl-3(S)-alkynyl-β- alanine ethyl ester hydrochloride (13-1 1 )
To a solution of 13-10 (550 mg, 1.39 mmmol) in EtOAc at 0°C was bubbled HCI gas for 5 minutes. The reaction was stirred an additional 5 minutes, followed by removal of the cooling bath and then purged with Argon for 20 minutes. Evaporative removal of the solvent gave 13-1 1 as a white solid. iH NMR (300 MHz, CD3OD) δ 5.02 (m, IH), 4.12 (m, 4H), 3.83 (m, 2H), 2.77 (m, 2H), 1.59 (m,lH), 1.25 (m, 6H).
5(R)-methyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydroll ,8]-naphthyridin-2- ylmethyl)-amino]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine ethyl ester (13-12)
To a soution of 13-1 1 (450 mg, 1.39 mmol) and 5,6,7,8- tetrahydro-[l ,8]naphthyridine-2-carbaldehyde (225 mg, 1.39 mmol) in dichloroethane at 0°C was added Na(OAc)3BH. After 1.5 h the reaction was quenched with sat. NaHC03, diluted with EtOAc, washed with sat. NaHC03, brine and dried over MgS04. Following evaporative removal of the solvent, the residue was chromatographed (silica gel, 70:20: 10 chloroform/ethyl acetate/MeOH to give 13-12 as a colorless foam. TLC Rf = 0.17 (70:15:15 chloroform/ethyl acetate/MeOH). iH NMR (300 MHz, CDCI3) δ 7.09 (d, J=6.8 Hz, IH), 7.03 (d, J=8.5 Hz, IH), 6.48 (d, J=7.3 Hz, IH), 5.05 (m, IH), 4.83 (bs, IH), 4.17 (q, J=6.4, IH), 3.92 (m, 2H), 3.74 (m, 2H), 3.58 (m, 4H), 3.40 (m, 2H), 2.70 (m, 4H), 2.54 (m, IH), 2.26 (s, IH), 1.90 (m, 2H), 1.55 (m, 2H), 1.25 (m, 6H).
5(R)-methyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,8J-naphthyridin-2- ylmethyl)-aminolpyrrolidin-l -yl)acetyl-3(S)-alkvnyl-β-alanine (13-13)
To a solution of 13-12 (108 mg, 0.24 mmol) in EtOH (2 mL) was added IN NaOH (0.270 ml, 0.264 mmol). After stirring for 1 h, the solvents were evaporated and the residue was chromatographed (silica gel, 25: 10: 1 : 1 to 15: 10: 1 : 1 ethyl acetate/EtOH/water/NH4θH) to give 13-13 as a colorless foam.
TLC Rf = 0.23 (12: 10:1 :1 ethyl acetate/EtOH/water/NH40H). iH NMR (300 MHz, D20) δ 7.53 (d, IH, J=7.3 Hz), 6.69 (d, IH, J=7.3 Hz), 4.41 (m, 2H), 3.71 (m, 2H), 3.45 (t, J=5.8 Hz, 2H), 2.79 (t, J=5.8 Hz, 2H), 2.6 (m, 4H), 1.92 (m, 3H), 1.50 (m, IH), 1.19 (m, 3H).
SCHEME 14
Figure imgf000162_0001
2-Dimethox vmethyl-f 1.81naphthyridine (14-1 )
A mixture containing hά (30 g, 0.245 mol), pyruvaldehyde dimethylacetal (87 g, 0.737 mol), and L-proline (7.0g, 0.062 mol) in MeOH (300 mL) was refluxed under argon for 16 h. The cooled solution was filtered, evaporated and the residue dissolved in CH2C12 (500 mL) and washed with water and brine then dried and concentrated to a volumn of ca. 100 mL. Hexane (300 mL) was added and the mixture was kept at 0°C for 3 h, then filtered affording 14-1 as an off-white crystalline solid. Η NMR (300 MHz, CDC13) δ, 9.14 (d, J = 2.2 Hz, IH); 8.26 (d, J = 8.7 Hz, IH); 8.21 (dd, J = 8.7, 2.2 Hz, IH); 7.8 (d, J = 8.3 Hz, IH); 7.5 (m, lH); 5.48 (s, IH); 3.53 (s, 6H).
2-Dimethoxymethyl-5.6.7.8-tetrahydro-r 1.81naphthyridine (14-2) A solution ___ (10 g, 0.049 mol) in MeOH, (100 ml) was treated with 10% Pd on C (1.5 g) and the resulting mixture stirred under a H2 filled balloon for 12.5 h. The catalyst was removed by filtration through celite and the solution concentrated to afford 14-2 as a yellow crystalline solid. Η NMR (300 MHz, CDC13) δ 7.18 (d, J = 7.12 Hz, IH); 6.71 (d, J =
7.12 Hz, IH); 5.18 (s, IH); 4.96 (br, s, IH); 3.43 (s, 6H); 3.4 (m, 2H);
2.65 (m, 2H); 1.91 (m, 2H).
5.6.7.8-tetrahydro-π .81naphthyridine-2-carboxaldehyde (14-3) __2 (10 g, 0.048 mol) was trifluoroacetic acid (50 mL) and the resulting solution stirred under argon for 12.5 h. The TFA was removed at reduced pressure and the residue partitioned between sat. NaHCθ3 and CH2C12. The organic layer was dried, concentrated and passed through a 3 in. pad of silica gel (10% acetone/CH2Cl2) and concentrated to afford 14-3 as a yellow crystalline solid.
Η NMR (300 MHz, CDC13) δ 9.80 (s, IH); 7.31 (d, J = 7.32 Hz, IH); 7.16 (d, J = 7.32 Hz, IH); 5.31 (br, s, IH); 3.48 (m, 2H); 2.81 (m, 2H); 1.94 (m, 2H). SCHEME15
Figure imgf000164_0001
PPA, PhMe
Figure imgf000164_0002
Bn 15-5 15-6 SCHEME 15 (CONT'D)
Figure imgf000165_0001
l-Bromo-3-(2.2-diethoxy-ethoxy)-benzene (15-2)
To a suspension of NaH (2.77 g, 115.6 mmol) in DMF (100 mL) at 0 °C was added a solution of 3-bromophenol 15-1 in DMF (40 mL) over 40 min. After the addition was complete, the solution was stirred for an additional 30 min. The solution was then treated with neat bromoacetaldehyde diethyl acetal (17.36 g, 1 15.6 mmol). The solution was heated at 100 °C for 8 h, cooled to room temperature, and extracted with Et2θ (3 x 200 mL). The combined organic extracts were washed with 10% aq NaOH (100 mL) and brine (100 mL), dried over MgSθ4, filtered and concentrated to give 15-2 as a yellow oil. TLC Rf = 0.4 (10% ethyl acetate/hexanes). iH NMR (300 MHz, CHC13) δ 7.19-7.05 (m, 3H), 6.85 (d, IH), 4.81 (t, IH, J=6.8 Hz), 3.99 (d, 2H, J=6.8 Hz), 3.71 (m, 4H), 1.22 (t, 6H, J=7.1 Hz) ppm.
6-Bromo-benzofuran (15-3)
To a solution of the acetal 15-2 in toluene (200 mL) was added polyphosphoric acid (20 g). The biphasic mixture was heated to 100 °C and stirred at this temperature for 4 h. The mixture was cooled to room temperature, poured onto ice, and extracted with Et2θ ( 2 x 200 mL). The combined organic extracts were washed with saturated aq NaHCθ3 and brine. The solution was dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography (100% hexanes) to give the product 15-3 as a yellow oil. TLC Rf = 0.3 (100% hexanes). iH NMR (300 MHz, CHCI3) δ 7.68 (s, IH), 7.60 (d, IH, J=2.1 Hz), 7.46 (d, IH, J=8.4 Hz), 7.36 (dd, IH, J=8.1 , 1.5 Hz), 6.75 (dd, IH, J=7.1 , 0.9 Hz) ppm.
3-Benzofuran-6-yl-acrylic acid ethyl ester (15-4)
A mixture of the 6-bromobenzofuran 15-3 (1.74 g, 8.79 mmol), ethyl acrylate (1.09 g, 10.98 mmol), Pd(OAc)2 (0.099 g, 0.44 mmol), tri-ø-tolylphosphine (0.268 g, 0.880 mmol), and sodium acetate (3.60 g, 43.9 mmol) in DMF (10 mL) was heated to 100 °C in a sealed tube for 4 h. The mixture was cooled to room temperature, diluted with water, and extracted with Et2θ (2 x 40 mL). The combined organic extracts were washed with brine (30 mL), dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography (10% ethyl acetate/hexanes) to give the ester 15-4 as an off-white solid.
TLC Rf = 0.3 (10% ethyl acetate/hexanes). iH NMR (300 MHz, CHCI3) δ 7.78 (d, IH, J=15.9 Hz), 7.68 (d, IH, J=2.4 Hz), 7.66 (s, IH), 7.59 (d, IH, J=8.4 Hz), 7.43 (dd, IH, J=9.0, 1.5 Hz), 6.78 (m, IH), 6.47 (d, IH, J-15.9 Hz), 4.27 (q, 2H, J=7.2 Hz), 1.34 (t, 3H, J=7.2 Hz) ppm.
3-(S)-Benzofuran-6-yl-3-[benzyl-(l(R)-phenyl-ethyl)-amino]-proρionic acid ethyl ester (15-5) A solution of benzyl-α-( ?)-methylbenzylamine (1.32 g,
6.30 mmol) in THF (25 mL) at 0 °C was treated with n-BuLi (2.52 mL of a 2.5 M soln in hexanes). The resulting solution was stirred at 0 °C for 30 min and then cooled to -78 °C. A solution of acrylate 15-4 (0.681 g, 3.15 mmol) in THF (5 mL) was added. After stirring for 15 min at -78 °C, satd aq NH4CI soln (5 mL) was added and the cold bath removed. The mixture was warmed to room temperature, and extracted with Et2θ (2 x 40 mL). The combined organic extracts were washed with brine (30 mL), dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography (10% ethyl acetate/hexanes) to give the β-aminoester 15-5 as a yellow oil. TLC Rf = 0.8 (10% ethanol/dichloromethane). iH NMR (300 MHz, CHCI3) δ 7.58 (m, 3H), 7.41 (m, 2H), 7.22 (m, 9H), 7.59 (s, IH), 4.58 (m, IH), 4.05 (m, IH), 3.91 (q, 2H, J=7.1 Hz), 3.72 (m, 2H), 2.62 (m, 2H), 1.21 (d, 3H, J=7.2 Hz), 1.03 (t, 3H, J=7.1 Hz) ppm.
3(5)-Amino-3-(2,3-dihydro-benzofuran-6-yl)-propionic acid ethyl ester H 5-6) A mixture of the dibenzylamine 15-5 (1.19 g, 2.78 mmol) in EtOH/H2θ/AcOH (26 mL/3 mL/1.0 mL) was degassed with argon and treated with Pd(OH)2 (1.19 g). The mixture was placed under 1 atm of H2- After stirring for 18 h, the mixture was diluted with EtOAc, and filtered through celite. The filtrate was concentrated and the residue purified by flash chromatography (10% ethyl acetate/dichloromethane) to give the ester 15-6 as a white solid. TLC Rf = 0.25 (10% ethanol/dichloromethane). lU NMR (300 MHz, CD3OD) as the trifluoroacetate salt: δ 7.25 (d, IH, J=8.1 Hz), 6.88 (m, IH), 7.66 (s, IH), 6.82 (s, IH), 4.58 (m, 3H), 4.12 (m, 2H), 3.30 (m, IH), 3.19 (m, 2H), 2.98 (m, 2H), 1.11 (t, 3H, J=7.2 Hz) ppm.
3(5)-(2,3-Dihydro-benzofuran-6-yl)-3-(2- { 2-oxo-3(S)-[2-(5,6,7,8- tetrahydro-[ 1 ,8]naphthyridin-2-yl)-ethyl]-pyrrolidin- 1 -yl } - acetylamino)-propionic acid ethyl ester (15-7)
A solution of the amine 15-6 (0.100 g, 0.425 mmol), acid 3-1 1 (0.155 g, 0.511 mmol), EDC (0.098 g, 0.51 1 mmol), NMM (0.103 g, 1.02 mmol), and HOAT (0.069 g, 0.51 1 mmol) in DMF ( 6 mL) was stirred at room temperature for 48 h. The solution was diluted with satd aq NaHC03 (3 mL) and extracted with EtOAc (2 x 10 mL). The combined organic extracts were washed with brine (10 mL), dried over MgSθ4, filtered, and concentrated. The residue was purified by flash chromatography (8% ethanol/dichloromethane) to give the ester 15-7 as an yellow oil.
TLC Rf = 0.3 (10% ethanol/dichloromethane).
! H NMR (300 MHz, CHCI3) δ 7.12 (m, 2H), 6.78 (m, IH), 6.65 (s, IH), 6.39 (m, IH), 5.36 (m,lH), 4.99 (br s, IH), 4.55 (t, J=7.2 Hz, 2H), 4.1 1 (m, 2H), 3.91 (m, 2H), 3.39 (m, 2H), 3.19 (m, 2H), 2.79 (m, 2H), 2.70 (m, 2H), 2.51 (m, IH), 2.28 (m, 2H), 1.85 (m, 3H), 1.18 (m, 3H) ppm.
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-{ 2-oxo-3(S)-[2-(5,6,7,8- tetrahydro-[ 1 ,8]naphthyridin-2-yl)-ethy l]-pyrrolidin- 1-yl }- acetylaminoVpropionic acid (15-8) A solution of the ester 15-7 (0.038 g, 0.073 mmol) in EtOH/H2θ (4.5 mL/0.5 mL) was treated with LiOH (0.009 g, 0.365 mmol) and the homogeneous solution stirred at room temperature for 4 h. The solution was concentrated to a solid residue which was dissolved in H2θ and purified by preparative HPLC (gradient conditions: 95:05 to 50:50 H2θ/MeCN with 0.1 % TFA) to give the acid _5_ as a white solid (as the bis-trifluoroacetate salt). MS (LR, FAB) M +1 calcd 493, found 493.39. iH NMR (300 MHz, CHCI3) δ 7.91 (m, IH), 7.35 (m, IH), 7.09 (m, IH), 6.76 (m, IH), 6.68 (s, IH), 6.43 (m, 2H), 5.28 (m, IH), 4.53 (m, 2H), 4.41 (m, IH), 3.38 (m, 7H), 3.14 (m, 3H), 2.81 (m, 5H), 2.60 (m, IH), 2.28 (m, IH), 2.05 (m, 3H) ppm.
SCHEME 16
Figure imgf000170_0001
__l ___
Figure imgf000170_0002
HCI EtOAc
CbzN
Figure imgf000170_0003
N
EDC, HOBT DMF
2HCI H,N^^C°2B
±_
CbzNH
Figure imgf000170_0004
__ SCHEME1β(cQnt,)
Figure imgf000171_0001
16-6
Figure imgf000171_0002
16-8 3-Benzylox vcarbonylamino-6-methyl-2-pyridinone ( 16-2).
CbzNH
Figure imgf000172_0001
DPPA (35.6 ml, 165 mmol) was added to a stirred solution of 2- hydroxy-6-methylpyridine-3-carboxylic acid ( 16- 1 : Aldrich; 22.97 g, 165 mmol) and triethylamine (23.0 ml, 165 mmol) in dry dioxane (300 ml) and the resulting solution was heated to reflux. After 16 h more triethylamine (23.0 ml, 165 mmol) and benzyl alcohol (17.1 ml, 165 mmol) were added and the solution was refluxed for a further 24 h.
The reaction was concentrated in vacuo to remove most of the volatiles. The residue was partitioned between methylene chloride (500 ml) and brine (500 ml), acidified to pH 1 with 1 M HCI (165 ml). The aqueous layer was extracted methylene chloride (two times) and the combined organic layers were washed with sodium hydrogen carbonate solution and brine, dried (Na2Sθ4) and evaporated in vacuo to a brown solid. This was recrystallized from methanol, to give the title compound 16-2 as a tan solid: *H NMR (300 MHz, CDCI3) δ 2.29 (s, 3H, CH3), 5.20 (s, 2H, PhCH2), 6.06 (d, J=7.6 Hz, pyridinone-5-H), 7.32-7.43 (m, 5H, Ph), 7.67 (br s, IH, CbzNH), 8.03 (br d, pyridinone-4-H).
2-[6-methyl-2-oxo-3-(benzyloxycarbonylamino)-2/ -pyridin-l -yl]acetic acid t-butyl ester (16-3).
Figure imgf000172_0002
Sodium hydride (5.3 g, 0.22 mol) was added to a stirred slurry of 3- benzyloxycarbonylamino-6-methyl-2-pyridinone (16-2: 53.2 g, 0.20 mol) in THF at 0°C. t-Butylbromoacetate (45 ml, 0.27 mol) was added to the resulting solution and a precipitate rapidly forms. The reaction was warmed to it over lh and after 2h the solvent was evaporated in vacuo and the residue was partitioned between 1 : 1 water/brine (200 ml) and 6:1 THF/methylene chloride (700 ml). The organic layer was dried (Na2Sθ4) and evaporated in vacuo to a solid which was triturated with hexane to give the title compound 16-3 as a crystalline solid: i H NMR (400 Mz, CDCI3) δ 1.47 (s, 9H), 2.25 (s, 3H), 4.75 (s, 2 H), 5.19 (s, 2H), 6.09 (d, J=7.8 Hz), 7.30-7.40 (m, 5H), 7.75 (br s, IH), 7.94 (br d, IH).
2-[6-methyl-2-oxo-3-(benzyloxycarbonylamino)-2//-pyridin-l-ylJacetic acid (16-4).
Figure imgf000173_0001
HCI gas was bubbled through a stirred suspension of 2-[6-methyl-2-oxo- 3-(benzyloxycarbonylamino)-2H-pyridin-l -yl]acetic acid t-butyl ester (16-3: 12.3 g, 33 mmol) in ethyl acetate (250 ml) at -15°C for 20 min. The resulting solution was allowed to warm to room temperature and was then stirred there for 3 h. After purging with argon, the bulk of the solvent was rotavapped off and ether added to the residue. The solid which precipitated was filtered off and washed with ether. The title compound 16-4 was thus obtained as a white fluffy powder: *H NMR (CD3OD) δ 2.32 (s, 3 H), 4.86 (s, 2 H), 5.18 (s, 2 H), 6.24 (d, J = 7.9 Hz, 1 H), 7.31 -7.41 (m, 6 H), 7.94 (br s, 1 H).
3-(2- { 6-methyl-2-oxo-3-(benzyloxycarbonylamino)-2 -pyridin- 1 -yl } - acetylamino)-3(S)-pyridin-3-yl-propionic acid ethyl ester (16-5).
Figure imgf000174_0001
To a solution of the acid 2_ (150 mg, 0.47 mmol) and the amine _9 (Rico et al; J. Org. Chem., 1993, 58, 7948; 139 mg, 0.52 mmol) in DMF (3 mL) was added HOBT (77 mg, 0.57 mmol) then Et3N (200 μL, 1.42 mmol). After 15 minutes, EDC (136 mg, 0.71 mmol) was added and the mixture was stirred for 16 hours. The solution was poured into EtOAc, washed with saturated NaHC03 then brine, dried (MgSθ4), and evaporated to give the title compound 16-5 as a white solid which was used as such in the next step. *H NMR (CDCI3) δ 1.14 (3H, t), 2.40 (3H, s), 2.8-2.9 (2H, m), 4.05 (2H, q), 4.78 (2H, m), 5.22 (2H, s), 5.4 (IH, q), 6.17 (IH, d), 7.22 (IH, m), 7.3-7.45 (4H, m), 7.59 (IH, m), 7.7-7.8 (2H, m), 8.0 (IH, m), 8.52 (2H, m).
3-(2- { 6-methyl-2-oxo-3-amino-2/ -pyridin- 1 -yl } -acetylamino)-3(S)- pyridin-3-yl-propionic acid ethyl ester (16-6).
Figure imgf000174_0002
To a degassed solution of the pyridone 16-5 (243 mg; 0.49 mmol) in EtOH (20 mL) was added 10% Pd on carbon (25 mg) and this was then stirred under an atmosphere of hydrogen gas (balloon) for 3 hours. The mixture was filtered through a pad of celite and the solvent removed to give the title compound (16-6) as a viscous oil which was used as such in the next step. 3-(2-{6-methyl-2-oxo-3-[(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2- ylmethyl)-amino]-2 -pyridin- 1 -yl } -acetylamino)-3(S)-pyridin-3-yl- propionic acid ethyl ester (16-7).
Figure imgf000175_0001
To a solution of the amine 16-6 (155 mg, 0.433 mmol), the aldehyde 14-3 (70 mg, 0.433 mmol) in CH2CICH2CI was added crushed 4λ seives, AcOH (20 μL) and then NaB(OAc)3H (184 mg, 0.866 mmol). After stirring for 48 hours, the mixture was filtered through celite, poured into EtOAc and washed with saturated NaHCθ3 then brine. The dried (MgSθ4) solution was concentrated in vacuo to give a foam type solid. Column chromatography (5%MeOH in CHCI3) afforded the title compound 16-7 as a foam type solid. Analysis calculated for C27H32N6O4O.25CHCI3 C, 61.24; H, 6.08; N, 15.73 found C, 61.33; H, 6.09; N, 15.85.
FAB mass spectrum, m/z = 505.34 (M+H)
3-(2-{6-methyl-2-oxo-3-[(5,6,7,8-tetrahydro-[l ,81naphthyridin-2- ylmethyl)-amino]-2//-pyridin- 1 -yl } -acetylamino)-3(S)-pyridin-3-yl- propionic acid bis trifluoroacetate (16-8).
Figure imgf000175_0002
The ester 16-7 (120 mg, 0.238 mmol) was dissloved in H2θ (1 mL) and THF (1 mL) and then IN LiOH (1 mL, 1 mmol) was added. After 2 hours, the mixture was purified by reverse phase HPLC (Waters PrepPak C1 column eluting with H2θ/acetonitrile gradient) to give, after lyophilization, the title compound 16-8 as a powder Analysis calculated for C25H28N6θ4«2.5TFA«0.55H2θ
C, 46.70; H, 4.13; N, 10.89 found C, 46.70; H, 4.14; N, 1 1.04.
FAB mass spectrum, m/z = 477.2 (M+H)
SCHEME 17
Figure imgf000177_0001
Figure imgf000177_0002
__ i__
Figure imgf000177_0003
SCHEME 17 (cont.l
Figure imgf000178_0001
17-7
Figure imgf000178_0003
Figure imgf000178_0002
β-N.N-Dimethylaminoethenylcyclopropyl ketone (17-2).
Figure imgf000179_0001
A mixture of cyclopropyl methyl ketone (5.88 ml, 59 mmol) and N,N-dimethylformaldehyde dimethyl acetal (7.83 ml, 59 mmol) was heated in the presence of a catalytic quantity of p- toluenesulfonic acid for 48 hours. The resulting crude sample of the title compound (17-2. a pale yellow oil) was used in subsequent reactions without further purification: *H NMR (CDCI3) δ 0.74 (m, 2 H), 1.00 (m, 2 H), 1.75 (m, 1 H), 3.48 (s, 3 H), 3.50 (s, 3 H), 5.20 (d, 1 H), 7.55 (d, 1 H).
6-Cvclopropyl-3-nitro-2-(lH)-pyridinone (17-3).
A mixture of crude β-N,N- dimethylaminoethenylcyclopropyl ketone (17-2: 12 g, < 86 mmol), nitroacetamide (9 g, 86 mmol) and aqueous piperidinium acetate (10 ml) [prepared from glacial acetic acid (42 ml), water (100 ml) and piperidine (72 ml)] was stirred at room temperature overnight. Following dilution with water (20 ml), the yellow precipitate was isolated via filtration and drying in vacuo to yield the title compound 17_3: iH NMR (CDCI3) δ 1.15 (m, 2 H), 1.36 (m, 2 H), 2.10 (m, 1 H), 6.02 (br d, J = 8.0 Hz, 1 H), 8.41 (d, J = 8.0 Hz, 1 H).
3-Nitro-6-cyclopropyl-l -(t-butyl-carhoxymethylene)-2-pyridinone (17- 4}
Figure imgf000180_0001
Solid 6-cyclopropyl-3-nitro-2-(lH)-pyridinone (17-3: 1.4 g, 7.78 mmol) was added in small portions to a suspension of sodium hydride (260 mg, 10.8 mmol) in THF (30 ml) at room temperature. After stirring the resulting solution for 20 min, fe/ r-butylbromoacetate (4 ml, 27 mmol) was added. The mixture was stirred for an additional 30 min. then heated at 55°C for 15 hrs. After cooling to room temperature the THF was evaporated in vacuo and ice carefully added to the residue to destoy any excess sodium hydride. The resu tting miture was extracted with 2:1 :1 ethyl acetate:ether:chloroform and the extracts dried over magnesium sulfate. Filtration and evaporation of the filtrate gave a yellow oil as a 3:1 mixture of N and O-alkylated products respectively. Flash column chromatography eluting with 1 :1 hexane/ethyl acetate gave the title compound 17-4 as a yellow crystalline solid: ΪH NMR (CDCI3) δ 0.94 (m, 2 H), 1.18 (m, 2 H), 1.49 (s, 9 H), 1.79 (m, 1 H), 5.04 (s, 2 H), 6.10 (d, J = 8.1 Hz, 1 H), 8.33 (d, J = 8.1 Hz, 1 H).
3-Amino-6-cyclopropyl- 1 -(t-butyl-carboxymethylene)-2-pyridinone H 7-5)
Figure imgf000180_0002
A mixture of 3-nitro-6-cyclopropyl-l-(t-butyl-methylene- carboxy)-2-pyridinone (17-4; 760 mg, 2.58 mmol) and platinum oxide (250 mg) in ethanol (30 ml) was stirred at 0° C under an atmosphere of hydrogen for 3 hours. Following removal of most of the catalyst by filtration through a bed of Celite, the filtrate was concentrated and the residue purified by flash column chromatography eluting with 2: 1 hexane/ethyl acetate. This yielded the title product 17-5 as a viscous orange gum: *H NMR (CDCI3) δ 0.67 (m, 2 H), 0.89 (m, 2 H), 1.49 (s, 9 H), 1.63 (m, 1 H), 4.07 (br s, 2 H), 4.99 (s, 2 H), 5.91 (dd, J = 1.2 and 7.4 Hz, 1 H), 6.47 (d, J = 7.4 Hz, 1 H).
{ 6-Cyclopropyl-2-oxo-3-[(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2- ylmethyl) -aminol-2 -pyridin-l -yl ) -acetic acid ter/-butyl ester (17-6)
Figure imgf000181_0001
Following the procedure described for the synthesis of 16-7. the amine 17-5 was coupled with 14-3 to yield the title compound 17-6 as an oil. Rf (silica gel; 5%MeOH in CHCI3) = 0.39
{ 6-Cyclopropyl-2-oxo-3-[(5,6,7,8-tetrahydro-f 1 ,8]naphthyridin-2- ylmethyl) -aminol-2H-pyridin-l -yl l-acetic acid (17-7).
Figure imgf000181_0002
Following the procedure described for the preparation of 16-8. the ester 17-6 was hydrolysed to give the title compound 17-7. ^H NMR (CD3OD) δ 0.66 (m, 2 H), 0.9 (m, 2 H), 1.78 (m, 1 H), 1.9 (m, 2H), 2.75 (m, 2H), 3.4 (m, 2H), 4.6 (br s, 2 H), 6.02 (d, IH), 6.19 (d, IH), 6.58 (m, 1 H), 7.27 (m, IH).
Ethyl 3-amino-3(S)-(3-fluorophenyl)propionate hvdrochloride (17-8).
Figure imgf000182_0001
The title compound was prepared starting from 3-fluorobenzaldehyde (Aldrich) by conversion to ethyl 3-fluorocinnamate and employing the asymmetric addition/hydrogenolysis methodology described by Rico et al; J. Org. Chem., 1993, 58, 7948. iH NMR (CD3OD) δ 1.21 (t, 3H), 3.03 (dd, IH), 3.13 (dd, I H), 4.15 (q, 2H), 4.77 (t, IH), 7.19 (m, IH), 7.3 (m, 2H), 7.5 (m, IH).
3-(2-{6-Cyclopropyl-2-oxo-3-[(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2- ylmethy l)-amino] -2//-pyridin- 1 -y 1 } -acety lamino)-3(SM propionic acid ethyl ester (17-9).
Figure imgf000182_0002
Following the procedure described for the preparation of 16-5, the acid 17-7 was coupled with the amine 17-8 to yield the title compound 17-9. Analysis calculated for C30H34N5O4 F 1 -0.25H2O C, 65.26; H, 6.30; N, 12.69 found C, 65.20; H, 6.04; N, 13.00. FAB mass spectrum, m/z = 548.12 (M+H)
3-(2-{ 6-Cyclopropyl-2-oxo-3-[(5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2- ylmethyl)-amino]-2 -pyridin-l -yl}-acetylamino)-3(S)-(3-fluorophenyl)- propionic acid ditrifluoroacetate (17-10).
Figure imgf000183_0001
Following the procedure described for the preparation of 16-8. the ester 17-9 was hydrolysed to give the title compound 17-10. Analysis calculated for C28H30N5O4 Fι «2.15TFA«0.5H2θ
C, 55.16; H, 4.91; N, 10.62 found C, 55.19; H, 4.91 ; N, 10.89.
FAB mass spectrum, m/z = 520.05 (M+H)
3-(2-{6-Cyclopropyl-2-oxo-3-[(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2- ylmethyl)-amino]-2 -pyridin- 1 -yl } -acetylamino)-3(S)-(3-pyridyl)- propionic acid ditrifluoroacetate (17-11).
Figure imgf000183_0002
Following the procedures described for Scheme 16, the acid 17-7 was coupled with the amine J_9 followed by saponification of the ester to afford the title compound 17-1 1. Analysis calculated for C27H3θN6θ4»2.5TFA«0.6H2θ C, 48.13; H, 4.25; N, 10.53 found C, 48.11 ; H, 4.23; N, 10.64.
FAB mass spectrum, m/z = 503.25 (M+H)
3-(2- { 6-Cyclopropyl-2-oxo-3-[(5,6,7,8-tetrahydro-[ 1 ,8 lnaphthyridin-2- ylmethyl)-amino]-2H-pyridin-l -yl } -acetylamino)-3(S)-(alkynyl)- propionic acid ethyl ester (17-12).
Figure imgf000184_0001
Following the procedures described for Scheme 16, the acid 17-7 was coupled with 3-amino-3(S)-(alkynyl)-propionic acid ethyl ester 2-9 (Zablokie et al, J. Med. Chem., 1995, 38, 2378) to afford the title compound 17-12. Analysis calculated for C26H3lN5θ4»0.35H2θ
C, 64.53; H, 6.60; N, 14.47 found C, 64.52; H, 6.71 ; N, 14.54.
FAB mass spectrum, m/z = 478.35 (M+H)
3-(2- { 6-Cyclopropyl-2-oxo-3-[(5,6,7,8-tetrahydro-f 1 ,8]naphthyridin-2- ylmethyl)-aminol-2 -pyridin-l -yl } -acetylamino)-3(S)-(alkynyl)- propionic acid (17-13).
Figure imgf000184_0002
Following the procedure described for the preparation of 16-8. the ester 17-12 was hydrolysed to give the title compound 17-13. FAB mass spectrum, m/z = 450.23 (M+H)
SCHEME 18
Figure imgf000186_0001
MeOPhCH2 NH2,
EtOAc
Figure imgf000186_0002
1__
Figure imgf000186_0003
__ 18-6
Figure imgf000186_0004
__7
SCHEME 18 (conU
Figure imgf000187_0001
18-9 Benzyl-N-(l -cvanoethyl)glvcine hvdrochloride (18-2).
NC^ /
HIM ^C02Bn
TMSCN (18.8 mL, 141 mmol) was added cautiosly to a stirred solution of benzylglycine free base (23.3 g 141 mmol - from the HCI salt by partition between EtOAc and brine basified with saturated Na2Cθ3 solution) and acetaldehyde (7.88 mL, 141 mmol) in CH2CI2 (50 mL). After 4 h the volatiles were removed in vacuo and the residue was taken up in EtOAc and washed with brine, dried (Na2Sθ4) and evaporated in vacuo to an oil. The oil was redissolved in EtOAc and 9.9 M HCI in EtOH (15.25 mL, 151 mmol) was added to give a crystalline precipitate which was isolated by filtration, washing with EtOAc and Et2θ to give the title compound (18-2): iH NMR (CD3OD) δ 1.70 (d, 3H), 4.16 (d, IH), 4.21 (d, IH), 4.64 (q,
IH), 5.31 (s, 2H), 7.35-7.44 (m, 5H).
1 -Benzyloxycarbonylmethyl-3.5-dichloro-6-meth ylpyrazinone (18-3).
Figure imgf000188_0001
A stirred mixture of oxalyl chloride (40.4 mL, 463 mmol) and 18-2 (29.51 g, 116 mmol) in 1 ,2-dichlorobenzene (1 10 mL) was heated to 100°C for 15 h. The volatiles were removed in vacuo and the residue was purified by chromatography (silica gel; hexanes followed by 30%EtOAc in hexanes) to give a solid which was heated in EtOAC/hexanes 2:5 (140 mL), cooled and collected by filtration to give the title compound 18-3 as a pale green solid: i H NMR (CDCI3) δ 2.35 (s, 3H), 4.88 (s, 2H), 5.24 (s, 2H), 7.38 (m, 5H).
3-(4-Methoxybenzylamino)-5-chloro-6-methyl-l - benzyloxycarbonylmethyl -pyrazinone (18-4).
Figure imgf000189_0001
A solution of the pyrazinone 18-3 (5 g, 15.3 mmol) and 4 methoxybenzylamine (6.0 mL, 45.9 mmol) in EtOAc (60 mL) was heated at 80°C for 2 h. The solution was cooled and filtered. The filtrate was concentrated in vacuo, the residue swished with MeOH and filtered to afford the title compound as a solid: iH NMR (CDCI3) δ 2.23 (s, 3H), 3.82 (s, 3H), 4.5 (d, 2H), 4.81 (s, 2H), 5.22 (s, 2H), 6.25 (t, IH), 6.85 (m, 2H), 7.27 (m, 2H), 7.38 (m, 5H).
3-(4-Methoxybenzylamino)-5-chloro-6-methyl- 1 -carboxymethyl pyrazinone (18-5).
Figure imgf000189_0002
A solution of the benzyl ester 18-4 ( 1.06 g, 2.48 mmol) in toluene (60 mL) was degassed with argon and then 150 mg 10% palladium on carbon was added. The mixture was stirred under an atmosphere of hydrogen gas for 16 h. The solution was filtered through celite and the solvent evaporated to give the title compound 18-5 as a white solid: iH NMR (CD3OD) δ 2.25 (s, 3H), 3.78 (s, 3H), 4.45 (s, 2H), 4.81 (s, 2H), 4.90 (s, 2H), 6.85 (d, 2H), 7.28 (d, 2H).
3-(4-Methoxybenzylamino)- 6-methyl-l -carboxymethyl pyrazinone (18-6).
Figure imgf000190_0001
The acid 18-5 (810 mg) was dissolved in 40 mL 1 N NaOH and 40 mL MeOH at room temperature and was treated with Raney nickel suspension (~5 g). A second charge of Raney nickel (~5 g) and 1 N NaOH (20 mL) was added after 3 h. After 6 h, the suspension was filtered through celite washing with water and MeOH. The volatiles were removed in vacuo and the residue then taken up 1 N HCI (~5 mL). Saturated NaHCθ3 solution was added until pH~7-8 and the solution was extracted exhaustively with EtOAc/THF. After drying (MgSθ4), the solvent was removed to give the title compound 18-6 as a solid which was used as such: iH NMR (CD3OD) δ 2.16 (s, 3H), 3.76 (s, 3H), 4.46 (s, 2H), 4.64 (s, 2H), 4.86 (s, 2H), 6.65 (s, IH), 6.85 (d, 2H), 7.25 (d, 2H).
3-Amino-6-methyl-l-carboxymethylpyrazinone (18-7).
Figure imgf000190_0002
The pyrazinone 1 -6 (900 mg) was heated at reflux in trifluoroacetic acid (20 mL) for 7 h. The volatiles were removed in vacuo and the residue was azeotroped with CH2CI2, then EtOAc then MeOH. MeOH was added to the residue and the solution filtered to remove impurities. Removal of the methanol then afforded the title compound 1 -7 which was used as such: i H NMR (CD3OD) δ 2.22 (s, 3H), 4.82 (s, 2H), 6.58 (s, IH).
3-(3-Fluorophenyl)-3-(2- { 6-methyl-2-oxo-3-aminoJ-2H-pyrazin- 1 -yl } - acetylamino)propionic acid ethyl ester (18-8).
Figure imgf000191_0001
Following the procedure described for the preparation of 16-6, the acid 18-7 was coupled with the amine 17-8 to yield the title compound 18-8. iH NMR (CDCI3) δ 1.15 (t, 3H), 2.23 (s, 3H), 2.78 (dd, IH), 2.84 (dd, IH), 4.05 (q, 2H), 4.68 (ABq, 2H), 5.30 (br s, 2H), 5.35 (m, I H), 6.68 (s, IH), 6.9-7.1 (m, 3H), 7.27 (m, IH), 7.57 (d, 2H).
3-(3-Fluorophenyl)-3-(2- { 6-methyl-2-oxo-3-[(5,6,7,8-tetrahydro-
[ 1 ,8]naphthyridin-2-ylmethy l)-amino]-2//-pyrazin- 1 -yl } -acety lamino)- propionic acid ditrifluoroacetate (18-9).
Figure imgf000191_0002
Following the procedure described for the synthesis of 16-9. the amine 18-8 was coupled with 14-3 and the product hydrolyzed to yield the title compound 1 -9. Analysis calculated for C25H27N6θ4F»2.25TFA«0.85H2θ
C, 46.23; H, 4.07; N, 10.97 found C, 46.22; H, 4.00; N, 11.12.
FAB mass spectrum, m/z = 495.26 (M+H)
SCHEME 19
Figure imgf000193_0003
Figure imgf000193_0001
1__
Figure imgf000193_0002
__7 SCHEME 19 (Cont'd)
Figure imgf000194_0001
proline (cat.)
19-7
Figure imgf000194_0002
H2, Pd/C
Figure imgf000194_0003
19-10 SCHEME 19 (Cont'd)
Figure imgf000195_0001
19-1Q
Figure imgf000195_0002
19-11
Figure imgf000195_0003
___ The test procedures employed to measure vβ3 binding and the bone resoφtion inhibiting activity of the compounds of the present invention are described below.
BONE RESORPTION-PIT ASSAY
When osteoclasts engage in bone resoφtion, they will literally cause the formation of pits in the surface of bone that they are acting upon. Therefore, when testing compounds for their ability to inhibit osteoclasts, it is useful to measure the ability of osteoclasts to excavate these resoφtion pits when the inhibiting compound is present. Consecutive 200 micron thick cross sections from a six mm cylinder of bovine femur diaphysis were cut with a low speed diamond saw (Isomet, Beuler, Ltd., Lake Bluff, II). Bone slices were pooled, placed in a 10% ethanol solution and refrigerated until further use. Prior to experimentation, bone slices were ultrasonicated twice, 20 minutes each in H2θ. Cleaned slices were placed in 96 well plates such that two control lanes and one lane for each drug dosage are available. Each lane represents either triplicate or quadruplicate cultures. The bone slices in 96 well plates were sterilized by UV irradiation. Prior to incubation with osteoclasts, the bone slices were hydrated by the addition of 0.1 ml Medium 199, pH 6.9 containing 15% fetal bovine serum and 1 % penicillin/streptomycin.
Osteoclasts were isolated from the long bones of 1 to 3 day old rat pups (Sprague-Dawley) by modifications of Chambers et al.. (_, Cell. Science. 66:383-399). The resulting suspension (0.75 ml/bone) was gently triturated 90-120 times using a wide bore transfer pipet. The cellular population was separated from bone fragments by a cell strainer with a 100 micron nylon mesh. 100 μl of the cell suspension was placed onto each bone slice. Test compounds were then added at the desired experimental concentrations.
Bone slices exposed to osteoclasts for 20-24 hrs were processed for staining. Tissue culture media was removed from each bone slice. Each well was washed with 200 μl of H2O, and the bone slices were then fixed for 20 minutes in 2.5% glutaraldehyde, 0.1 M cacodylate, pH 7.4. After fixation, any remaining cellular debris was removed by 2 min. ultrasonication in the presence of 0.25 M NH4OH followed by 2 X 15 min ultrasonication in H2θ. The bone slices were immediately stained for 6-8 min with filtered 1 % toluidine blue and 1 % borax.
After the bone slices have dried, resoφtion pits were counted in test and control slices. Resoφtion pits were viewed in a Microphot Fx (Nikon) fluorescence microscope using a polarizing Nikon IGS filter cube. Test dosage results were compared with controls and resulting IC50 values were determined for each compound tested.
The appropriateness of extrapolating data from this assay to utility and use in mammalian (including human) disease states is supported by the teaching found in Sato, M., et al, Journal of Bone and Mineral Research. Vol. 5, No. 1, 1990. That article teaches that certain bisphosphonates have been used clinically and appear to be effective in the treatment of Paget's disease, hypercalcemia of malignancy, osteolytic lesions produced by bone metastases, and bone loss due to immobilization or sex hormone deficiency. These same bisphosphonates are then tested in the resoφtion pit assay described above to confirm a correlation between their known utility and positive performance in the assay.
EIB ASSAY
Duong et ah, J. Bone Miner. Res.. 8:S 378, describe a system for expressing the human integrin αvβ3. It has been suggested that the integrin stimulates attachment of osteoclasts to bone matrix, since antibodies against the integrin, or RGD-containing molecules, such as echistatin (European Publication 382 451 ), can effectively block bone resoφtion.
Reaction Mixture:
1. 175 μl TBS buffer (50 mM Tris«HCl pH 7.2, 150 mM NaCl, 1 % BSA, 1 mM CaCl2, 1 mM MgCl2). 2. 25 μl cell extract (dilute with 100 mM octylglucoside buffer to give 2000 cpm/25 μl).
3. 125ϊ_echistatin (25 μl/50,000 cpm) (see EP 382 451).
4. 25 μl buffer (total binding) or unlabeled echistatin (non- specific binding).
The reaction mixture was then incubated for 1 h at room temp. The unbound and the bound αvβ3 were separated by filtration using a Skatron Cell Harvester. The filters (prewet in 1.5% poly- ethyleneimine for 10 mins) were then washed with the wash buffer (50 mM Tris HCI, ImM CaCl2/MgCl2, pH 7.2). The filter was then counted in a gamma counter.
SPA ASSAY
MATERIALS:
I . Wheatgerm agglutinin Scintillation Proximity Beads (SPA): Amersham 2. Octylglucopyranoside: Calbiochem
3. HEPES: Calbiochem
4. NaCl: Fisher
5. CaCl2: Fisher
6. MgCl2: SIGMA 7. Phenylmethylsulfonylfluoride (PMSF): SIGMA
8. Optiplate: PACKARD
9. Compound 8-10 (specific activity 500- 1000 Ci/mmole)
10. test compound
I I . Purified integrin receptor: ctvβ3 was purified from 293 cells overexpressing ocvβ3 (Duong et al., J. Bone Min. Res., #:S378,
1993) according to Pytela (Methods in Enzymology, 144:475, 1987) 12. Binding buffer: 50 mM HEPES, pH 7.8, 100 mM NaCl, 1 mM Ca2+/Mg2+, 0.5 mM PMSF 13. 50 mM octylglucoside in binding buffer: 50-OG buffer
PROCEDURE:
1. Pretreatment of SPA beads: 500 mg of lyophilized SPA beads were first washed four times with 200 ml of 50-OG buffer and once with 100 ml of binding buffer, and then resuspended in 12.5 ml of binding buffer.
2. Preparation of SPA beads and receptor mixture In each assay tube, 2.5 μl (40 mg/ml) of pretreated beads were suspended in 97.5 μl of binding buffer and 20 μl of 50-OG buffer. 5 μl (~30 ng/μl) of purified receptor was added to the beads in suspension with stirring at room temperature for 30 minutes. The mixture was then centrifuged at 2,500 φm in a Beckman GPR Benchtop centrifuge for 10 minutes at 4°C. The pellets were then resuspended in 50 μl of binding buffer and 25 μl of 50-OG buffer.
3. Reaction The following were sequentially added into Optiplate in corresponding wells: (i) Receptor/beads mixture (75 μl) (ii) 25 μl of each of the following: compound to be tested, binding buffer for total binding or _8 for non-specific binding (final concentration 1 μM)
(iii) 8-10 in binding buffer (25 μl, final concentration 40 pM)
(iv) Binding buffer (125 μl)
(v) Each plate was sealed with plate sealer from PACKARD and incubated overnight with rocking at 4°C
4. Plates were counted using PACKARD TOPCOUNT
5. % inhibition was calculated as follows: A = total counts B = nonspecific counts
C = sample counts
% inhibition = [{ (A-B)-(C-B) }/(A-B)]/(A-B) x 100
OCFORM ASSAY
Osteoblast-like cells (1.8 cells), originally derived from mouse calvaria, were plated in CORNING 24 well tissue culture plates in α MEM medium containing ribo- and deoxyribonucleosides, 10% fetal bovine serum and penicillin-streptomycin. Cells were seeded at 40,000/well in the morning. In the afternoon, bone marrow cells were prepared from six week old male Balb/C mice as follows:
Mice were sacrificed, tibiae removed and placed in the above medium. The ends were cut off and the marrow was flushed out of the cavity into a tube with a 1 mL syringe with a 27.5 gauge needle. The marrow was suspended by pipetting up and down. The suspension was passed through >100 μm nylon cell strainer. The resulting suspension was centrifuged at 350 x g for seven minutes. The pellet was resuspended, and a sample was diluted in 2% acetic acid to lyse the red cells. The remaining cells were counted in a hemacytometer. The cells were pelleted and resuspended at 1 x 10°" cells/mL. 50 μL was added to each well of 1.8 cells to yield 50,000 cells/well and 1,25-dihydroxy- vitamin D3(D3) was added to each well to a final concentration of 10 nM. The cultures were incubated at 37°C in a humidified, 5% Cθ2 atmosphere. After 48 h, the medium was changed. 72 h after the addition of bone marrow, test compounds were added with fresh medium containing D3 to quadruplicate wells. Compounds were added again after 48 h with fresh medium containing D3. After an additional 48 h the medium was removed, cells were fixed with 10% formaldehyde in phosphate buffered saline for 10 minutes at room temperature, followed by a 1 -2 minute treatment with ethanol :acetone (1 : 1) and air dried. The cells were then stained for tartrate resistant acid phosphatase as follows:
The cells were stained for 10-15 minutes at room temperature with 50 mM acetate buffer, pH 5.0 containing 30 mM sodium tartrate, 0.3 mg/mL Fast Red Violet LB Salt and 0.1 mg/mL Naphthol AS -MX phosphate. After staining, the plates were washed extensively with deionized water and air dried. The number of multinucleated, positive staining cells were counted in each well.
ccvβ5 ATTACHMENT ASSAY
Duong et aL, J. Bone Miner. Res.. 11 :S 290, describe a system for expressing the human αvβ5.
Materials:
1. Media and solutions used in this assay are purchased from BRL/Gibco, except BSA and the chemicals are from Sigma.
2. Attachment medium: HBSS with 1 mg/ml heat-inactivated fatty acid free BSA and 2 mM CaCl2- 3. Glucosaminidase substrate solution: 3.75 mM p-nitrophenyl-N- acetyl-beta-D-glucosaminide, 0.1 M sodium citrate, 0.25% Triton, pH 5.0. 4. Glycine-EDTA developing solution: 50 mM glycine, 5 mM EDTA, pH 10.5.
Methods:
1. Plates (96 well, Nunc Maxi Soφ) were coated overnight at 4 °C with human vitronectin (3 ug/ml) in 50 mM carbonate buffer (pH 9/.6), using 100 μl/well. Plates were then washed 2X with DPBS and blocked with 2% BSA in DPBS for 2h at room temperature. After additional washes (2X) with DPBS, plates were used for cell attachment assay.
2. 293 (alpha v beta 5) cells were grown in MEM media in presence of 10% fetal calf serum to 90% confluence. Cells were then lifted from dishes with 1 X Trypsin/EDTA and washed 3X with serum free MEM. Cells were resuspended in attachment medium (3 X 10^ cells/ml).
3. Test compounds were prepared as a series of dilutions at 2X concentrations and added as 50 μl/well. Cell suspension was then added as 50 ml/well. Plates were incubated at 37 °C with 55 Cθ2 for 1 hour to allow attachment. 4. Non-adherent cells were removed by gently washing the plates (3X) with DPBS and then incubated with glucosaminidase substrate solution (100 μl/well), overnight at room temperature in the dark. To quantitate cell numbers, standard curve of glucosaminidase activity was determined for each experiment by adding samples of cell suspension directly to wells containing the enzyme substrate solution. 5. The next day, the reaction was developed by addition of 185 μl/well of gylcine/EDTA solution and reading absorbance at 405 nm using a Molecular Devices V-Max plate reader. Average test absorbance values (4 wells per test samples) were calculated. Then, the number of attached cells at each drug concentration was quantitated versus the standard curve of cells using the Softmax program.
EXAMPLE OF A PHARMACEUTICAL FORMULATION
As a specific embodiment of an oral composition, 100 mg of compound 3-13 is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size O hard gel capsule.
Representative compounds of the present invention were tested and found to bind to human αvβ3 integrin. These compounds were found to have IC50 values in the range of 0.1 to 100 nM in the SPA assay.
Representative compounds of the present invention were tested and found to inhibit > 50% the attachment of ccvβ5 expressing cells to plates coated with vitronectin at concentrations of 1 μM.
While the invention has been described and illustrated in reference to certain preferred embodiments thereof, those skilled in the art will appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit and scope of the invention. For example, effective dosages other than the preferred doses as set forth hereinabove may be applicable as a consequence of variations in the responsiveness of the mammal being treated for severity of bone disorders caused by resoφtion, or for other indications for the compounds of the invention indicated above. Likewise, the specific pharmacological responses observed may vary according to and depending upon the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be limited only by the scope of the claims which follow and that such claims be inteφreted as broadly as is reasonable.

Claims

WHAT IS CLAIMED IS:
1. A method of eliciting a vitronectin receptor antagonizing effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound of the formula
Figure imgf000204_0001
wherein X is selected from
.R1
N NR'
" 1 _2
-C-NR1R2 — N ^C-NR^R
a 5- or 6-membered monocyclic aromatic or nonaromatic ring system containing 0, 1 , 2, 3 or 4 heteroatoms selected from N, O or S wherein the 5- or 6-membered ring system is either unsubstituted or substituted with one or more groups chosen from R J , R2, Rl5 0r Rl6;
a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1 , 2, 3 or 4 heteroatoms selected from N, O or S, and wherein the polycyclic ring system is either unsubstituted or substituted with one or more groups chosen from Rl , R2, Rl5 or Rl6;
Y is selected from R3 °
• II
•(CH2)-N-(CH2)— , — (CHaJ C-fCHater
Figure imgf000205_0001
— (CH2)-S(0)2-N-(CH2)- , — (CH2)r-N— S(0)2- (CH2)m RΣ R^
— (CH2)-S(0)q-(CH2)^ , — (CH2)r O-(CH2)^ or - (CH2)r-;
Z is a 5-1 1 membered aromatic or nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted with one or more groups independently selected from R4, R5, R6 and R7; provided that Z is not a 6-membered monocyclic aromatic ring system, an isoxazoline ring or an isoxazole ring;
Rl , R2, R4, R5? Rl 3? R 14? R 15 and Rl6 are each independently selected from hydrogen, halogen, Cl -10 alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, C3-8 cycloalkyl Cl-6 alkyl, C3-8 cycloheteroalkyl Cl-6 alkyl, aryl, aryl Cl-8 alkyl, amino, amino Cl -8 alkyl, Cl-3 acylamino, Cl-3 acylamino Cl -8 alkyl, (Cl -6 alkyOqamino, (Cl -6 alkyOqamino Cl-8 alkyl, Cl-4 alkoxy, Cl-4 alkoxy Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl-6 alkyl, Cl-3 alkoxycarbonyl, Cl-3 alkoxycarbonyl Cl -6 alkyl, hydroxy carbonyl -
Cl -6 alkyloxy, hydroxy, hydroxy Cl-6 alkyl, Cl-6 alkyloxy- Cl -6 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, Cl -8 alkyl-S(0)q, (Cl -8 alkyOqaminocarbonyl, Cl-8 alkyloxycarbonylamino, (Cl-8 alkyOqaminocarbonyloxy, oxo, (aryl Cl -8 alkyOqamino, (aryl)qamino, aryl Cl-8 alkylslfonylamino or Cl-8 alkylsulfonylamino;
elected from hydrogen, aryl, aryl-(CH2)p-, hydroxyl, Cl -5 alkoxy, aminocarbonyl,
C3-8 cycloalkyl, amino Cl -6 alkyl,
(aryOqaminocarbonyl, (aryl Cl-5 alkyOqaminocarbonyl, hydroxycarbonyl Cl-6 alkyl,
Cl-8 alkyl, aryl Cl-6 alkyl,
(Cl-6 alkyOqamino Cl -6 alkyl, (aryl Cl -6 alkyOqamino Cl -6 alkyl,
Cl-8 alkylsulfonyl,
Cl-8 alkoxycarbonyl, aryloxycarbonyl, aryl Cl -8 alkoxycarbonyl, Cl-8 alkylcarbonyl, arylcarbonyl, aryl Cl-6 alkylcarbonyl,
(Cl-8 alkyOqaminocarbonyl, aminosulfonyl, Cl-8 alkylaminosulfonyl,
(aryl)qaminosulfonylamino,
(aryl Cl-8 alkyOqaminosulfonyl,
Cl-6 alkylsulfonyl, arylsulfonyl, aryl Cl -6 alkylsulfonyl, aryl Cl-6 alkylcarbonyl,
Cl-6 alkylthiocarbonyl, arylthiocarbonyl, or aryl Cl -6 alkylthiocarbonyl, wherein any of the alkyl groups may be unsubstituted or substituted with Rl 3 and Rl4;
R6, R7, R ? R9? R I O and R 1 are each independently selected from hydrogen, aryl, aryl-(CH2)p-, aryl-(CH2)n-0-(CH2)πr, aryl-(CH2)n-S(0)q-(CH2)m-, aryl-(CH2)n-C(0)-(CH2)m-, aryl-(CH2)n-C(0)-N(R3)-(CH2)m-, aryl-(CH2)n-N(R3)-C(0)-(CH2)m-, aryl-(CH2)n-N(R3)-(CH2)m-, halogen, hydroxyl,
Cl-8 alkylcarbonylamino, aryl Cl-5 alkoxy,
Cl-5 alkoxycarbonyl,
(Cl -8 alkyOqaminocarbonyl, Cl-6 alkylcarbonyloxy,
C3-8 cycloalkyl, oxo,
(Cl -6 alkyOqamino, amino Cl -6 alkyl, arylaminocarbonyl, aryl Cl_5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl -6 alkyl,
Cl-8 alkyl, either unsubstituted or substituted, with one or more groups selected from: halogen, hydroxyl, Cl-5 alkylcarbonylamino, aryl Cl-5 alkoxy, Cl-5 alkoxycarbonyl, aminocarbonyl, (Cl -5 alkyOqaminocarbonyl, Cl-5 alkylcarbonyloxy, C3-8 cycloalkyl, oxo, (Cl -3 alkyOqamino, amino Cl -3 alkyl, (aryOqaminocarbonyl, (aryl Cl-5 alkyOqaminocarbonyl, aminocarbonyl, aminocarbonyl Cl -4 alkyl, hydroxycarbonyl or hydroxycarbonyl Cl -5 alkyl,
CH≡C-(CH2)s-, Cl-6 alkyl-C≡C-(CH2)s-, C3-7 cycloalkyl-C≡C-(CH2)s-, aryl-C≡C-(CH2)s-, Cl-6 alkylaryl-C≡C-(CH2)s-,
CH2=CH-(CH2)s-, Cl-6 alkyl-CH=CH-(CH2)s-, C3-7 cycloalkyl-CH=CH-(CH2)s-, aryl-CH=CH-(CH2)s-, Cl-6 alkylaryl-CH=CH-(CH2)s-,
Cl -6 alkyl-Sθ2-(CH2)s-, Cl -6 alkylaryl-Sθ2-(CH2)s-, Cl -6 alkoxy, aryl Cl -6 alkoxy, aryl Cl-6 alkyl,
(Cl -6 alkyOqamino Cl -6 alkyl, (aryl)qamino, (aryl)qamino Cl -6 alkyl, (aryl Cl-6 alkyOqamino, (aryl Cl-6 alkyOqamino Cl -6 alkyl, arylcarbonyloxy, aryl Cl -6 alkylcarbonyloxy, (Cl -6 alkyOqaminocarbonyloxy, Cl-8 alkylsulfonylamino, ary 1 sulf ony lamino ,
Cl -8 alkylsulfonylamino Cl-6 alkyl, arylsulfonylamino Cl -6 alkyl, aryl Cl -6 alkylsulfonylamino, aryl Cl-6 alkylsulfonylamino Cl-6 alkyl,
Cl-8 alkoxycarbonylamino,
Cl -8 alkoxycarbonylamino Cl-8 alkyl, aryloxycarbonylamino Cl-8 alkyl, aryl Cl -8 alkoxycarbonylamino, aryl Cl-8 alkoxycarbonylamino Cl -8 alkyl,
Cl-8 alkylcarbonylamino,
Cl -8 alkylcarbonylamino Cl-6 alkyl, arylcarbonylamino Cl -6 alkyl, aryl Cl -6 alkylcarbonylamino, aryl Cl-6 alkylcarbonylamino Cl-6 alkyl, aminocarbonylamino Cl-6 alkyl,
(Cl -8 alkyOqaminocarbonylamino,
(Cl-8 alkyOqaminocarbonylamino Cl-6 alkyl,
(aryOqaminocarbonylamino Cl-6 alkyl, (aryl Cl -8 alkyOqaminocarbonylamino,
(aryl Cl-8 alkyOqaminocarbonylamino Cl-6 alkyl, aminosulfony lamino Cl -6 alkyl,
(Cl -8 alkyOqaminosulfonylamino,
(Cl-8 alkyOqaminosulfonylamino Cl-6 alkyl, (aryl)qaminosulfonylamino Cl-6 alkyl,
(aryl Cl-8 alkyOqaminosulfonylamino,
(aryl Cl-8 alkyOqaminosulfonylamino Cl-6 alkyl,
Cl-6 alkylsulfonyl,
Cl -6 alkylsulfonyl Cl-6 alkyl, arylsulfonyl Cl-6 alkyl, aryl Cl-6 alkylsulfonyl, aryl Cl-6 alkylsulfonyl Cl-6 alkyl,
Cl-6 alkylcarbonyl,
Cl-6 alkylcarbonyl Cl -6 alkyl, arylcarbonyl Cl-6 alkyl, aryl Cl-6 alkylcarbonyl, aryl Cl-6 alkylcarbonyl Cl -6 alkyl,
Cl -6 alkylthiocarbonylamino, Cl -6 alkylthiocarbonylamino Cl-6 alkyl, arylthiocarbonylamino Cl-6 alkyl, aryl Cl -6 alkylthiocarbonylamino, aryl Cl-6 alkylthiocarbonylamino Cl-6 alkyl,
(Cl -8 alkyOqaminocarbonyl C] -6 alkyl, (aryOqaminocarbonyl Cl -6 alkyl,
(aryl Cl-8 alkyOqaminocarbonyl, or
(aryl Cl-8 alkyOqaminocarbonyl Cl-6 alkyl, wherein any of the alkyl groups may be unsubstituted or substituted with Rl and R l4; and provided that the carbon atom to which R& and R^ are attached is itself attached to no more than one heteroatom; and provided further that the carbon atom to which RlO and Rl 1 are attached is itself attached to no more than one heteroatom;
R 2 is selected from hydrogen,
Cl -8 alkyl, aryl, aryl Cl-8 alkyl,
Cl-8 alkylcarbonyloxy Cl -4 alkyl, aryl Cl-8 alkylcarbonyloxy Cl-4 alkyl,
Cl-8 alkylaminocarbonylmethylene, or
Cl -8 dialkylaminocarbonylmethylene;
m, s and t are each independently an integer from 0 to 3; n is an integer from 1 to 3; p is an integer from 1 to 4; q is an integer from 0 to 2; r is an integer from 0 to 6; and the pharmaceutically acceptable salts thereof.
2. The method of Claim 1, wherein
X is a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1 , 2, 3 or 4 heteroatoms selected from N, O or S, and wherein the polycyclic ring system is either unsubstituted or substituted with Rl and R2; and
Z is selected from
Figure imgf000211_0001
Figure imgf000212_0001
Figure imgf000212_0002
and the pharmaceutically acceptable salts thereof.
3. The method of Claim 2, wherein
Z is selected from
Figure imgf000212_0003
Figure imgf000213_0001
and the pharmaceutically acceptable salts thereof.
4. The method of Claim 3 wherein the compound has the formula
Figure imgf000214_0001
wherein X is selected from
Figure imgf000214_0002
Y is selected from -(CH2)r or -(CH2)m-NR3-(CH2)f R3 is selected from hydrogen, aryl-(CH2)p-,
Cl-5 alkoxycarbonyl,
C3-8 cycloalkyl,
(aryl)qaminocarbonyl, (aryl Cl-5 alkyOqaminocarbonyl,
Cl-8 alkyl, aryl C 1-6 alkyl,
Cl-8 alkylsulfonyl, arylsulfonyl, aryl Cl -6 alkylsulfonyl,
Cl-8 alkoxycarbonyl, aryloxycarbonyl, aryl Cl -8 alkoxycarbonyl,
Cl-8 alkylcarbonyl, arylcarbonyl, aryl Cl -6 alkylcarbonyl,
(Cl -8 alkyOqaminocarbonyl, Cl-6 alkylsulfonyl, or aryl Cl -6 alkylcarbonyl, wherein any of the alkyl groups may be unsubstituted or substituted with R13 and R14;
R4 is selected from hydrogen, Cl-6 alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl,
C3-8 cycloalkyl Cl-6 alkyl, C3-8 cycloheteroalkyl Cl-6 alkyl, aryl or aryl Cl -8 alkyl,
R8 is selected from hydrogen, aryl, aryl-(CH2)p-> CH≡C-(CH2)s-,
Cl-6 alkyl-C≡C-(CH2)s-,
C3-7 cycloalkyI-C≡C-(CH2)s-, aryl-C≡C-(CH2)s-,
Cl -6 alkylaryl-C≡C-(CH2)s-, CH2=CH-(CH2)S-,
Cl-6 alkyl-CH=CH-(CH2)s-,
C3-7 cycloalkyl-CH=CH-(CH2)s-, aryl-CH=CH-(CH2)s-,
Cl-6 alkylaryl-CH=CH-(CH2)s-, Cl-6 alkyl-S02-(CH2)s-,
Cl-6 alkylaryl-Sθ2-(CH2)s-; and
r is an integer from 0 to 3;
and the pharmaceutically acceptable salts thereof.
5. The method of Claim 4 wherein the compound has the formula
Figure imgf000216_0001
wherein Z is selected from
Figure imgf000216_0002
R8 is selected from hydrogen,
Figure imgf000216_0003
indolyl-(CH2)p-,
CH≡C-(CH2)s-,
Cl-6 alky l-C≡C-(CH2)s-,
C3-7 cycloalkyl-C≡C-(CH2)s-, aryl-C≡C-(CH2)s-, Cl-6 alkylaryl-C≡C-(CH2)s-, CH2=CH-(CH2)s-, Cl-6 alkyl-CH=CH-(CH2)s-, C3-7 cycloalkyl-CH=CH-(CH2)s-, aryl-CH=CH-(CH2)s-,
Cl-6 alkylaryl-CH=CH-(CH2)s-,
Cl -6 alkyl-Sθ2-(CH2)s-,
Cl-6 alkylaryl-S02-(CH2)s-; and
Rl2 is selected from hydrogen or Cl-8 alkyl; s is an integer from 0 to 3; and the pharmaceutically acceptable salts thereof.
6. The method of Claim 5, wherein the compound is selected from
2-Oxo-3-[2-(5,6,7,8-tetrahydro[l,8]-naρhthyridin-2-yl)ethyl]piperidin- l -yl-acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-3-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2-yl)ethyllpiperin- 1 -yl-acetyl-3(S)-pyridin-3-yl-β-alanine trifluoroacetate;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l -yl)acetyl-3(S)-alkynyl-β-alanine ethyl ester;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- yl)ethyllpyrrolidin-l -yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2-yl)ethyl]- pyrrolidin-l -yl)acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-pyridin-3-yl-β-alanine; 2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naρhthyridin-2- y l)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine ethyl ester;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- yl)ethy l]pyrrolidin- 1 -y I)acety l-3(S)-alkynyl-β-alanine;
2-Oxo-3(R)-f2-(5,6,7,8-tetrahydro[ l ,81-naphthyridin-2-yl)ethyl]- pyrrolidin-l-yl)acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[ 1 ,8J-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
Ethyl 2-oxo-3-[2-(5,6,7,8-tetrahydro[ 1 ,81naphthyridin-2-yl)ethylJ- tetrahydropyrimidin-l-yl-acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3-f 2-(5,6,7,8-tetrahydro[ 1 ,81naphthyridin-2-yl Jethyl]- tetrahydropyrimidin-l -yl-acetyl-3(S)-pyridin-3-yl-β-alanine;
Ethyl 2-oxo-3-[2-(5,6,7,8-tetrahydro[l ,8]naphthyridin-2- yl)ethyl]imidazolidin-l-yl-acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3-[2-(5,6,7,8-tetrahydro[ 1 ,8]naphthyridin-2-yl Jethyl]- imidazolidin- 1 -y l-acetyl-3(S)-pyridin-3-y 1-β-alanine;
Ethyl 2-oxo-3(R)-[2-(5,6,7,8-tetrahydrof 1 ,8]naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(R)-(2-ethylindol-3-yl)-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[ 1 ,8]naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(R)-(2-ethylindol-3-yl)-β-alanine;
Ethyl 3-(2-{ 2-oxo-3(S)-[(5,6,7,8-tetrahydro-[l ,8 ]naphthyridin-2- ylmethyl)-amino]-pyrrolidin-l -yl} -acetylamino)-3-(S)-pyridin-3-yl- propionic acid; 3-(2- { 2-Oxo-3(S)-[(5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-ylmethyl)- amino]pyrrolidin- 1 -yl } -acetylamino)-3-(S)-pyridin-3-yl-propionic acid;
3-{2-[6-Oxo-l -(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-ylmethyl)- hexahydro-(3aS, 6aS)pyrrolo[3,4-b]pyrroI-5-yl]-acetylamino} -3-(S)- pyridin-3-yl-propionic acid;
3- { 2-[6-Oxo- 1 -(5,6,7,8-tetrahydro-[ 1 ,8]naphthyridin-2-ylmethyl)- hexahydro-(3aR, 6aR)pyrrolo[3,4-blpyrrol-5-yl]-acetylamino }-3-(S)- pyridin-3-yl-propionic acid;
2-Oxo-5(R)-methyl-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2-yl)- ethyl]pyrrolidin-l-yl)acetyl-3(S)-alkynyl-β-alanine ethyl ester;
2-Oxo-5(R)-methyl-3(S)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- y l)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-5(S)-benzyl-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2-yl)- ethyl]pyrrolidin-l -yl)acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-5(S)-benzyl-3(S)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
5(R)-Methyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- y Imethy l)-amino]pyrrolidin- 1 -yl)acety l-3(S)-alkyny 1-β-alanine ethyl ester;
5(R)-Methyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- ylmethyl)-amino]pyrrolidin- 1 -y l)acetyl-3(S)-alkynyl-β-alanine;
3(5)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-{2-oxo-3(S)-[2-(5,6,7,8- tetrahydro-[ 1 ,81naphthyridin-2-y l)-ethyll-pyrrolidin- 1 -yl } - acetylamino)-propionic acid ethyl ester; 3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-{ 2-oxo-3(5)-[2-(5,6,7,8- tetrahydro-[ 1 ,8]naphthyridin-2-yl)-ethyl]-pyrrolidin- 1 -yl } - acetylamino)-propionic acid;
3-{ 2-(2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-yl)-ethyI]- pyrrolidin- 1 -y l)-acetylamino } -3(S)-quinolin-3-yl-propionic acid;
3-(2-(5(S)-Ethyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydro-[ l ,8]naphthyridin-2- yl)-ethyl]-pyrolidin-l-yl)-acetylamino)-3-(S)-quinolin-3-yl-propionic acid trifluoroacetate;
3-(2- { 6-Methyl-2-oxo-3-[(5,6,7,8-tetrahydro-l 1 ,8]naphthyridin-2- ylmethyl)-amino]-2H-pyridin-l-yl } -acetylamino)-3(S)-pyridin-3-yl- propionic acid bis trifluoroacetate; or
3-(2- { 6-Methyl-2-oxo-3-[(5,6,7,8-tetrahydro-[ 1 ,8]napthyridin-2- ylmethyl)-aminoJ-2H-pyridin-l -yl}-acetylamino)-3(S)-pyridin-3-yl- propionic acid ethyl ester;
and the pharmaceutically acceptable salts thereof.
7. The method of Claim 6, wherein the compound is selected from
2-Oxo-3-[2-(5,6,7,8-tetrahydro[ 1 ,81-naphthyridin-2-yl)ethyl]piperin- 1 -yl-acetyl-3(S)-pyridin-3-yl-β-alanine trifluoroacetate;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- yOethyljpyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(S)-pyridin-3-yl-β-alanine; 2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acety l-3(S)-alkynyl-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acety l-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3-f 2-(5,6,7,8-tetrahydro[ 1 ,81naphthyridin-2-yl Jethyl]- imidazolidin- 1 -yl-acetyl-3-(S)-pyridin-3-yl-β-alanine;
2-Oxo-3-[2-(5,6,7,8-tetrahydro[ 1 ,8]naphthyridin-2-yl jethyl]- tetrahydropyrimidin-l -yl-acetyl-3-(S)-pyridin-3-yl-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[ 1 ,8]naphthyridin-2- yl)ethylJpyrrolidin-l-yl)acetyl-3(R)-(2-ethylindol-3-yl)-β-alanine;
3-(2-{2-oxo-3(S)-[(5,6,7,8-tetrahydro-[l,8]naphthyridin-2-ylmethy0- aminojpyrrolidin- 1 -yl } -acetylamino)-3-(S)-pyridin-3-yl-propionic acid;
3-{ 2-[6-Oxo-l -(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-ylmethyl)- hexahydro-(3aS, 6aS)pyrrolo[3,4-b]pyιτol-5-yl]-acetylamino}-3-(S)- pyridin-3-yl-propionic acid;
3-{2-[6-Oxo-l-(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-ylmethyl)- hexahydro-(3aR, 6aR)pyrrolo[3,4-b]pyrrol-5-yl]-acetylamino}-3-(S)- pyridin-3-yl-propionic acid;
2-Oxo-5(R)-methyl-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-5(S)-benzyl-3(S)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
5(R)-Methyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- ylmethyl)-amino]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine; or 3(5)-(2,3-Dihydro-benzofuran-6-yl)-3-(2- {2-oxo-3(5)-[2-(5,6,7,8- tetrahydro-[ 1 ,8 Jnaphthyridin-2-yl)-ethyl]-pyrrolidin- 1 -y 1 } - acetylamino)-propionic acid;
and the pharmaceutically acceptable salts thereof.
8. The method of Claim 1 , wherein the vitronectin receptor antagonizing effect is an αvβ3 antagonizing effect.
9. The method of Claim 8 wherein the vβ3 antagonizing effect is selected from inhibition of: bone resoφtion, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation or tumor growth.
10. The method of Claim 9, wherein the αvβ3 antagonizing effect is the inhibition of bone resorption.
11. The method of Claim 1 , wherein the vitronectin receptor antagonizing effect is an αvβ5 antagonizing effect.
12. The method of Claim 1 1 wherein the αvβ5 antagonizing effect is selected from inhibition of: restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation or tumor growth.
13. The method of Claim 1 , wherein the vitronectin receptor antagonizing effect is a dual αvβ3/ocvβ5 antagonizing effect.
14. The method of Claim 13, wherein the dual vβ3/αvβ5 antagonizing effect is selected from inhibition of: bone resoφtion, restenosis, angiogenesis, diabetic retinopathy, macular degeneration, inflammation or tumor growth.
15. A method of treating or preventing a condition mediated by antagonism of a vitronectin receptor in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the compound of Claim 1.
16. The method of Claim 15, wherein the condition is selected from the group consisting of osteoporosis or cancer.
17. A method of inhibiting bone resoφtion in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the compound of Claim 1.
18. A method of treating osteoporosis in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the compound of Claim 1.
19. A compound of the formula
Figure imgf000223_0001
wherein X is a 9- to 10-membered polycyclic ring system, wherein one or more of the rings is aromatic, and wherein the polycyclic ring system contains 0, 1, 2, 3 or 4 heteroatoms selected from N, O or S, and wherein the polycyclic ring system is either unsubstituted or substituted with one or more groups chosen from Rl , R2, R15 or Rl6;
Y is selected from R0 o
I
■(CH2)-N-(CH2) m (CH^C- CH^
0 o i t ■(CH2)-C-N- (CH2); m ■(CH2)-N_c-(CH2) m R3 R3
■(CH2)— S(0)2-N-(CH2)s- , — (CH2)r-N— S(0)2-(CH2)m R3 R3
(CH2)-S(0)q-(CH2)^ , (CH2) O-(CH2fe- or - (CH2)-;
Z is a 5-1 1 membered aromatic or nonaromatic mono- or polycyclic ring system containing 0 to 6 double bonds, and containing 0 to 6 heteroatoms chosen from N, O and S, and wherein the ring system is either unsubstituted or substituted with one or more groups independently selected from R4, R5, R6 and l; provided that Z is not a 6-memberedmonocyclic aromatic ring system, an isoxazoline ring or an isoxazole ring;
R1 , R2, R4, R5, Rl3, Rl4? R15 and R1^ are each independently selected from hydrogen, halogen, Cl-10 alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, C3-8 cycloalkyl Cl-6 alkyl, C3-8 cycloheteroalkyl Cl-6 alkyl, aryl, aryl Cl-8 alkyl, amino, amino Cl -8 alkyl, Cl-3 acylamino, Cl-3 acylamino Cl -8 alkyl, (Cl -6 alkyOqamino, (Cl-6 alkyOqamino Cl-8 alkyl, Cl-4 alkoxy, Cl -4 alkoxy Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl -6 alkyl, Cl-3 alkoxycarbonyl, Cl-3 alkoxycarbonyl Cl-6 alkyl, hydroxycarbonyl -
Cl-6 alkyloxy, hydroxy, hydroxy Cl-6 alkyl, Cl -6 alkyloxy- Cl -6 alkyl, nitro, cyano, trifluoromethyl, trifluoromethoxy, trifluoroethoxy, Cl -8 alkyl-S(0)q, (Cl -8 alkyOqaminocarbonyl, Cl -8 alkyloxycarbonylamino, (Cl -8 alkyOqaminocarbonyloxy, oxo, (aryl Cl-8 alkyOqamino, (aryl)qamino, aryl Cl-8 alkylsulfonylamino or Cl -8 alkylsulfonylamino;
selected from hydrogen, aryl, aryl-(CH2)p-, hydroxyl, Ci-5 alkoxy, aminocarbonyl,
C3-8 cycloalkyl, amino Cl -6 alkyl,
(aryl)qaminocarbonyl, (aryl Cl-5 alkyOqaminocarbonyl, hydroxycarbonyl Cl -6 alkyl,
Cl-8 alkyl, aryl Cl-6 alkyl,
(Cl-6 alkyOqamino Cl-6 alkyl, (aryl Cl-6 alkyOqamino Cl -6 alkyl,
Cl -8 alkylsulfonyl,
Cl-8 alkoxycarbonyl, aryloxycarbonyl, aryl Cl -8 alkoxycarbonyl, Cl-8 alkylcarbonyl, arylcarbonyl, aryl Cl-6 alkylcarbonyl,
(Cl -8 alkyOqaminocarbonyl, aminosulfonyl, Cl-8 alkylaminosulfonyl,
(aryl)qaminosulfonylamino,
(aryl Cl-8 alkyOqaminosulfonyl,
Cl-6 alkylsulfonyl, arylsulfonyl, aryl Cl-6 alkylsulfonyl, aryl Cl-6 alkylcarbonyl,
C l -6 alkylthiocarbonyl, arylthiocarbonyl, or aryl Cl -6 alkylthiocarbonyl, wherein any of the alkyl groups may be unsubstituted or substituted with R*3 and R 14;
R6, R7, R 9? R IO and R l 1 are each independently selected from hydrogen, aryl, aryl-(CH2)p-, aryl-(CH2)n-0-(CH2)m-, aryl-(CH2)n-S(0)q-(CH2)m-, aryl-(CH2)n-C(0)-(CH2)πr, aryl-(CH2)n-C(0)-N(R )-(CH2)m-, aryl-(CH2)n-N(R3)-C(0)-(CH2)m-, aryl-(CH2)n-N(R )-(CH2)m-, halogen, hydroxyl,
Cl -8 alkylcarbonylamino, aryl Cl -5 alkoxy,
Cl-5 alkoxycarbonyl,
(Cl -8 alkyOqaminocarbonyl, Cl-6 alkylcarbonyloxy,
C3-8 cycloalkyl, oxo,
(Cl-6 alkyOqamino, amino Cl -6 alkyl, arylaminocarbonyl, aryl Cl -5 alkylaminocarbonyl, aminocarbonyl, aminocarbonyl Cl-6 alkyl, hydroxycarbonyl, hydroxycarbonyl Cl -6 alkyl,
Cl-8 alkyl, either unsubstituted or substituted, with one or more groups selected from: halogen, hydroxyl, Cl-5 alkylcarbonylamino, aryl Cl -5 alkoxy, Cl-5 alkoxycarbonyl, aminocarbonyl, (Cl-5 alkyOqaminocarbonyl, Cl-5 alkylcarbonyloxy, C3- cycloalkyl, oxo, (Cl -3 alkyOqamino, amino Cl -3 alkyl, (aryOqaminocarbonyl, (aryl Cl-5 alkyOqaminocarbonyl, aminocarbonyl, aminocarbonyl Cl -4 alkyl, hydroxycarbonyl or hydroxycarbonyl Cl -5 alkyl,
CH≡C-(CH2)s-,
Cl-6 alkyl-C≡C-(CH2)s-,
C3-7 cycloalkyl-C≡C-(CH2)s-, aryl-C≡C-(CH2)s-, Cl-6 alky laryl-C≡C-(CH2)s-,
CH2=CH-(CH2)s-,
Cl-6 alkyl-CH=CH-(CH2)s-,
C3-7 cycloalkyl-CH=CH-(CH2)s-, aryl-CH=CH-(CH2)s-, Cl-6 alkylary l-CH=CH-(CH2)s-,
Cl -6 alkyl-S02-(CH2)s-,
Cl-6 alkylaryl-Sθ2-(CH2)s-,
Cl -6 alkoxy, aryl Cl -6 alkoxy, aryl Cl -6 alkyl,
(Cl-6 alkyOqamino Cl-6 alkyl,
(aryl)qamino,
(aryl)qamino Cl-6 alkyl,
(aryl Cl-6 alkyOqamino, (aryl Cl -6 alkyOqamino Cl -6 alkyl, arylcarbonyloxy, aryl Cl-6 alkylcarbonyloxy,
(Cl-6 alkyOqaminocarbonyloxy,
Cl -8 alkylsulfonylamino, arylsulfonylamino,
Cl -8 alkylsulfonylamino Cl-6 alkyl, arylsulfonylamino Cl-6 alkyl, aryl Cl-6 alkylsulfonylamino, aryl Cl-6 alkylsulfonylamino Cl-6 alkyl,
Cl-8 alkoxycarbonylamino,
Cl -8 alkoxycarbonylamino Cl -8 alkyl, aryloxycarbonylamino Cl-8 alkyl, aryl Cl -8 alkoxycarbonylamino, aryl Cl-8 alkoxycarbonylamino Cl -8 alkyl,
Cl -8 alkylcarbonylamino,
Cl -8 alkylcarbonylamino Cl -6 alkyl, arylcarbonylamino Cl -6 alkyl, aryl Cl-6 alkylcarbonylamino, aryl C l -6 alkylcarbonylamino Cl-6 alkyl , aminocarbonylamino Cl-6 alkyl,
(Cl-8 alkyOqaminocarbonylamino,
(Cl -8 alkyOqaminocarbonylamino Cl-6 alkyl,
(aryOqaminocarbonylamino Cl -6 alkyl, (aryl Cl -8 alkyOqaminocarbonylamino,
(aryl Cl-8 alkyOqaminocarbonylamino Cl -6 alkyl, aminosulfony lamino Cl -6 alkyl,
(Cl-8 alkyOqaminosulfonylamino,
(Cl-8 alkyOqaminosulfonylamino Cl-6 alkyl, (aryl)qaminosulfony lamino Cl -6 alkyl,
(aryl Cl-8 alkyOqaminosulfonylamino,
(aryl Cl-8 alkyOqaminosulfonylamino Cl -6 alkyl,
Cl -6 alkylsulfonyl,
Cl -6 alkylsulfonyl Cl-6 alkyl, arylsulfonyl Cl-6 alkyl, aryl C] -6 alkylsulfonyl, aryl Cl -6 alkylsulfonyl Cl -6 alkyl,
Cl-6 alkylcarbonyl,
Cl-6 alkylcarbonyl Cl -6 alkyl, arylcarbonyl Cl-6 alkyl, aryl Cl-6 alkylcarbonyl, aryl Cl-6 alkylcarbonyl Cl -6 alkyl,
Cl-6 alkylthiocarbonylamino, Cl -6 alkylthiocarbonylamino Cl-6 alkyl, arylthiocarbonylamino Cl-6 alkyl, aryl Cl-6 alkylthiocarbonylamino, aryl Cl-6 alkylthiocarbonylamino Cl-6 alkyl,
(Cl -8 alkyOqaminocarbonyl Cl -6 alkyl, (aryl)qaminocarbonyl Cl-6 alkyl,
(aryl Cl-8 alkyOqaminocarbonyl, or
(aryl Cl -8 alkyOqaminocarbonyl Cl-6 alkyl, wherein any of the alkyl groups may be unsubstituted or substituted with Rl 3 and Rl4; and provided that the carbon atom to which R& and R9 are attached is itself attached to no more than one heteroatom; and provided further that the carbon atom to which RlO and RU are attached is itself attached to no more than one heteroatom;
Rl is selected from hydrogen,
Cl-8 alkyl, aryl, aryl Cl -8 alkyl,
Cl-8 alkylcarbonyloxy Cl-4 alkyl, aryl Cl-8 alkylcarbonyloxy Cl-4 alkyl,
Cl-8 alkylaminocarbonylmethylene, or Cl-8 dialkylaminocarbony Imethy lene; m, s and t are each independently an integer from 0 to 3; n is an integer from 1 to 3; p is an integer from 1 to 4; q is an integer from 0 to 2; r is an integer from 0 to 6;
and the pharmaceutically acceptable salts thereof.
20. The compound of Claim 19, wherein Z is selected from
Figure imgf000230_0001
Figure imgf000230_0002
V H^
Figure imgf000230_0003
Figure imgf000231_0001
and the pharmaceutically acceptable salts thereof.
21. The compound of Claim 20, wherein Z is selected from
Figure imgf000231_0002
Figure imgf000231_0003
Figure imgf000232_0001
and the pharmaceutically acceptable salts thereof.
22. The compound of Claim 21 of the formula
Figure imgf000232_0002
wherein X is selected from
Figure imgf000233_0001
Y is selected from -(CH2)r or -(CH2)m-NR3-(CH2)t-; R3 is selected from hydrogen, aryl-(CH2)p-,
Cl-5 alkoxycarbonyl,
C3-8 cycloalkyl,
(aryOqaminocarbonyl,
(aryl Cl-5 alkyOqaminocarbonyl, Cl-8 alkyl, aryl Cl-6 alkyl,
Cl -8 alkylsulfonyl, arylsulfonyl, aryl Cl-6 alkylsulfonyl, Cl-8 alkoxycarbonyl, aryloxycarbonyl, aryl Cl -8 alkoxycarbonyl,
Cl-8 alkylcarbonyl, arylcarbonyl, aryl Cl-6 alkylcarbonyl,
(Cl-8 alkyOqaminocarbonyl,
Cl -6 alkylsulfonyl, or aryl Cl-6 alkylcarbonyl, wherein any of the alkyl groups may be unsubstituted or substituted with R 13 and R 1 ;
R4 is selected from hydrogen, Cl-6 alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, C3-8 cycloalkyl Cl-6 alkyl, C3-8 cycloheteroalkyl Cl-6 alkyl, aryl or aryl Cl -8 alkyl, R^ is selected from hydrogen, aryl, aryl-(CH2)p-,
CH≡C-(CH2)s-, Cl-6 alkyl-C≡C-(CH2)s-, C3-7 cycloalkyl-C≡C-(CH2)s-, aryl-C≡C-(CH2)s-, Cl -6 alkylaryl-C≡C-(CH2)s-,
CH2=CH-(CH2)s-, Cl-6 alkyl-CH=CH-(CH2)s-, C3-7 cycloalkyl-CH=CH-(CH2)s-, aryl-CH=CH-(CH2)s-, Cl-6 alkylaryl-CH=CH-(CH2)s-,
Cl-6 alkyl-Sθ2-(CH2)s-, Cl-6 alkylaryI-S02-(CH2)s-; and
r is an integer from 0 to 3;
and the pharmaceutically acceptable salts thereof.
23. The compound of Claim 22 of the formula
Figure imgf000234_0001
wherein Z is selected from
Figure imgf000235_0001
elected from hydrogen,
Figure imgf000235_0002
indolyl-(CH2)p-,
CH≡C-(CH2)s-,
Cl-6 alkyl-C≡C-(CH2)s-,
C3-7 cycloalkyl-C≡C-(CH2)s-, aryl-C≡C-(CH2)s-,
Cl -6 alkylaryl-C≡C-(CH2)s-,
CH2=CH-(CH2)s-,
Cl-6 alkyl-CH=CH-(CH2)s-,
C3-7 cycloalkyl-CH=CH-(CH2)s-, aryl-CH=CH-(CH2)s-,
Cl-6 alkylaryl-CH=CH-(CH2)s-, Cl-6 alkyl-S02-(CH2)s-,
Cl-6 alkylaryl-Sθ2-(CH2)s-; and
Rl2 is selected from hydrogen or Cl -8 alkyl; and s is an integer from 0 to 3; and the pharmaceutically acceptable salts thereof.
24. The compound of Claim 23 selected from
2-Oxo-3-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2-yl)ethyl]piperidin- l -yl-acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-3-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2-yl)ethyl]piperin- 1 -yl-acetyl-3(S)-pyridin-3-yl-β-alanine trifluoroacetate;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine ethyl ester;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2-yl)ethyl ]- pyrrolidin-l-yl)acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydrof 1 ,8]-naphthyridin-2- yl)ethylJpyrrolidin-l -yl)acetyl-3(S)-alkynyl-β-alanine ethyl ester;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[l,81-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine; 2-Oxo-3(R)-12-(5,6,7,8-tetrahydrof l ,81-naphthyridin-2-yl)ethylJ- pyrrolidin-l-yl)acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[l,8]-naphthyridin-2- y0ethyl]pyrrolidin-l-yl)acetyl-3(S)-ρyridin-3-yl-β-alanine;
Ethyl 2-0X0-3-12-(5,6,7,8-tetrahydro[ 1 ,8]naphthyridin-2-yl)ethyl]- tetrahydropyrimidin-l-yl-acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3-[2-(5,6,7,8-tetrahydro[ l ,8]naphthyridin-2-yl}ethyl]- tetrahydropyrimidin-l -yl-acetyl-3(S)-ρyridin-3-yl-β-alanine;
Ethyl 2-oxo-3-[2-(5,6,7,8-tetrahydro[l ,8]naphthyridin-2- yl)ethyl]imidazolidin-l-yl-acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3-[2-(5,6,7,8-tetrahydro[ 1 ,8]naphthyridin-2-yl }ethyl]- imidazolidin- 1 -yl-acetyl-3(S)-pyridin-3-yl-β-alanine;
Ethyl 2-oxo-3(R)-[2-(5,6,7,8-tetrahydrof 1 ,8]naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(R)-(2-ethylindol-3-yl)-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[ 1 ,8]naρhthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(R)-(2-ethylindol-3-yl)-β-alanine;
Ethyl 3-(2-{2-oxo-3(S)-[(5,6,7,8-tetrahydro-[l,81naphthyridin-2- ylmethyl)-amino]-pyrrolidin-l -yl } -acetylamino)-3-(S)-pyridin-3-yl- propionic acid;
3-(2-{2-Oxo-3(S)-[(5,6,7,8-tetrahydro-[l,8]naphthyridin-2-y Imethy 0- aminojpyrrolidin- 1 -yl } -acetylamino)-3-(S)-pyridin-3-yl-propionic acid;
3-{ 2-[6-Oxo-l -(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-ylmethy0- hexahydro-(3aS, 6aS)pyrrolo[3,4-b]pyrrol-5-yl]-acety lamino }-3-(S)- pyridin-3-yl-propionic acid; 3-{2-[6-Oxo-l -(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2-ylmethy0- hexahydro-(3aR, 6aR)pyrrolo[3,4-bJpyrrol-5-yl]-acetylamino } -3-(S)- pyridin-3-yl-propionic acid;
2-Oxo-5(R)-methyl-3(S)-[2-(5,6,7,8-tetrahydro| l ,8]-naphthyridin-2-y0- ethyl]pyrrolidin-l -yl)acetyl-3(S)-alkynyl-β-alanine ethyl ester;
2-Oxo-5(R)-methyl-3(S)-[2-(5,6,7,8-tetrahydrol l ,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-5(S)-benzyl-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2-y0- ethyl]pyrrolidin-l -yl)acetyl-3(S)-pyridin-3-yl-β-alanine ethyl ester;
2-Oxo-5(S)-benzyl-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
5(R)-Methyl-2-oxo-3(S)-f2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- ylmethyl)-amino]pyrrolidin-l-yl)acetyl-3(S)-alkynyl-β-alanine ethyl ester;
5(R)-Methyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,81-naphthyridin-2- ylmethyl)-amino]pyrrolidin-l-yl)acetyl-3(S)-alkynyl-β-alanine;
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2- { 2-oxo-3(S)-[2-(5,6,7,8- tetrahydro-[ 1 ,81naphthyridin-2-yl)-ethyl]-pyrrolidin- 1 -yl } - acetylamino)-propionic acid ethyl ester;
3(S)-(2,3-Dihydro-benzofuran-6-yl)-3-(2-{2-oxo-3(S)-[2-(5,6,7,8- tetrahydro-[ 1 ,8]naphthyridin-2-yl)-ethylJ-pyrrolidin- 1 -yl } - acetylamino)-propionic acid;
3- { 2-(2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro-[ 1 ,8Jnaphthyridin-2-yl)-ethyl]- pyrrolidin-l -yl)-acetylamino}-3(S)-quinolin-3-yl-propionic acid; 3-(2-(5(S)-Ethyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydro-[l ,8]naphthyridin-2- yl)-ethyl]-pyrolidin-l -yl)-acetylamino)-3-(S)-quinolin-3-yl-propionic acid trifluoroacetate;
3-(2-{6-Methyl-2-oxo-3-[(5,6,7,8-tetrahydro-[l,8]naphthyridin-2- ylmethyl)-amino]-2H-pyridin-l-yl }-acetylamino)-3(S)-pyridin-3-yl- propionic acid bis trifluoroacetate; or
3-(2-{ 6-Methyl-2-oxo-3-[(5,6,7,8-tetrahydro-Ll ,8]napthyridin-2- ylmethyl)-amino]-2H-pyridin- 1 -yl } -acetylamino)-3(S)-pyridin-3-yl- propionic acid ethyl ester;
and the pharmaceutically acceptable salts thereof.
25. The compound of Claim 24, selected from
2-Oxo-3-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2-yl)ethyl]piperin- 1 -yl-acetyl-3(S)-pyridin-3-yl-β-alanine trifluoroacetate;
2-Oxo-3(S)-f2-(5,6,7,8-tetrahydrof l ,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-3(S)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- yl)ethyl]pyrrolidin- 1 -yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[ 1 ,8]-naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- yl)ethy l]pyrrolidin- 1 -yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
2-Oxo-3-[2-(5,6,7,8-tetrahydro[l ,8]naphthyridin-2-yl}ethyl]- imidazolidin- 1 -yl-acetyl-3-(S)-pyridin-3-yl-β-alanine; 2-Oxo-3-r2-(5,6,7,8-tetrahydro[ 1 ,8Jnaρhthyridin-2-yl JethylJ- tetrahydropyrimidin-l -yl-acetyl-3-(S)-pyridin-3-yl-β-alanine;
2-Oxo-3(R)-[2-(5,6,7,8-tetrahydro[ 1 ,8Jnaphthyridin-2- yl)ethyllpyrrolidin-l-yl)acetyl-3(R)-(2-ethylindol-3-yl)-β-alanine;
3-(2-{ 2-Oxo-3(S)-[(5,6,7,8-tetrahydro-[l ,8Jnaphthyridin-2-ylmethy0- aminoJpyrrolidin-l-yl }-acetylamino)-3-(S)-pyridin-3-yl-propionic acid;
3-{2-[6-Oxo-l-(5,6,7,8-tetrahydro-ll ,8Jnaphthyridin-2-ylmethyl)- hexahydro-(3aS, 6aS)pyrrolol3,4-bJpyrrol-5-ylJ-acetylamino}-3-(S)- pyridin-3-yl-propionic acid; or
3-{2-[6-Oxo-l -(5,6,7,8-tetrahydro-[l ,8Jnaphthyridin-2-ylmethy0- hexahydro-(3aR, 6aR)pyrrolof3,4-b]pyrrol-5-ylJ-acetylamino }-3-(S)- pyridin-3-yl-propionic acid;
2-Oxo-5(R)-methyl-3(S)-12-(5,6,7,8-tetrahydro[l ,8]-naphthyridin-2- yOethylJpyrrolidin- 1 -y l)acetyl-3(S)-alkynyl-β-alanine;
2-Oxo-5(S)-benzyl-3(S)-[2-(5,6,7,8-tetrahydro[ l,8J-naphthyridin-2- yl)ethyl]pyrrolidin-l-yl)acetyl-3(S)-pyridin-3-yl-β-alanine;
5(R)-Methyl-2-oxo-3(S)-[2-(5,6,7,8-tetrahydroll,8J-naphthyridin-2- ylmethyO-aminoJpyrrolidin- 1 -yl)acetyl-3(S)-alkynyl-β-alanine; or
3(5)-(2,3-Dihydro-benzofuran-6-yl)-3-(2- {2-oxo-3(S)-[2-(5,6,7,8- tetrahydro-[ 1 ,8 Jnaphthyridin-2-y l)-ethyl J-pyrrolidin- 1 -yl } - acetylamino)-propionic acid;
and the pharmaceutically acceptable salts thereof.
26. A pharmaceutical composition comprising the compound of Claim 19 and a pharmaceutically acceptable carrier.
27. A pharmaceutical composition made by combining a compound of Claim 19 and a pharmaceutically acceptable carrier.
28. A process for making a pharmaceutical composition comprising combining a compound of Claim 19 and a pharmaceutically acceptable carrier.
29. A method of eliciting a vitronectin receptor antagonizing effect in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the composition of Claim 26.
30. A method of treating or preventing a condition mediated by antagonism of a vitronectin receptor in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the composition of Claim 26.
31. A method of inhibiting bone resoφtion in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the composition of Claim 26.
32. A method of treating osteoporosis in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the composition of Claim 26.
33. A method of treating tumor growth in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound of Claim 19 and one or more agents known to be cytotoxic or antiproliferative.
PCT/US1997/014912 1996-08-29 1997-08-25 Integrin antagonists WO1998008840A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP51178398A JP2002511052A (en) 1996-08-29 1997-08-25 Integrin antagonist
US09/242,885 US6211184B1 (en) 1996-08-29 1997-08-25 Integrin antagonists
CA002263999A CA2263999A1 (en) 1996-08-29 1997-08-25 Integrin antagonists
AU40865/97A AU724191B2 (en) 1996-08-29 1997-08-25 Integrin antagonists
EP97938568A EP0934305A4 (en) 1996-08-29 1997-08-25 Integrin antagonists

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US2512396P 1996-08-29 1996-08-29
US3357996P 1996-12-19 1996-12-19
GB9703015.9 1997-02-13
GBGB9703015.9A GB9703015D0 (en) 1997-02-13 1997-02-13 Alpha v B3 antagonists
US4717797P 1997-05-20 1997-05-20
US60/047,177 1997-05-20
US60/033,579 1997-05-20
US60/025,123 1997-05-20

Publications (1)

Publication Number Publication Date
WO1998008840A1 true WO1998008840A1 (en) 1998-03-05

Family

ID=27451604

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/014912 WO1998008840A1 (en) 1996-08-29 1997-08-25 Integrin antagonists

Country Status (5)

Country Link
EP (1) EP0934305A4 (en)
JP (1) JP2002511052A (en)
AU (1) AU724191B2 (en)
CA (1) CA2263999A1 (en)
WO (1) WO1998008840A1 (en)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052551A1 (en) * 1998-04-15 1999-10-21 King's College London Therapy of atherosclerosis
WO1999052872A1 (en) 1998-04-09 1999-10-21 Meiji Seika Kaisha, Ltd. AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS
WO1999052879A1 (en) * 1998-04-14 1999-10-21 American Home Products Corporation Acylresorcinol derivatives as selective vitronectin receptor inhibitors
WO1999052896A1 (en) * 1998-04-10 1999-10-21 G.D. Searle & Co. Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
EP0997474A1 (en) * 1998-08-14 2000-05-03 Pfizer Inc. Antithrombotic agents
US6066648A (en) * 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
US6090944A (en) * 1998-08-13 2000-07-18 Merck & Co., Inc. Alkanoic acid derivatives as αv integrin receptor antagonists
WO2000061551A2 (en) * 1999-04-13 2000-10-19 Basf Aktiengesellschaft Pyrimidine-2-one derivatives as integrin receptor ligands
EP1065207A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
US6211191B1 (en) 1997-12-17 2001-04-03 Merck & Co., Inc. Integrin receptor antagonists
US6211184B1 (en) 1996-08-29 2001-04-03 Merck & Co., Inc. Integrin antagonists
WO2001024827A2 (en) * 1999-10-06 2001-04-12 Basf Aktiengesellschaft INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
WO2001043743A1 (en) * 1999-12-15 2001-06-21 Celgene Corp. Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
US6297233B1 (en) 1999-02-09 2001-10-02 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
EP1189881A1 (en) * 1999-05-07 2002-03-27 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6410526B1 (en) 1999-06-02 2002-06-25 Merck & Co., Inc. αv integrin receptor antagonists
US6413955B1 (en) 1999-10-04 2002-07-02 Merck & Co., Inc. Integrin receptor antagonists
US6444811B1 (en) 1999-07-19 2002-09-03 Merck Frosst Canada & Co. Pyrazinones, compositions containing such compounds and methods of use
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6472403B2 (en) 2000-01-20 2002-10-29 Merck & Co., Inc. αV integrin receptor antagonists
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
WO2003024933A1 (en) * 2001-09-12 2003-03-27 Kaken Pharmaceutical Co., Ltd. 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
US6555542B1 (en) 2001-01-30 2003-04-29 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of FXa and method
WO2003066624A1 (en) * 2002-02-06 2003-08-14 Abbott Gmbh & Co. Kg Pyrimidinonesulfamoylureas as integrin ligands
US6624180B2 (en) 2000-11-20 2003-09-23 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6686484B2 (en) 2000-04-17 2004-02-03 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
US6689754B1 (en) 1998-04-10 2004-02-10 G. D. Searle & Co. Heterocyclic glycyl β-alanine derivatives
US6693121B2 (en) 2000-04-05 2004-02-17 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6750219B1 (en) 1999-08-05 2004-06-15 Meiji Seika Kaisha, Ltd. Ω-amino-α-hydroxycarboxylic acid derivatives having integrin ανβ3 antagonistic activity
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6875791B2 (en) 2000-04-05 2005-04-05 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
EP1589029A3 (en) * 1998-06-11 2006-01-18 Johnson &amp; Johnson Pharmaceutical Research &amp; Development L.L.C. Pyrazinone protease inhibitors
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US7105559B2 (en) 2001-10-03 2006-09-12 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
WO2010136168A2 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
EP2292251A1 (en) 2001-04-24 2011-03-09 Merck Patent GmbH Combination therapy using anti-angiogenic agents and TNF-alpha
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
WO2018160521A2 (en) 2017-02-28 2018-09-07 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US11021480B2 (en) 2018-08-29 2021-06-01 Morphic Therapeutic, Inc. Inhibiting (α-V)(β-6) integrin
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US11426473B2 (en) 2013-09-24 2022-08-30 Fujifilm Corporation Nitrogen-containing compound or salt thereof, or metal complex thereof
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
TWI834321B (en) 2017-02-28 2024-03-01 美商莫菲克醫療股份有限公司 INHIBITORS OF αvβ6 INTEGRIN

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007015427A (en) * 2005-06-07 2008-04-16 Pharmacopeia Inc Azinone and diazinone v3 inhibitors for depression and stress disorders.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260277A (en) * 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5534524A (en) * 1994-05-09 1996-07-09 Board Of Regents, The University Of Texas System Suppression of bone resorption by quinolines
US5668159A (en) * 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416099A (en) * 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
AU674553B2 (en) * 1992-10-14 1997-01-02 Merck & Co., Inc. Fibrinogen receptor antagonists
PT730590E (en) * 1993-11-24 2001-05-31 Du Pont Pharm Co ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS ANTAGONISTS OF FIBRINOGENIC RECIPIENTS
NZ276631A (en) * 1993-11-24 1997-06-24 Du Pont Merck Pharma Isoxazoline derivatives and medicaments
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
EP0760658B1 (en) * 1994-05-27 2002-11-13 Merck & Co. Inc. Compounds for inhibiting osteoclast-mediated bone resorption

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260277A (en) * 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5534524A (en) * 1994-05-09 1996-07-09 Board Of Regents, The University Of Texas System Suppression of bone resorption by quinolines
US5668159A (en) * 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0934305A4 *

Cited By (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211184B1 (en) 1996-08-29 2001-04-03 Merck & Co., Inc. Integrin antagonists
US6784190B2 (en) 1997-12-17 2004-08-31 Merck & Co., Inc. Integrin receptor antagonists
US6268378B1 (en) 1997-12-17 2001-07-31 Merck & Co., Inc. Integrin receptor antagonists
US6297249B1 (en) 1997-12-17 2001-10-02 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6066648A (en) * 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
US6211191B1 (en) 1997-12-17 2001-04-03 Merck & Co., Inc. Integrin receptor antagonists
WO1999052872A1 (en) 1998-04-09 1999-10-21 Meiji Seika Kaisha, Ltd. AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS
WO1999052896A1 (en) * 1998-04-10 1999-10-21 G.D. Searle & Co. Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists
US6689754B1 (en) 1998-04-10 2004-02-10 G. D. Searle & Co. Heterocyclic glycyl β-alanine derivatives
WO1999052879A1 (en) * 1998-04-14 1999-10-21 American Home Products Corporation Acylresorcinol derivatives as selective vitronectin receptor inhibitors
WO1999052551A1 (en) * 1998-04-15 1999-10-21 King's College London Therapy of atherosclerosis
EP1589029A3 (en) * 1998-06-11 2006-01-18 Johnson &amp; Johnson Pharmaceutical Research &amp; Development L.L.C. Pyrazinone protease inhibitors
US6090944A (en) * 1998-08-13 2000-07-18 Merck & Co., Inc. Alkanoic acid derivatives as αv integrin receptor antagonists
US6180627B1 (en) 1998-08-14 2001-01-30 Pfizer Inc. Antithrombotic agents
EP0997474A1 (en) * 1998-08-14 2000-05-03 Pfizer Inc. Antithrombotic agents
US6297233B1 (en) 1999-02-09 2001-10-02 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
WO2000061551A3 (en) * 1999-04-13 2000-12-28 Basf Ag Pyrimidine-2-one derivatives as integrin receptor ligands
WO2000061551A2 (en) * 1999-04-13 2000-10-19 Basf Aktiengesellschaft Pyrimidine-2-one derivatives as integrin receptor ligands
US7125883B1 (en) 1999-04-13 2006-10-24 Abbott Gmbh & Co. Kg Integrin receptor ligands
EP1189881A4 (en) * 1999-05-07 2002-11-27 Texas Biotechnology Corp Propanoic acid derivatives that inhibit the binding of integrins to their receptors
CZ304225B6 (en) * 1999-05-07 2014-01-15 Encysive Pharmaceuticals Inc. Propionic acid derivatives inhibiting integrin bond to receptors thereof
JP2012006932A (en) * 1999-05-07 2012-01-12 Encysive Pharmaceuticals Inc Propanoic acid derivative that inhibits the binding of integrins to their receptors
EP1189881A1 (en) * 1999-05-07 2002-03-27 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
JP4841729B2 (en) * 1999-05-07 2011-12-21 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド Propanoic acid derivatives that inhibit integrin binding to its receptor
JP2002544187A (en) * 1999-05-07 2002-12-24 テキサス・バイオテクノロジー・コーポレイシヨン Propanoic acid derivatives inhibit the binding of integrins to their receptors
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6870056B1 (en) 1999-05-19 2005-03-22 Pharmacia Corporation Substitituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6410526B1 (en) 1999-06-02 2002-06-25 Merck & Co., Inc. αv integrin receptor antagonists
EP1065207A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
WO2001002399A1 (en) * 1999-07-02 2001-01-11 Aventis Pharma Deutschland Gmbh Substituted purine derivatives as inhibitors of cell adhesion
EA005372B1 (en) * 1999-07-02 2005-02-24 Авентис Фарма Дойчланд Гмбх Substituted purine derivatives as inhibitors of cell adhesion
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
US6747016B1 (en) 1999-07-02 2004-06-08 Aventis Pharma Deutschland Gmbh Substituted purine derivatives as inhibitors of cell adhesion
WO2001002398A1 (en) * 1999-07-02 2001-01-11 Aventis Pharma Deutschland Gmbh Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them
US6444811B1 (en) 1999-07-19 2002-09-03 Merck Frosst Canada & Co. Pyrazinones, compositions containing such compounds and methods of use
US6750219B1 (en) 1999-08-05 2004-06-15 Meiji Seika Kaisha, Ltd. Ω-amino-α-hydroxycarboxylic acid derivatives having integrin ανβ3 antagonistic activity
US6413955B1 (en) 1999-10-04 2002-07-02 Merck & Co., Inc. Integrin receptor antagonists
WO2001024827A3 (en) * 1999-10-06 2002-05-10 Basf Ag INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
WO2001024827A2 (en) * 1999-10-06 2001-04-12 Basf Aktiengesellschaft INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αVβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
EP2016942A1 (en) * 1999-12-15 2009-01-21 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
WO2001043743A1 (en) * 1999-12-15 2001-06-21 Celgene Corp. Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
JP2003520800A (en) * 2000-01-20 2003-07-08 メルク エンド カムパニー インコーポレーテッド αv integrin receptor antagonist
US6472403B2 (en) 2000-01-20 2002-10-29 Merck & Co., Inc. αV integrin receptor antagonists
JP4787447B2 (en) * 2000-01-20 2011-10-05 メルク・シャープ・エンド・ドーム・コーポレイション αv integrin receptor antagonist
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6852761B2 (en) 2000-03-13 2005-02-08 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6916847B2 (en) 2000-04-05 2005-07-12 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
US6875791B2 (en) 2000-04-05 2005-04-05 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
US6693121B2 (en) 2000-04-05 2004-02-17 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
US6686484B2 (en) 2000-04-17 2004-02-03 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
US6624180B2 (en) 2000-11-20 2003-09-23 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
US6828338B2 (en) 2000-11-20 2004-12-07 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US7166586B2 (en) 2001-01-30 2007-01-23 Bristol Myers Squibb Co. Sulfonamide lactam inhibitors of FXa and method
US6555542B1 (en) 2001-01-30 2003-04-29 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of FXa and method
EP2292251A1 (en) 2001-04-24 2011-03-09 Merck Patent GmbH Combination therapy using anti-angiogenic agents and TNF-alpha
US7361679B2 (en) 2001-09-12 2008-04-22 Kaken Pharmaceutical Co., Ltd. 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
WO2003024933A1 (en) * 2001-09-12 2003-03-27 Kaken Pharmaceutical Co., Ltd. 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
US7105559B2 (en) 2001-10-03 2006-09-12 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
US6969715B2 (en) 2001-10-03 2005-11-29 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
WO2003066624A1 (en) * 2002-02-06 2003-08-14 Abbott Gmbh & Co. Kg Pyrimidinonesulfamoylureas as integrin ligands
EP2335733A1 (en) 2006-01-18 2011-06-22 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
EP2338518A1 (en) 2006-01-18 2011-06-29 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
EP2441464A1 (en) 2007-01-18 2012-04-18 Merck Patent GmbH Specific therapy and medicament using integrin ligands for treating cancer
EP2578225A1 (en) 2007-07-18 2013-04-10 Merck Patent GmbH Specific Therapy and Medicament Using Integrin Ligands for Treating Cancer
WO2010136168A2 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
US11426473B2 (en) 2013-09-24 2022-08-30 Fujifilm Corporation Nitrogen-containing compound or salt thereof, or metal complex thereof
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
US11046669B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP3589627A4 (en) * 2017-02-28 2020-08-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2018160521A2 (en) 2017-02-28 2018-09-07 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US11040955B2 (en) 2017-02-28 2021-06-22 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US11795167B2 (en) 2017-02-28 2023-10-24 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
CN110573499A (en) * 2017-02-28 2019-12-13 莫菲克医疗股份有限公司 inhibitors of α v β 6 integrin
TWI834321B (en) 2017-02-28 2024-03-01 美商莫菲克醫療股份有限公司 INHIBITORS OF αvβ6 INTEGRIN
EP4159727A1 (en) * 2017-02-28 2023-04-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
CN110573499B (en) * 2017-02-28 2023-04-21 莫菲克医疗股份有限公司 Inhibitors of αvβ6 integrin
US11827621B2 (en) 2017-02-28 2023-11-28 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US11021480B2 (en) 2018-08-29 2021-06-01 Morphic Therapeutic, Inc. Inhibiting (α-V)(β-6) integrin
US11739087B2 (en) 2018-08-29 2023-08-29 Morphic Therapeutic, Inc. Inhibiting (α-v)(β-6) integrin
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Also Published As

Publication number Publication date
CA2263999A1 (en) 1998-03-05
JP2002511052A (en) 2002-04-09
AU724191B2 (en) 2000-09-14
EP0934305A4 (en) 2001-04-11
AU4086597A (en) 1998-03-19
EP0934305A1 (en) 1999-08-11

Similar Documents

Publication Publication Date Title
EP0934305A1 (en) Integrin antagonists
US6090944A (en) Alkanoic acid derivatives as αv integrin receptor antagonists
US5981546A (en) Integrin antagonists
US6268378B1 (en) Integrin receptor antagonists
US6017926A (en) Integrin receptor antagonists
EP1040111B1 (en) Integrin receptor antagonists
US6040311A (en) Integrin receptor antagonists
EP1044001B1 (en) Integrin receptor antagonists
US6297249B1 (en) Integrin receptor antagonists
EP0946165B1 (en) Integrin antagonists
AU717283B2 (en) Integrin antagonists
US6413955B1 (en) Integrin receptor antagonists
US5919792A (en) Integrin antagonists
EP1047425A1 (en) Integrin receptor antagonists
US6358970B1 (en) Integrin receptor antagonists
AU1822099A (en) Integrin receptor antagonists
US5952341A (en) Integrin antagonists
US6232308B1 (en) Bezazepine derivatives as αv integrin receptor antagonists
US6211184B1 (en) Integrin antagonists
US6211191B1 (en) Integrin receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997938568

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2263999

Country of ref document: CA

Ref country code: CA

Ref document number: 2263999

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09242885

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997938568

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997938568

Country of ref document: EP